Compositions and Methods for Detecting or Quantifying Hepatitis B Virus

ABSTRACT

This disclosure provides oligomers, compositions, and kits for detecting and quantifying Hepatitis B virus (HBV), including different genotypes and variants thereof, and related methods and uses. In some embodiments, oligomers target the P and/or S open reading frames of HBV and are configured to provide substantially equivalent quantification of different genotypes and variants of HBV.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of application Ser. No. 15/816,036,filed Nov. 17, 2017, which claims the benefit of priority of provisionalApplication No. 62/424,956, filed Nov. 21, 2016, the entire contents ofeach application is incorporated herein by reference in their entirety.

SEQUENCE LISTING

The present application is filed with a Sequence Listing in electronicformat. The Sequence Listing is provided as a file entitled“2019-10-30_01159-0003-01US_Seq_List_ST25” created on Oct. 30, 2019,which is 54,188 bytes in size. The information in the electronic formatof the sequence listing is incorporated herein by reference in itsentirety.

INTRODUCTION AND SUMMARY

Hepatitis B Virus (HBV) can cause acute and chronic disease, withinfected individuals being at risk of liver cirrhosis and cancer.Approximately 240 million individuals worldwide are estimated to beinfected, with more than 680,000 deaths per year attributable tohepatitis B-related liver disease according to the July 2016 WHOHepatitis B Fact Sheet. Transmission of HBV can occur through sexualtransmission, birth from an infected mother, and other contact withbodily fluids, including on shared items such as toothbrushes and razorsas well as needles, and represents an occupational hazard for healthcare workers.

HBV is a partially double-stranded DNA (dsDNA) virus. Its distributionis worldwide, with genotypes A through H and multiple subtypes known.Antiviral therapy can be effective against chronic HBV, but reliable andsensitive nucleic acid-based detection and quantification arecomplicated by genetic heterogeneity that results in part from theerror-prone nature of HBV replication, in which new viral DNA isreverse-transcribed from RNA by an enzyme lacking proofreading activity.See, e.g., Huang C-J et al. (2013), “Impact of Genetic Heterogeneity inPolymerase of Hepatitis B Virus on Dynamics of Viral Load and HepatitisB Progression,” PLoS ONE 8(7): e70169, doi:10.1371/journal.pone.0070169.Hepatitis B is not readily distinguishable on clinical grounds fromother types of hepatitis, further emphasizing the importance ofmolecular detection approaches such as nucleic acid assays.Quantification can be useful, e.g., in monitoring viral load before,during or after antiviral therapy, or in assessing severity ofinfection. However, assaying for HBV nucleic acid in a manner thatreliably detects and quantifies multiple genotypes is nontrivial in thata small set of e.g., two amplification oligomers and one probe isunlikely to amplify and quantify the many known genotypes and subtypesin a comparable manner and may be particularly susceptible to falsenegatives for some genotypes at low concentrations. On the other hand,using an increased number of oligomers can be complicated by factorsthat can impact accuracy, sensitivity, or specificity such as increasedpotential for interactions between oligomers or with unintended targetsequences, differential amplification efficiency, resource competition,etc.

Accordingly, there is a need for sensitive, specific, and accuratedetection and quantification of HBV irrespective of genotype.Compositions, kits, and methods are provided herein to meet this need,provide other benefits, or at least provide the public with a usefulchoice.

Provided herein is a composition or kit comprising at least first,second, third, and fourth amplification oligomers, wherein: the firstamplification oligomer comprises a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of one of SEQ ID NOs: 2 or3; the second amplification oligomer comprises a target-hybridizingsequence comprising at least 10 contiguous nucleotides of one of SEQ IDNOs: 20, 21, or 22; the third amplification oligomer comprises atarget-hybridizing sequence comprising at least 10 contiguousnucleotides of SEQ ID NO: 41; and the fourth amplification oligomercomprises a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 34 or 35; wherein thetarget-hybridizing sequences of the first, second, third, and fourthamplification oligomers each comprise at least about 14 contiguousnucleotides of Hepatitis B virus sequence or a complement thereof.

Also provided is a method of detecting Hepatitis B virus in a sample,comprising contacting the sample with at least first, second, third, andfourth amplification oligomers, thereby forming a composition,performing a nucleic acid amplification reaction in the compositionwhich produces at least first and second amplicons in the presence of aHepatitis B virus nucleic acid, and quantifying the first and secondamplicons, wherein: the first amplicon is produced through extension ofthe first and second amplification oligomers in the presence of theHepatitis B virus nucleic acid; the second amplicon is produced throughextension of the third and fourth amplification oligomers in thepresence of the Hepatitis B virus nucleic acid; the first amplificationoligomer comprises a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 2 or 3; the secondamplification oligomer comprises a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of one of SEQ ID NOs: 20,21, or 22; the third amplification oligomer comprises atarget-hybridizing sequence comprising at least 10 contiguousnucleotides of SEQ ID NO: 41; and the fourth amplification oligomercomprises a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 34 or 35; wherein thetarget-hybridizing sequences of the first, second, third, and fourthamplification oligomers each comprise at least about 14 contiguousnucleotides of Hepatitis B virus sequence or a complement thereof.

In some embodiments, one or more of the first, second, third, and fourthamplification oligomers is a promoter-primer. In some embodiments, thesecond amplification oligomer is a promoter-primer. In some embodiments,the fourth amplification oligomer is a promoter-primer. In someembodiments, one or more of the promoter-primers comprises a T7 promoterlocated 5′ of the target-hybridizing sequence. In some embodiments, oneor more promoter-primers comprises the sequence of SEQ ID NO: 8, 9, 10,11, 12, or 13.

In some embodiments, one or more of the first, second, third, and fourthamplification oligomers comprises a non-nucleotide detectable label.

In some embodiments, the first amplification oligomer comprises atarget-hybridizing sequence comprising at least one, two, or three ofSEQ ID NOs: 4, 5, 6, or 7. In some embodiments, the second amplificationoligomer comprises a target-hybridizing sequence comprising at leastone, two, three, four, or five of SEQ ID NOs: 23, 24, 25, 26, 27, and28. In some embodiments, the third amplification oligomer comprises atarget-hybridizing sequence comprising at least one, two, or three ofSEQ ID NOs: 42, 43, and 44. In some embodiments, the fourthamplification oligomer comprises a target-hybridizing sequencecomprising at least one, two, or three of SEQ ID NOs: 36, 37, 38, and39.

In some embodiments, the first amplification oligomer comprises at least11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleotides of SEQID NO: 3. In some embodiments, the first amplification oligomercomprises the sequence of SEQ ID NO: 3. In some embodiments, the firstamplification oligomer comprises at least 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, or 22 contiguous nucleotides of SEQ ID NO: 2. In someembodiments, the first amplification oligomer comprises the sequence ofSEQ ID NO: 2.

In some embodiments, the composition or kit further comprises anadditional amplification oligomer different from the first amplificationoligomer, comprising at least 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20contiguous nucleotides of SEQ ID NO: 3. In some embodiments, theadditional amplification oligomer comprises the sequence of SEQ ID NO:3.

In some embodiments, the second amplification oligomer comprises atleast 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 contiguousnucleotides of SEQ ID NO: 21. In some embodiments, the secondamplification oligomer comprises the sequence of SEQ ID NO: 21. In someembodiments, the second amplification oligomer comprises the sequence ofSEQ ID NO: 14. In some embodiments, the second amplification oligomercomprises at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, or 26 contiguous nucleotides of SEQ ID NO: 22. In someembodiments, the second amplification oligomer comprises the sequence ofSEQ ID NO: 22. In some embodiments, the second amplification oligomercomprises the sequence of SEQ ID NO: 15. In some embodiments, the secondamplification oligomer comprises at least 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 contiguous nucleotides ofSEQ ID NO: 20. In some embodiments, the second amplification oligomercomprises the sequence of SEQ ID NO: 20.

In some embodiments, the third amplification oligomer comprises at least11, 12, 13, 14, 15, 16, 17, 18, or 19 contiguous nucleotides of SEQ IDNO: 41. In some embodiments, the third amplification oligomer comprisesthe sequence of SEQ ID NO: 41.

In some embodiments, the fourth amplification oligomer comprises atleast 10 contiguous nucleotides of SEQ ID NO: 35 including the inosineat position 30 of SEQ ID NO: 35. In some embodiments, the fourthamplification oligomer comprises at least 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 contiguous nucleotides ofSEQ ID NO: 34. In some embodiments, the fourth amplification oligomercomprises the sequence of SEQ ID NO: 34. In some embodiments, the fourthamplification oligomer comprises the sequence of SEQ ID NO: 30.

In some embodiments, the composition or kit further comprises a fifthamplification oligomer comprising at least 10 contiguous nucleotides ofthe sequence of SEQ ID NO: 69 and at least about 14 contiguousnucleotides of Hepatitis B virus sequence or a complement thereof. Insome embodiments, the fifth amplification oligomer comprises at leastone or two of SEQ ID NO: 70, 71, or 72. In some embodiments, the fifthamplification oligomer comprises at least 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 contiguous nucleotidesof SEQ ID NO: 69. In some embodiments, the fifth amplification oligomercomprises the sequence of SEQ ID NO: 69. In some embodiments, the fifthamplification oligomer is a promoter-primer. In some embodiments, thefifth amplification oligomer comprises the sequence of SEQ ID NO: 67.

In some embodiments, the composition or kit further comprises a sixthamplification oligomer comprising at least 10 contiguous nucleotides ofthe sequence of SEQ ID NO: 73 and at least about 14 contiguousnucleotides of Hepatitis B virus sequence or a complement thereof. Insome embodiments, the sixth amplification oligomer comprises at leastone or two of SEQ ID NO: 74, 75, or 76. In some embodiments, the sixthamplification oligomer comprises at least 11, 12, 13, 14, 15, 16, 17,18, or 19 contiguous nucleotides of SEQ ID NO: 73. In some embodiments,the sixth amplification oligomer comprises the sequence of SEQ ID NO:73.

In some embodiments, the composition further comprises HBV nucleic acid.

In some embodiments, the composition or kit further comprises at leastone DNA polymerase. In some embodiments, the DNA polymerase is a reversetranscriptase. In some embodiments, the DNA polymerase is thermophilic.In some embodiments, the DNA polymerase is mesophilic.

In some embodiments, the composition or kit further comprises an RNApolymerase. In some embodiments, the RNA polymerase is T7 RNApolymerase.

In some embodiments, the composition or kit further comprises at leastone, at least two, or each of Mg2+, a buffer, and dNTPs. In someembodiments, the composition or kit further comprises rNTPs.

In some embodiments, the composition or kit further comprises a firstcontrol amplification oligomer and a second control amplificationoligomer that do not hybridize specifically to HBV. In some embodiments,the first control amplification oligomer comprises at least 10, 11, 12,13, 14, 15, 16, 17, 18, or 19 contiguous nucleotides of the sequence ofSEQ ID NO: 77. In some embodiments, the second control amplificationoligomer comprises at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, or 22 contiguous nucleotides of the sequence of SEQ ID NO: 86. Insome embodiments, the first control amplification oligomer or the secondcontrol amplification oligomer is a promoter-primer. In someembodiments, the composition or kit further comprises at least onecontrol probe oligomer configured to hybridize specifically to anamplicon produced from the first and second control amplificationoligomers. In some embodiments, the control probe oligomer comprises atleast 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23contiguous nucleotides of the sequence of SEQ ID NO: 79.

In some embodiments, the composition or kit further comprises at leastone probe oligomer configured to hybridize specifically to an ampliconproduced from the first and second amplification oligomers. In someembodiments, the probe oligomer comprises at least 10 contiguousnucleotides of the sequence of SEQ ID NO: 29 and at least about 14contiguous nucleotides of Hepatitis B virus sequence or a complementthereof. In some embodiments, the probe oligomer comprises at least 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or28 contiguous nucleotides of SEQ ID NO: 82. In some embodiments, theprobe oligomer comprises the sequence of SEQ ID NO: 82. In someembodiments, the probe oligomer comprises at least 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 contiguousnucleotides of SEQ ID NO: 82. In some embodiments, the probe oligomercomprises the sequence of SEQ ID NO: 29.

In some embodiments, the composition or kit further comprises at leastone probe oligomer configured to hybridize specifically to an ampliconproduced from the third and fourth amplification oligomers. In someembodiments, the probe oligomer comprises at least 10 contiguousnucleotides of the sequence of SEQ ID NO: 40 and at least about 14contiguous nucleotides of Hepatitis B virus sequence or a complementthereof. In some embodiments, the probe oligomer comprises at least 10,11, 12, 13, 14, or 15 contiguous nucleotides of SEQ ID NO: 83. In someembodiments, the probe oligomer comprises the sequence of SEQ ID NO: 83.In some embodiments, the probe oligomer comprises at least 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotidesof SEQ ID NO: 40. Also provided is a probe oligomer comprising atarget-hybridizing region comprising the sequence of SEQ ID NO: 83. Insome embodiments, the probe oligomer comprises the sequence of SEQ IDNO: 84. In some embodiments, the probe oligomer comprises the sequenceof SEQ ID NO: 85. In some embodiments, the probe oligomer comprises atleast 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25contiguous nucleotides of SEQ ID NO: 40. In some embodiments, the probeoligomer comprises the sequence of SEQ ID NO: 40.

Also provided is an amplification oligomer comprising atarget-hybridizing region comprising at least 10 contiguous nucleotidesof SEQ ID NO: 35 including the inosine at position 30 of SEQ ID NO: 35and at least 14 contiguous nucleotides of HBV sequence. In someembodiments, the amplification oligomer comprising a subsequence of SEQID NO: 34 or 35 comprises at least 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 contiguousnucleotides of SEQ ID NO: 35. In some embodiments, the amplificationoligomer comprising a subsequence of SEQ ID NO: 34 or 35 comprises thesequence of SEQ ID NO: 35. In some embodiments, the amplificationoligomer comprising a subsequence of SEQ ID NO: 34 or 35 comprises thesequence of SEQ ID NO: 31.

In some embodiments, at least one probe oligomer comprises anon-nucleotide detectable label. In some embodiments, the non-nucleotidedetectable label is a fluorescent label. In some embodiments, the probeoligomer comprises a quencher. In some embodiments, the non-nucleotidedetectable label is a fluorescent label and the quencher absorbsfluorescence to a greater extent when the probe is free than when theprobe is annealed to a target nucleic acid. In some embodiments, thefluorescent label is FAM, HEX, or acridine. In some embodiments, thequencher is DABCYL or ROX. In some embodiments, the fluorescent label isattached to the 5′-terminus of the probe oligomer and the quencher isattached to the 3′-terminus of the probe oligomer, or the fluorescentlabel is attached to the 3′-terminus of the probe oligomer and thequencher is attached to the 5′-terminus of the probe oligomer. In someembodiments, at least about half, at least about 90%, or all of thesugars in the probe oligomer are 2′-O-methyl-ribose. In someembodiments, the probe oligomer comprises a first self-complementaryregion at its 5′ end and a second self-complementary region at its 3′end. In some embodiments, the self-complementary regions can hybridizeto form about 4 to 7 Watson-Crick or wobble base pairs. In someembodiments, the self-complementary regions can hybridize to form about5 Watson-Crick or wobble base pairs.

Also provided is a composition or kit comprising two or more differentcapture oligomers selected from the following capture oligomers(i)-(iv): (i) a first capture oligomer comprising a target-hybridizingsequence comprising at least 10 contiguous nucleotides of SEQ ID NO: 49or 99; (ii) a second capture oligomer comprising a target-hybridizingsequence comprising at least 10 contiguous nucleotides of SEQ ID NO: 53,100, 101, or 104; (iii) a third capture oligomer comprising atarget-hybridizing sequence comprising at least 10 contiguousnucleotides of SEQ ID NO: 57, 96, or 102; (iv) a fourth capture oligomercomprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of SEQ ID NO: 61, 97, 98, or 103; wherein thetarget-hybridizing sequences of the two or more different captureoligomers each comprise at least about 14 contiguous nucleotides ofHepatitis B virus sequence or a complement thereof.

Also provided is a method of isolating HBV nucleic acid from a sample,comprising contacting the sample with two or more different captureoligomers selected from the following capture oligomers (i)-(iv) underconditions permissive for forming one or more complexes of a captureoligomer and HBV nucleic acid, thereby forming a composition: (i) afirst capture oligomer comprising a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of SEQ ID NO: 49 or 99;(ii) a second capture oligomer comprising a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of SEQ ID NO: 53, 100,101, or 104; (iii) a third capture oligomer comprising atarget-hybridizing sequence comprising at least 10 contiguousnucleotides of SEQ ID NO: 57, 96, or 102; (iv) a fourth capture oligomercomprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of SEQ ID NO: 61, 97, 98, or 103; wherein thetarget-hybridizing sequences of the two or more different captureoligomers each comprise at least about 14 contiguous nucleotides ofHepatitis B virus sequence or a complement thereof, and isolating thecapture oligomers from the composition. In some embodiments, isolatingthe capture oligomers comprises associating the capture oligomers with asolid support, and washing the solid support. In some embodiments, thesolid support comprises a poly-N sequence which is complementary to aportion of at least one or at least two capture oligomers. In someembodiments, the solid support comprises a binding agent that recognizesan affinity tag present in at least one or at least two captureoligomers.

In some embodiments, the composition or kit comprises at least three ofthe capture oligomers (i)-(iv). In some embodiments, the composition orkit comprises capture oligomers (i)-(iv).

In some embodiments, the first capture oligomer comprises atarget-hybridizing sequence comprising at least one of SEQ ID NOs: 50,51, and 52. In some embodiments, the first capture oligomer comprises atleast 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24contiguous nucleotides of SEQ ID NO: 49. In some embodiments, the firstcapture oligomer comprises the sequence of SEQ ID NO: 49.

In some embodiments, the second capture oligomer comprises atarget-hybridizing sequence comprising at least one of SEQ ID NOs: 54,55, and 56. In some embodiments, the second capture oligomer comprisesthe sequence at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, or 24 contiguous nucleotides of SEQ ID NO: 53. In some embodiments,the second capture oligomer comprises of SEQ ID NO: 53.

In some embodiments, the third capture oligomer comprises atarget-hybridizing sequence comprising at least one of SEQ ID NOs: 58,59, and 60. In some embodiments, the third capture oligomer comprises atleast 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25contiguous nucleotides of SEQ ID NO: 57. In some embodiments, the thirdcapture oligomer comprises the sequence of SEQ ID NO: 57.

In some embodiments, the fourth capture oligomer comprises atarget-hybridizing sequence comprising at least one of SEQ ID NOs: 62,63, and 64. In some embodiments, the fourth capture oligomer comprisesat least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,or 27 contiguous nucleotides of SEQ ID NO: 61. In some embodiments, thefourth capture oligomer comprises the sequence of SEQ ID NO: 61.

In some embodiments, at least one of the capture oligomers furthercomprises a non-nucleotide affinity label. In some embodiments, at leastone of the capture oligomers further comprises a non-HBV sequence. Insome embodiments, the two, three, or four capture oligomers furthercomprise a non-HBV sequence. In some embodiments, at least one, two,three, or four capture oligomers further comprise a poly-N sequence. Insome embodiments, the poly-N sequence is a poly-A or poly-T sequence.

In some embodiments, the composition or kit further comprises at leastone amplification oligomer selected from a first amplification oligomercomprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 2 or 3; a secondamplification oligomer comprising a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of one of SEQ ID NOs: 20,21, or 22; a third amplification oligomer comprising atarget-hybridizing sequence comprising at least 10 contiguousnucleotides of SEQ ID NO: 41; a the fourth amplification oligomercomprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 34 or 35; wherein thetarget-hybridizing sequences of the first, second, third, and fourthamplification oligomers each comprise at least about 14 contiguousnucleotides of Hepatitis B virus sequence or a complement thereof.

In some embodiments, the composition or kit comprises a firstamplification oligomer disclosed herein. In some embodiments, thecomposition or kit comprises a second amplification oligomer disclosedherein. In some embodiments, the second amplification oligomer comprisesat least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or26 contiguous nucleotides of SEQ ID NO: 22 and the composition or kitfurther comprises an additional amplification oligomer that is differentfrom the second amplification oligomer and comprises at least 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28contiguous nucleotides of SEQ ID NO: 20. In some embodiments, the secondamplification oligomer comprises the sequence of SEQ ID NO: 22. In someembodiments, the additional amplification oligomer comprises thesequence of SEQ ID NO: 20. The composition, kit, or method of any one ofclaims 113-118, wherein the composition or kit comprises a thirdamplification oligomer disclosed herein. In some embodiments, thecomposition or kit comprises a amplification oligomer comprising atarget-hybridizing sequence comprising at least 10 contiguousnucleotides of one of SEQ ID NOs: 34 or 35 disclosed herein.

In some embodiments, a method further comprises performing a linearamplification wherein at least one amplification oligomer is extended.In some embodiments, prior to the linear amplification, theamplification oligomer is associated with a complex of HBV nucleic acidand a capture oligomer and the complex is associated with a solidsupport, and the method comprises washing the solid support. In someembodiments, the solid support is a population of microbeads. In someembodiments, the microbeads of the population are magnetic. In someembodiments, following the washing step, the method comprises adding oneor more additional amplification oligomers oppositely oriented to anamplification oligomer associated with the complex of HBV nucleic acidand the capture oligomer. In some embodiments, one or more oppositelyoriented additional amplification oligomer is a promoter-primer. In someembodiments, one or more oppositely oriented additional amplificationoligomer is not a promoter-primer. In some embodiments, the one or moreoppositely oriented additional amplification oligomer includes a thefirst amplification oligomer disclosed herein. In some embodiments, theone or more oppositely oriented additional amplification oligomerincludes a second amplification oligomer disclosed herein. In someembodiments, the one or more oppositely oriented additionalamplification oligomer includes a third amplification oligomer disclosedherein. In some embodiments, the one or more oppositely orientedadditional amplification oligomer includes a amplification oligomercomprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 34 or 35 disclosed herein.

In some embodiments, a method further comprises performing anexponential amplification following the linear amplification. In someembodiments, the exponential amplification is transcription-mediatedamplification.

In some embodiments, one, two, three, four, or more target-hybridizingsequences of an oligomer comprise at least about 15, 16, 17, 18, 19, 20,21, 22, 23, 24, or 25 contiguous nucleotides of Hepatitis B virussequence or a complement thereof.

Also provided is a method of determining a level of Hepatitis B virus ina sample comprising first and second Hepatitis B amplicons associatedwith first and second labels, respectively, the method comprising:detecting a first signal emitted from the first label; detecting asecond signal emitted from the second label; determining whether thefirst signal or the second signal is above a predetermined threshold;and calculating a level of Hepatitis B virus in the sample, wherein ifthe first signal or the second signal is above a predeterminedthreshold, the level is calculated from the greater of the first andsecond signals; and wherein if the first signal and the second signalare below a predetermined threshold, the level is calculated from anaverage of the first and second signals.

In some embodiments, the sample is an in vitro sample. In someembodiments, the method comprises determining the average of the firstand second signals by determining first and second levels correspondingto the first and second signals, and arithmetically averaging the firstand second levels. In some embodiments, the level of Hepatitis B virusis a concentration. In some embodiments, the level of Hepatitis B virusis an amount. In some embodiments, one or both of the first and secondamplicons comprise sequence from the S ORF of HBV. In some embodiments,one or both of the first and second amplicons comprise sequence from theP ORF of HBV. In some embodiments, one or both of the first and secondamplicons comprise sequence from the overlap of the S and P ORFs of HBV.In some embodiments, the first amplicon comprises at least 10, 11, 12,13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleotides of one of SEQID NOs: 2 or 3. In some embodiments, the first amplicon comprises atleast 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguousnucleotides of one of SEQ ID NOs: 20, 21, or 22. In some embodiments,the second amplicon comprises at least 10, 11, 12, 13, 14, 15, 16, 17,18, 19, or 20 contiguous nucleotides of SEQ ID NO: 41. In someembodiments, the second amplicon comprises at least 10, 11, 12, 13, 14,15, 16, 17, 18, 19, or 20 contiguous nucleotides of one of SEQ ID NOs:34 or 35.

In some embodiments, the predetermined threshold is at a value whereexpected random error is greater than or about equal to expected errordue to a point mutation. In some embodiments, the predeterminedthreshold is at a value where expected error due to a point mutation isgreater than or about equal to expected random error. In someembodiments, the predetermined threshold corresponds to a concentrationin the range of about 10 IU/ml to about 200 IU/ml. In some embodiments,the predetermined threshold is in the range of about 20 IU/ml to about40 IU/ml, about 40 IU/ml to about 60 IU/ml, about 60 IU/ml to about 80IU/ml, or about 80 IU/ml to about 100 IU/ml.

In some embodiments, the first label, the second label, or both arefluorescent. In some embodiments, at least one of the first and secondlabels is attached to a probe. In some embodiments, the probe comprisesa quencher.

Also provided is a kit or composition comprising a probe oligomerdisclosed herein. Also provided is a kit or composition comprising anamplification oligomer disclosed herein. In some embodiments, the kit orcomposition further comprises a probe oligomer disclosed herein.

In some embodiments, a kit or composition further comprises at leastone, two, three, or four of a first amplification oligomer disclosedherein; a second amplification oligomer disclosed herein; a thirdamplification oligomer disclosed herein; or a fourth amplificationoligomer disclosed herein.

In some embodiments, a kit or composition further comprises at leastone, two, three, or four of a first capture oligomer disclosed herein; asecond capture oligomer disclosed herein; a third capture oligomerdisclosed herein; or a fourth capture oligomer disclosed herein.

In some embodiments, a kit or composition further comprises at least oneor two of a fifth amplification oligomer disclosed herein; or a sixthamplification oligomer disclosed herein.

In some embodiments, a kit or composition further comprises anadditional amplification oligomer disclosed herein, wherein, if the kitor composition comprises a second amplification oligomer disclosedherein, the additional amplification oligomer is different from thesecond amplification oligomer.

In some embodiments, one, two or more oligomers disclosed herein areprovided in a kit. In some embodiments, one, two or more oligomersdisclosed herein are provided in a composition. In some embodiments, thecomposition is aqueous, frozen, or lyophilized.

Section headings are provided for the convenience of the reader and donot limit the scope of the disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows an alignment of exemplary target capture oligomers 0707band 733 with HBV clone sequences representative of genotypes A-H.

FIGS. 1B-C show an alignment of exemplary target capture oligomers 1290and 1168, respectively, with the 10 most common HBV database sequencesat the corresponding locations. Rows are labeled with individual letters(which do not necessarily correspond to HBV genotype nomenclature) andthe frequency of matching sequences is indicated. Dots indicate matchesto the oligomer and mismatches are shown with letters. The series of N'sin row H of FIG. 1B and row G of FIG. 1C indicate HBV sequences with aninternal deletion.

FIG. 1D shows an alignment of exemplary oligomers with sequences ofdifferent HBV clones in a region encompassing HBV positions 376-474.FIG. 1D (cont.) is a continuation of the alignment from the right end ofFIG. 1D.

FIG. 2A shows an alignment of exemplary oligomers with sequences ofdifferent HBV clones in which differences relative to the 376-402 T7amplification oligomer (SEQ ID NO: 15) are shown.

FIG. 2B shows an alignment of exemplary oligomers, a representative HBVgenotype A sequence, and the HBV sequence of GenBank Accession No.AB674430, which contains a 108 nucleotide deletion. FIG. 2B (cont.) is acontinuation of the alignment from the right end of FIG. 2B.

FIG. 3 shows an alignment of exemplary oligomers with sequences ofdifferent HBV clones in a region encompassing HBV positions 640-720.FIG. 3 (cont.) is a continuation of the alignment from the right end ofFIG. 3.

FIGS. 4A-D show emergence curves for experiments in the absence (A-B)and presence (C-D) of initial amplification oligomers A376 and A35.FIGS. 4A and 4C show detection of the amplicon detected by the 408-435probe oligomer. FIGS. 4B and 4D show detection of the amplicon detectedby the 668A probe oligomer. Arrows indicate traces for 2,000 IU/mlsamples and brackets indicate traces for lower-concentration samples.Traces for the lowest concentration (2 IU/ml) are in gray and traces forthe intermediate concentration (10 IU/ml) are in black.

FIG. 5 shows log difference of observed relative to expectedquantification for an exemplary quantification method (white bars)compared to commercially available assays from Abbott (striped bars) andRoche (black bars) performed on the PEI Genotype Panel.

FIG. 6A shows a scatter plot demonstrating reproducibility of HBVquantification.

FIGS. 6B-C show calibration curves for converting emergence time to logcopies/ml for amplicons 1 and 2, respectively.

DETAILED DESCRIPTION A. Definitions

Before describing the present teachings in detail, it is to beunderstood that the disclosure is not limited to specific compositionsor process steps, as such may vary. It should be noted that, as used inthis specification and the appended claims, the singular form “a”, “an”and “the” include plural references unless the context clearly dictatesotherwise. Thus, for example, reference to “an oligomer” includes aplurality of oligomers and the like.

It will be appreciated that there is an implied “about” prior to thetemperatures, concentrations, times, etc. discussed in the presentdisclosure, such that slight and insubstantial deviations are within thescope of the present teachings herein. In general, the term “about”indicates insubstantial variation in a quantity of a component of acomposition not having any significant effect on the activity orstability of the composition. Also, the use of “comprise”, “comprises”,“comprising”, “contain”, “contains”, “containing”, “include”,“includes”, and “including” are not intended to be limiting. It is to beunderstood that both the foregoing general description and detaileddescription are exemplary and explanatory only and are not restrictiveof the teachings. To the extent that any material incorporated byreference is inconsistent with the express content of this disclosure,the express content controls.

Unless specifically noted, embodiments in the specification that recite“comprising” various components are also contemplated as “consisting of”or “consisting essentially of” the recited components; embodiments inthe specification that recite “consisting of” various components arealso contemplated as “comprising” or “consisting essentially of” therecited components; and embodiments in the specification that recite“consisting essentially of” various components are also contemplated as“consisting of” or “comprising” the recited components (thisinterchangeability does not apply to the use of these terms in theclaims).

“Sample” includes any specimen that may contain hepatitis B virus (HBV)or components thereof such as nucleic acids or fragments of nucleicacids. Samples include “biological samples” which include any tissue ormaterial derived from a living or dead human that may contain HBV ortarget nucleic acid derived therefrom, including e.g., peripheral blood,plasma, serum, lymph node, gastrointestinal tissue (e.g., liver), orother body fluids or materials. The biological sample may be treated tophysically or mechanically disrupt tissue or cell structure, thusreleasing intracellular components into a solution which may furthercontain enzymes, buffers, salts, detergents and the like, which are usedto prepare, using standard methods, a biological sample for analysis.Also, samples may include processed samples, such as those obtained frompassing samples over or through a filtering device, or followingcentrifugation, or by adherence to a medium, matrix, or support.

“Nucleic acid” refers to a multimeric compound comprising two or morecovalently bonded nucleosides or nucleoside analogs having nitrogenousheterocyclic bases, or base analogs, where the nucleosides are linkedtogether by phosphodiester bonds or other linkages to form apolynucleotide. Nucleic acids include RNA, DNA, or chimeric DNA-RNApolymers or oligonucleotides, and analogs thereof. A nucleic acid“backbone” may be made up of a variety of linkages, including one ormore of sugar-phosphodiester linkages, peptide-nucleic acid bonds (in“peptide nucleic acids” or PNAs, see, e.g., International PatentApplication Pub. No. WO 95/32305), phosphorothioate linkages,methylphosphonate linkages, or combinations thereof. Sugar moieties ofthe nucleic acid may be either ribose or deoxyribose, or similarcompounds having known substitutions such as, for example, 2′-methoxysubstitutions and 2′-halide substitutions (e.g., 2′-F). Nitrogenousbases may be conventional bases (A, G, C, T, U), analogs thereof (e.g.,inosine, 5-methylisocytosine, isoguanine; see, e.g., The Biochemistry ofthe Nucleic Acids 5-36, Adams et al., ed., 11th ed., 1992; Abraham etal., 2007, BioTechniques 43: 617-24), which include derivatives ofpurine or pyrimidine bases (e.g., N⁴-methyl deoxyguanosine, deaza- oraza-purines, deaza- or aza-pyrimidines, pyrimidine bases havingsubstituent groups at the 5 or 6 position, purine bases having analtered or replacement substituent at the 2, 6 and/or 8 position, suchas 2-amino-6-methylaminopurine, O⁶-methylguanine, 4-thio-pyrimidines,4-amino-pyrimidines, 4-dimethylhydrazine-pyrimidines, andO⁴-alkyl-pyrimidines, and pyrazolo-compounds, such as unsubstituted or3-substituted pyrazolo[3,4-d]pyrimidine; U.S. Pat. Nos. 5,378,825,6,949,367 and International Patent Application Pub. No. WO 93/13121,each incorporated by reference herein). Nucleic acids may include“abasic” residues in which the backbone does not include a nitrogenousbase for one or more residues (see. e.g., U.S. Pat. No. 5,585,481,incorporated by reference herein). A nucleic acid may comprise onlyconventional sugars, bases, and linkages as found in RNA and DNA, or mayinclude conventional components and substitutions (e.g., conventionalbases linked by a 2′-methoxy backbone, or a nucleic acid including amixture of conventional bases and one or more base analogs). Nucleicacids may include “locked nucleic acids” (LNA), in which one or morenucleotide monomers have a bicyclic furanose unit locked in an RNAmimicking sugar conformation, which enhances hybridization affinitytoward complementary sequences in single-stranded RNA (ssRNA),single-stranded DNA (ssDNA), or double-stranded DNA (dsDNA) (Vester etal., Biochemistry 43:13233-41, 2004, incorporated by reference herein).Nucleic acids may include modified bases to alter the function orbehavior of the nucleic acid, e.g., addition of a 3′-terminaldideoxynucleotide to block additional nucleotides from being added tothe nucleic acid. Synthetic methods for making nucleic acids in vitroare well-known in the art although nucleic acids may be purified fromnatural sources using routine techniques.

A sequence is a “Hepatitis B virus sequence” if it or its complementoccurs in, is at least about 90% or at least about 95% identical to, orcontains no more than one mismatch relative to any genotype, subtype, orisolate of HBV, thereto, such that, for example, “14 contiguousnucleotides of Hepatitis B virus sequence” refers to a 14-mer thatmatches at least 13 out of 14 positions of a genotype, subtype, orisolate of HBV, or the complement thereof. The presence of a U isconsidered equivalent to a T and vice versa for purposes of determiningwhether a sequence qualifies as a Hepatitis B virus sequence. Thetarget-hybridizing regions of exemplary oligomers disclosed herein, theHBV-derived sequence of in vitro transcripts disclosed herein, andsubsequences thereof are also considered Hepatitis B virus sequence.Thus, examples of Hepatitis B virus sequence include SEQ ID NOs: 1-7,20-28, 34-39, 49-64, 69-76, 82-84, and 96-125, along with the full HBVgenomic sequences referred to by accession number in the Table ofSequences. In some embodiments, the genotype, subtype, or isolate of HBVreferred to above is a known genotype, subtype, or isolate of HBV, e.g.,which is present in a sequence database or publication available at thedate of this disclosure. When numeric positions in an HBV nucleic acidare referred to, such positions are with reference to SEQ ID NO: 1,which is an HBV genotype A1 sequence. It is understood that positionsmay vary in other genotypes; for example, position 700 in SEQ ID NO: 1aligns to position 703 of the HBV genotype F1a sequence of SEQ ID NO:101. Corresponding positions can be determined using an appropriatealignment algorithm such as the Needleman-Wunsch algorithm with standardparameters.

When an oligomer comprises, e.g., “at least 10 contiguous nucleotidesof” a specified SEQ ID NO and “at least about 14 contiguous nucleotidesof Hepatitis B virus sequence,” the same nucleotides can be countedtoward both (i) and (ii), e.g., the at least 14 contiguous nucleotidesof Hepatitis B virus sequence can comprise any or all of the at least 10contiguous nucleotides of the specified SEQ ID NO, to the extentconsistent with the foregoing definition of Hepatitis B virus sequence.Similarly, an “oligomer comprises a target-hybridizing sequencecomprising at least two” (or more) of a plurality of specified SEQ IDNOs if each of the sequence of the SEQ ID NOs is present, regardless ofwhether they overlap. Thus, as a simplified example, CAT comprises bothCA and AT.

For two molecules to “anneal to at least N common position(s)” meansthat the molecules have hybridization sites that overlap by N or morenucleotides on the same or opposite strands of a target nucleic acid,e.g., an HBV nucleic acid. For example, a first oligomer that isconfigured to specifically hybridize to positions 655-681 and a secondoligomer that is configured to specifically hybridize to positions679-699 anneal to three common positions (679, 680, and 681) regardlessof whether (i) they are both configured to specifically hybridize to thesame strand or (ii) one is configured to specifically hybridize to thesense or (+) strand and the other is configured to specificallyhybridize to the antisense or (−) strand.

The term “polynucleotide” as used herein denotes a nucleic acid chain.Throughout this application, nucleic acids are designated by the5′-terminus to the 3′-terminus. Synthetic nucleic acids, e.g., DNA, RNA,DNA/RNA chimerics, (including when non-natural nucleotides or analoguesare included therein), are typically synthesized “3′-to-5′,” i.e., bythe addition of nucleotides to the 5′-terminus of a growing nucleicacid.

A “nucleotide” as used herein is a subunit of a nucleic acid consistingof a phosphate group, a 5-carbon sugar, and a nitrogenous base (alsoreferred to herein as “nucleobase”). The 5-carbon sugar found in RNA isribose. In DNA, the 5-carbon sugar is 2′-deoxyribose. The term alsoincludes analogs of such subunits, such as a methoxy group at the 2′position of the ribose (also referred to herein as “2′-O-Me” or“2′-methoxy”). As used herein, methoxy oligonucleotides containing “T”residues have a methoxy group at the 2′ position of the ribose moiety,and a uracil at the base position of the nucleotide.

A “non-nucleotide unit” as used herein is a unit that does notsignificantly participate in hybridization of a polymer. Such units donot, for example, participate in any significant hydrogen bonding with anucleotide, and would exclude units having as a component one of thefive nucleotide bases or analogs thereof.

A “target nucleic acid” as used herein is a nucleic acid comprising atarget sequence to be amplified. Target nucleic acids may be DNA or RNAas described herein, and may be either single-stranded ordouble-stranded. The target nucleic acid may include other sequencesbesides the target sequence, which may not be amplified.

The term “target sequence” as used herein refers to the particularnucleotide sequence of the target nucleic acid that is to be amplifiedand/or detected. The “target sequence” includes the complexing sequencesto which oligonucleotides (e.g., priming oligonucleotides and/orpromoter oligonucleotides) complex during an amplification processes(e.g., TMA). Where the target nucleic acid is originallysingle-stranded, the term “target sequence” will also refer to thesequence complementary to the “target sequence” as present in the targetnucleic acid. Where the target nucleic acid is originallydouble-stranded, the term “target sequence” refers to both the sense (+)and antisense (−) strands. The (+) strand corresponds to the viral mRNAsequence and the (−) is the complement thereof. The exemplary genotype Asequence of SEQ ID NO: 1 represents a (+) strand.

“Target-hybridizing sequence” is used herein to refer to the portion ofan oligomer that is configured to hybridize with a target nucleic acidsequence. In some embodiments, the target-hybridizing sequences areconfigured to specifically hybridize with a target nucleic acidsequence. Target-hybridizing sequences may be 100% complementary to theportion of the target sequence to which they are configured tohybridize, but not necessarily. Target-hybridizing sequences may alsoinclude inserted, deleted and/or substituted nucleotide residuesrelative to a target sequence. Less than 100% complementarity of atarget-hybridizing sequence to a target sequence may arise, for example,when the target nucleic acid is a plurality strains within a species,such as would be the case for an oligomer configured to hybridize tovarious genotypes of HBV. It is understood that other reasons exist forconfiguring a target-hybridizing sequence to have less than 100%complementarity to a target nucleic acid.

The term “targets a sequence” as used herein in reference to a region ofHBV nucleic acid refers to a process whereby an oligonucleotidehybridizes to the target sequence in a manner that allows foramplification and detection as described herein. In one preferredembodiment, the oligonucleotide is complementary with the targeted HBVnucleic acid sequence and contains no mismatches. In another preferredembodiment, the oligonucleotide is complementary but contains 1, 2, 3,4, or 5 mismatches with the targeted HBV nucleic acid sequence. In someembodiments, the oligonucleotide that hybridizes to the HBV nucleic acidsequence includes at least 10 to as many as 50 nucleotides complementaryto the target sequence. It is understood that at least 10 and as many as50 is an inclusive range such that 10, 50 and each whole number therebetween are included. In some embodiments, the oligomer specificallyhybridizes to the target sequence.

The term “configured to” denotes an actual arrangement of thepolynucleotide sequence configuration of a referenced oligonucleotidetarget-hybridizing sequence. For example, amplification oligomers thatare configured to generate a specified amplicon from a target sequencehave polynucleotide sequences that hybridize to the target sequence andcan be used in an amplification reaction to generate the amplicon. Alsoas an example, oligonucleotides that are configured to specificallyhybridize to a target sequence have a polynucleotide sequence thatspecifically hybridizes to the referenced sequence under stringenthybridization conditions.

The term “configured to specifically hybridize to” as used herein meansthat the target-hybridizing region of an amplification oligonucleotide,detection probe, or other oligonucleotide is designed to have apolynucleotide sequence that could target a sequence of the referencedHBV target region. Such an oligonucleotide is not limited to targetingthat sequence only, but is rather useful as a composition, in a kit, orin a method for targeting a HBV target nucleic acid. The oligonucleotideis designed to function as a component of an assay for amplification anddetection of HBV from a sample, and therefore is designed to target HBVin the presence of other nucleic acids commonly found in testingsamples. “Specifically hybridize to” does not mean exclusively hybridizeto, as some small level of hybridization to non-target nucleic acids mayoccur, as is understood in the art. Rather, “specifically hybridize to”means that the oligonucleotide is configured to function in an assay toprimarily hybridize the target so that an accurate detection of targetnucleic acid in a sample can be determined. “Upstream” refers to alocation closer to the 5′ end of the (+) strand (or the 3′ end of the(−) strand) than a given position. “Downstream” refers to a locationcloser to the 3′ end of the (+) strand (or the 5′ end of the (−) strand)than a given position.

The term “fragment,” as used herein in reference to the targeted HBVnucleic acid, refers to a piece of contiguous nucleic acid. In certainembodiments, the fragment includes contiguous nucleotides from an HBVRNA corresponding to SEQ ID NO: 1, wherein the number of contiguousnucleotides in the fragment are less than that for the entire sequencecorresponding to SEQ ID NO:1.

The term “region,” as used herein, refers to a portion of a nucleic acidwherein said portion is smaller than the entire nucleic acid. Forexample, when the nucleic acid in reference is an oligonucleotidepromoter primer, the term “region” may be used to refer to the smallerpromoter portion of the entire oligonucleotide. Similarly, and also asexample only, when the nucleic acid is an HBV nucleic acid, the term“region” may be used to refer to a smaller area of the nucleic acid,wherein the smaller area is targeted by one or more oligonucleotides ofthe disclosure. As another non-limiting example, when the nucleic acidin reference is an amplicon, the term region may be used to refer to thesmaller nucleotide sequence identified for hybridization by thetarget-hybridizing sequence of a probe.

The interchangeable terms “oligomer,” “oligo,” and “oligonucleotide”refer to a nucleic acid having generally less than 1,000 nucleotide (nt)residues, including polymers in a range having a lower limit of about 5nt residues and an upper limit of about 500 to 900 nt residues. In someembodiments, oligonucleotides are in a size range having a lower limitof about 12 to 15 nt and an upper limit of about 50 to 600 nt, and otherembodiments are in a range having a lower limit of about 15 to 20 nt andan upper limit of about 22 to 100 nt. Oligonucleotides may be purifiedfrom naturally occurring sources or may be synthesized using any of avariety of well-known enzymatic or chemical methods. The termoligonucleotide does not denote any particular function to the reagent;rather, it is used generically to cover all such reagents describedherein. An oligonucleotide may serve various different functions. Forexample, it may function as a primer if it is specific for and capableof hybridizing to a complementary strand and can further be extended inthe presence of a nucleic acid polymerase; it may function as a primerand provide a promoter if it contains a sequence recognized by an RNApolymerase and allows for transcription (e.g., a T7 Primer); and it mayfunction to detect a target nucleic acid if it is capable of hybridizingto the target nucleic acid, or an amplicon thereof, and further providesa detectible moiety (e.g., a fluorophore).

As used herein, an oligonucleotide “substantially corresponding to” aspecified reference nucleic acid sequence means that the oligonucleotideis sufficiently similar to the reference nucleic acid sequence such thatthe oligonucleotide has similar hybridization properties to thereference nucleic acid sequence in that it would hybridize with the sametarget nucleic acid sequence under stringent hybridization conditions.One skilled in the art will understand that “substantially correspondingoligonucleotides” can vary from a reference sequence and still hybridizeto the same target nucleic acid sequence. It is also understood that afirst nucleic acid corresponding to a second nucleic acid includes theRNA or DNA equivalent thereof as well as DNA/RNA chimerics thereof andincludes the complements thereof unless the context clearly dictatesotherwise. This variation from the nucleic acid may be stated in termsof a percentage of identical bases within the sequence or the percentageof perfectly complementary bases between the probe or primer and itstarget sequence. Thus, in certain embodiments, an oligonucleotide“substantially corresponds” to a reference nucleic acid sequence ifthese percentages of base identity or complementarity are from 100% toabout 80%. In some embodiments, the percentage is from 100% to about85%. In some embodiments, this percentage is from 100% to about 90%,e.g., from 100% to about 95%. Similarly, a region of a nucleic acid oramplified nucleic acid can be referred to herein as corresponding to areference nucleic acid sequence. One skilled in the art will understandthe various modifications to the hybridization conditions that might berequired at various percentages of complementarity to allowhybridization to a specific target sequence without causing anunacceptable level of non-specific hybridization.

As used herein, a “blocking moiety” is a substance used to “block” the3′-terminus of an oligonucleotide or other nucleic acid so that itcannot be efficiently extended by a nucleic acid polymerase. Oligomersnot intended for extension by a nucleic acid polymerase may include ablocker group that replaces the 3′ OH to prevent enzyme-mediatedextension of the oligomer in an amplification reaction. For example,blocked amplification oligomers and/or detection probes present duringamplification may not have functional 3′ OH and instead include one ormore blocking groups located at or near the 3′ end. In some embodimentsa blocking group near the 3′ end and may be within five residues of the3′ end and is sufficiently large to limit binding of a polymerase to theoligomer. In other embodiments a blocking group is covalently attachedto the 3′ terminus. Many different chemical groups may be used to blockthe 3′ end, e.g., alkyl groups, non-nucleotide linkers, alkane-dioldideoxynucleotide residues, and cordycepin.

An “amplification oligomer” is an oligomer, at least the 3′-end of whichis complementary to a target nucleic acid, and which hybridizes to atarget nucleic acid, or its complement, and participates in a nucleicacid amplification reaction. An example of an amplification oligomer isa “primer” that hybridizes to a target nucleic acid and contains a 3′ OHend that is extended by a polymerase in an amplification process. Insome embodiments, the 5′ region of an amplification oligonucleotide mayinclude a promoter sequence that is non-complementary to the targetnucleic acid (which may be referred to as a “promoter primer”). Anotherexample of an amplification oligomer is an oligomer that is not extendedby a polymerase (e.g., because it has a 3′ blocked end) but participatesin or facilitates amplification. For example, the 5′ region of anamplification oligonucleotide may include a promoter sequence that isnon-complementary to the target nucleic acid (which may be referred toas a “promoter provider”). Those skilled in the art will understand thatan amplification oligomer that functions as a primer may be modified toinclude a 5′ promoter sequence, and thus function as a promoter primer.Incorporating a 3′ blocked end further modifies the promoter primer,which is now capable of hybridizing to a target nucleic acid andproviding an upstream promoter sequence that serves to initiatetranscription, but does not provide a primer for oligo extension. Such amodified oligo is referred to herein as a “promoter provider” oligomer.Size ranges for amplification oligonucleotides include those that areabout 10 to about 70 nt long (not including any promoter sequence orpoly-A tails) and contain at least about 10 contiguous bases, or even atleast 12 contiguous bases that are complementary to a region of thetarget nucleic acid sequence (or a complementary strand thereof). Thecontiguous bases are at least 80%, or at least 90%, or completelycomplementary to the target sequence to which the amplification oligomerbinds. An amplification oligomer may optionally include modifiednucleotides or analogs, or additional nucleotides that participate in anamplification reaction but are not complementary to or contained in thetarget nucleic acid, or template sequence. It is understood that whenreferring to ranges for the length of an oligonucleotide, amplicon, orother nucleic acid, that the range is inclusive of all whole numbers(e.g., 19-25 contiguous nucleotides in length includes 19, 20, 21, 22,23, 24 & 25).

As used herein, a “promoter” is a specific nucleic acid sequence that isrecognized by a DNA-dependent RNA polymerase (“transcriptase”) as asignal to bind to the nucleic acid and begin the transcription of RNA ata specific site.

As used herein, a “promoter provider” or “provider” refers to anoligonucleotide comprising first and second regions, and which ismodified to prevent the initiation of DNA synthesis from its3′-terminus. The “first region” of a promoter provider oligonucleotidecomprises a base sequence that hybridizes to a DNA template, where thehybridizing sequence is situated 3′, but not necessarily adjacent to, apromoter region. The hybridizing portion of a promoter oligonucleotideis typically at least 10 nucleotides in length, and may extend up to 50or more nucleotides in length. The “second region” comprises a promotersequence for an RNA polymerase. A promoter oligonucleotide is engineeredso that it is incapable of being extended by an RNA- or DNA-dependentDNA polymerase, e.g., reverse transcriptase, In some embodimentscomprising a blocking moiety at its 3′-terminus as described above. Asreferred to herein, a “T7 Provider” is a blocked promoter provideroligonucleotide that provides an oligonucleotide sequence that isrecognized by T7 RNA polymerase.

A “terminating oligonucleotide” is an oligonucleotide comprising a basesequence that is substantially complementary to a sequence within thetarget nucleic acid in the vicinity of the 5′-end of the target region,so as to “terminate” primer extension of a nascent nucleic acid thatincludes a priming oligonucleotide, thereby providing a defined 3′-endfor the nascent nucleic acid strand. A terminating oligonucleotide isdesigned to hybridize to the target nucleic acid at a positionsufficient to achieve the desired 3′-end for the nascent nucleic acidstrand. The positioning of the terminating oligonucleotide is flexibledepending upon its design. A terminating oligonucleotide may be modifiedor unmodified. In certain embodiments, terminating oligonucleotides aresynthesized with at least one or more 2′-O-ME ribonucleotides. Thesemodified nucleotides have demonstrated higher thermal stability ofcomplementary duplexes. The 2′-O-ME ribonucleotides also function toincrease the resistance of oligonucleotides to exonucleases, therebyincreasing the half-life of the modified oligonucleotides. (See, e.g.,Majlessi et al., Nucleic Acids Res. 26:2224-9, 1988, incorporated byreference herein.) Other modifications as described elsewhere herein maybe utilized in addition to or in place of 2′-O-Me ribonucleotides. Forexample, a terminating oligonucleotide may comprise PNA or an LNA. (See.e.g., Petersen et al., J. Mol. Recognit. 13:44-53, 2000, incorporated byreference herein.) A terminating oligonucleotide of the presentdisclosure typically includes a blocking moiety at its 3′-terminus toprevent extension. A terminating oligonucleotide may also comprise aprotein or peptide joined to the oligonucleotide so as to terminatefurther extension of a nascent nucleic acid chain by a polymerase. Aterminating oligonucleotide of the present disclosure is typically atleast 10 bases in length, and may extend up to 15, 20, 25, 30, 35, 40,50 or more nucleotides in length. While a terminating oligonucleotidetypically or necessarily includes a 3′-blocking moiety, “3′-blocked”oligonucleotides are not necessarily terminating oligonucleotides.

“Amplification” refers to any known procedure for obtaining multiplecopies of a target nucleic acid sequence or its complement or fragmentsthereof. The multiple copies may be referred to as amplicons oramplification products. Amplification of “fragments” refers toproduction of an amplified nucleic acid that contains less than thecomplete target nucleic acid or its complement, e.g., produced by usingan amplification oligonucleotide that hybridizes to, and initiatespolymerization from, an internal position of the target nucleic acid.Known amplification methods include, for example, replicase-mediatedamplification, polymerase chain reaction (PCR), ligase chain reaction(LCR), strand-displacement amplification (SDA), andtranscription-mediated or transcription-associated amplification.Replicase-mediated amplification uses self-replicating RNA molecules,and a replicase such as QB-replicase (see. e.g., U.S. Pat. No.4,786,600, incorporated by reference herein). PCR amplification uses aDNA polymerase, pairs of primers, and thermal cycling to synthesizemultiple copies of two complementary strands of dsDNA or from a cDNA(see. e.g., U.S. Pat. Nos. 4,683,195; 4,683,202; and 4,800,159; eachincorporated by reference herein). LCR amplification uses four or moredifferent oligonucleotides to amplify a target and its complementarystrand by using multiple cycles of hybridization, ligation, anddenaturation (see. e.g., U.S. Pat. Nos. 5,427,930 and 5,516,663, eachincorporated by reference herein). SDA uses a primer that contains arecognition site for a restriction endonuclease and an endonuclease thatnicks one strand of a hemimodified DNA duplex that includes the targetsequence, whereby amplification occurs in a series of primer extensionand strand displacement steps (see. e.g., U.S. Pat. Nos. 5,422,252;5,547,861; and 5,648,211; each incorporated by reference herein).

As used herein, the term “linear amplification” refers to anamplification mechanism that is designed to produce an increase in thetarget nucleic acid linearly proportional to the amount of targetnucleic acid in the reaction. For instance, multiple RNA copies can bemade from a DNA target using a transcription-associated reaction, wherethe increase in the number of copies can be described by a linear factor(e.g., starting copies of template×100). In some embodiments, a firstphase linear amplification in a multiphase amplification procedureincreases the starting number of target nucleic acid strands or thecomplements thereof by at least 10 fold, e.g., by at least 100 fold, orby 10 to 1,000 fold before the second phase amplification reaction isbegun. An example of a linear amplification system is “T7-based LinearAmplification of DNA” (TLAD; see Liu et al., BMC Genomics, 4: Art. No.19, May 9, 2003). Other methods are known, e.g., from U.S. Pat. No.9,139,870, or disclosed herein. Accordingly, the term “linearamplification” refers to an amplification reaction which does not resultin the exponential amplification of a target nucleic acid sequence. Theterm “linear amplification” does not refer to a method that simply makesa single copy of a nucleic acid strand, such as the transcription of anRNA molecule into a single cDNA molecule as in the case of reversetranscription (RT)-PCR

As used herein, the term “exponential amplification” refers to nucleicacid amplification that is designed to produce an increase in the targetnucleic acid geometrically proportional to the amount of target nucleicacid in the reaction. For example, PCR produces one DNA strand for everyoriginal target strand and for every synthesized strand present.Similarly, transcription-associated amplification produces multiple RNAtranscripts for every original target strand and for every subsequentlysynthesized strand. The amplification is exponential because thesynthesized strands are used as templates in subsequent rounds ofamplification. An amplification reaction need not actually produceexponentially increasing amounts of nucleic acid to be consideredexponential amplification, so long as the amplification reaction isdesigned to produce such increases.

“Transcription-associated amplification” or “transcription-mediatedamplification” (TMA) refer to nucleic acid amplification that uses anRNA polymerase to produce multiple RNA transcripts from a nucleic acidtemplate. These methods generally employ an RNA polymerase, a DNApolymerase, deoxyribonucleoside triphosphates, ribonucleosidetriphosphates, and a template complementary oligonucleotide thatincludes a promoter sequence, e.g., a T7 promoter, and optionally mayinclude one or more other oligonucleotides. When a T7promoter-containing oligomer is used, it may be referred to as a “T7primer” or “T7 oligomer”; other primers/oligomers may be referred to as“non-T7” or “NT7” primers/oligomers. TMA methods and single-primertranscription-associated amplification methods are embodiments ofamplification methods used for detection of HBV target sequences asdescribed herein. Variations of transcription-associated amplificationare well-known in the art as previously disclosed in detail (see. e.g.,U.S. Pat. Nos. 4,868,105; 5,124,246; 5,130,238; 5,399,491; 5,437,990;5,554,516; and 7,374,885; and International Patent Application Pub. Nos.WO 88/01302; WO 88/10315; and WO 95/03430; each incorporated byreference herein). The person of ordinary skill in the art willappreciate that the disclosed compositions may be used in amplificationmethods based on extension of oligomer sequences by a polymerase.

As used herein, the term “real-time TMA” refers to single-primertranscription-mediated amplification (“TMA”) of target nucleic acid thatis monitored through real-time detection.

The term “amplicon” or “amplification product” as used herein refers tothe nucleic acid molecule generated during an amplification procedurethat is complementary or homologous to a sequence contained within thetarget sequence. The complementary or homologous sequence of an ampliconis sometimes referred to herein as a “target-specific sequence.”Amplicons generated using the amplification oligomers of the currentdisclosure may comprise non-target specific sequences. Amplicons can bedouble-stranded or single-stranded and can include DNA, RNA, or both.For example, DNA-dependent RNA polymerase transcribes single-strandedamplicons from double-stranded DNA during transcription-mediatedamplification procedures. These single-stranded amplicons are RNAamplicons and can be either strand of a double-stranded complex,depending on how the amplification oligomers are configured. Thus,amplicons can be single-stranded RNA. RNA-dependent DNA polymerasessynthesize a DNA strand that is complementary to an RNA template. Thus,amplicons can be double-stranded DNA and RNA hybrids. RNA-dependent DNApolymerases often include RNase activity, or are used in conjunctionwith an RNase, which degrades the RNA strand. Thus, amplicons can besingle stranded DNA. RNA-dependent DNA polymerases and DNA-dependent DNApolymerases synthesize complementary DNA strands from DNA templates.Thus, amplicons can be double-stranded DNA. RNA-dependent RNApolymerases synthesize RNA from an RNA template. Thus, amplicons can bedouble-stranded RNA. DNA-dependent RNA polymerases synthesize RNA fromdouble-stranded DNA templates, also referred to as transcription. Thus,amplicons can be single stranded RNA. Amplicons and methods forgenerating amplicons are known to those skilled in the art. Forconvenience herein, a single strand of RNA or a single strand of DNA mayrepresent an amplicon generated by an amplification oligomer combinationof the current disclosure. Such representation is not meant to limit theamplicon to the representation shown. Skilled artisans in possession ofthe instant disclosure will use amplification oligomers and polymeraseenzymes to generate any of the numerous types of amplicons, all withinthe spirit and scope of the current disclosure.

A “non-target-specific sequence,” as is used herein refers to a regionof an oligomer sequence, wherein said region does not stably hybridizewith a target sequence under standard hybridization conditions.Oligomers with non-target-specific sequences include, but are notlimited to, promoter primers and molecular beacons. An amplificationoligomer may contain a sequence that is not complementary to the targetor template sequence; for example, the 5′ region of a primer may includea promoter sequence that is non-complementary to the target nucleic acid(referred to as a “promoter primer”). Those skilled in the art willunderstand that an amplification oligomer that functions as a primer maybe modified to include a 5′ promoter sequence, and thus function as apromoter primer. Similarly, a promoter primer may be modified by removalof or synthesis without, a promoter sequence and still function as aprimer. A 3′ blocked amplification oligomer may provide a promotersequence and serve as a template for polymerization (referred to as a“promoter provider”). Thus, an amplicon that is generated by anamplification oligomer member such as a promoter primer will comprise atarget-specific sequence and a non-target-specific sequence.

“Detection probe,” “detection oligonucleotide,” “probe oligomer,” and“detection probe oligomer” are used interchangeably to refer to anucleic acid oligomer that hybridizes specifically to a target sequencein a nucleic acid, or in an amplified nucleic acid, under conditionsthat promote hybridization to allow detection of the target sequence oramplified nucleic acid. Detection may either be direct (e.g., a probehybridized directly to its target sequence) or indirect (e.g., a probelinked to its target via an intermediate molecular structure). Detectionprobes may be DNA, RNA, analogs thereof or combinations thereof (e.g.,DNA/RNA chimerics) and they may be labeled or unlabeled. Detectionprobes may further include alternative backbone linkages such as, e.g.,2′-O-methyl linkages. A detection probe's “target sequence” generallyrefers to a smaller nucleic acid sequence region within a larger nucleicacid sequence that hybridizes specifically to at least a portion of aprobe oligomer by standard base pairing. A detection probe may comprisetarget-specific sequences and other sequences that contribute to thethree-dimensional conformation of the probe (see. e.g., U.S. Pat. Nos.5,118,801; 5,312,728; 6,849,412; 6,835,542; 6,534,274; and 6,361,945;and US Patent Application Pub. No. 20060068417; each incorporated byreference herein).

By “stable” or “stable for detection” is meant that the temperature of areaction mixture is at least 2° C. below the melting temperature of anucleic acid duplex.

As used herein, a “label” refers to a moiety or compound joined directlyor indirectly to a probe that is detected or leads to a detectablesignal. Direct labeling can occur through bonds or interactions thatlink the label to the probe, including covalent bonds or non-covalentinteractions, e.g., hydrogen bonds, hydrophobic and ionic interactions,or formation of chelates or coordination complexes. Indirect labelingcan occur through use of a bridging moiety or “linker” such as a bindingpair member, an antibody or additional oligomer, which is eitherdirectly or indirectly labeled, and which may amplify the detectablesignal. Labels include any detectable moiety, such as a radionuclide,ligand (e.g., biotin, avidin), enzyme or enzyme substrate, reactivegroup, or chromophore (e.g., dye, particle, or bead that impartsdetectable color), luminescent compound (e.g., bioluminescent,phosphorescent, or chemiluminescent labels), or fluorophore. Labels maybe detectable in a homogeneous assay in which bound labeled probe in amixture exhibits a detectable change different from that of an unboundlabeled probe, e.g., instability or differential degradation properties.A “homogeneous detectable label” can be detected without physicallyremoving bound from unbound forms of the label or labeled probe (see.e.g., U.S. Pat. Nos. 5,283,174; 5,656,207; and 5,658,737; eachincorporated by reference herein). Labels include chemiluminescentcompounds, e.g., acridinium ester (“AE”) compounds that include standardAE and derivatives (see. e.g., U.S. Pat. Nos. 5,656,207; 5,658,737; and5,639,604; each incorporated by reference herein). Synthesis and methodsof attaching labels to nucleic acids and detecting labels are wellknown. (See. e.g., Sambrook et al. Molecular Cloning. A LaboratoryManual, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold SpringHarbor, N Y, 1989), Chapter 10, incorporated by reference herein. Seealso U.S. Pat. Nos. 5,658,737; 5,656,207; 5,547,842; 5,283,174; and4,581,333; each incorporated by reference herein). More than one label,and more than one type of label, may be present on a particular probe,or detection may use a mixture of probes in which each probe is labeledwith a compound that produces a detectable signal (see. e.g., U.S. Pat.Nos. 6,180,340 and 6,350,579, each incorporated by reference herein).

“Capture probe,” “capture oligonucleotide,” “capture oligomer,” “targetcapture oligomer,” and “capture probe oligomer” are used interchangeablyto refer to a nucleic acid oligomer that specifically hybridizes to atarget sequence in a target nucleic acid by standard base pairing andjoins to a binding partner on an immobilized probe to capture the targetnucleic acid to a support. One example of a capture oligomer includestwo binding regions: a sequence-binding region (e.g., target-specificportion) and an immobilized probe-binding region, usually on the sameoligomer, although the two regions may be present on two differentoligomers joined together by one or more linkers. Another embodiment ofa capture oligomer uses a target-sequence binding region that includesrandom or non-random poly-GU, poly-GT, or poly U sequences to bindnon-specifically to a target nucleic acid and link it to an immobilizedprobe on a support.

As used herein, an “immobilized oligonucleotide,” “immobilized probe,”“immobilized binding partner,” “immobilized oligomer,” or “immobilizednucleic acid” refers to a nucleic acid binding partner that joins acapture oligomer to a support, directly or indirectly. An immobilizedprobe joined to a support facilitates separation of a capture probebound target from unbound material in a sample. One embodiment of animmobilized probe is an oligomer joined to a support that facilitatesseparation of bound target sequence from unbound material in a sample.Supports may include known materials, such as matrices and particlesfree in solution, which may be made of nitrocellulose, nylon, glass,polyacrylate, mixed polymers, polystyrene, silane, polypropylene, metal,or other compositions, of which one embodiment is magneticallyattractable particles. Supports may be monodisperse magnetic spheres(e.g., uniform size+5%), to which an immobilized probe is joineddirectly (via covalent linkage, chelation, or ionic interaction), orindirectly (via one or more linkers), where the linkage or interactionbetween the probe and support is stable during hybridization conditions.

By “complementary” is meant that the nucleotide sequences of similarregions of two single-stranded nucleic acids, or two different regionsof the same single-stranded nucleic acid, have a nucleotide basecomposition that allow the single-stranded regions to hybridize togetherin a stable double-stranded hydrogen-bonded region under stringenthybridization or amplification conditions. Sequences that hybridize toeach other may be completely complementary or partially complementary tothe intended target sequence by standard nucleic acid base pairing(e.g., G:C, A:T, or A:U pairing). By “sufficiently complementary” ismeant a contiguous sequence that is capable of hybridizing to anothersequence by hydrogen bonding between a series of complementary bases,which may be complementary at each position in the sequence by standardbase pairing or may contain one or more residues, including abasicresidues, that are not complementary. Sufficiently complementarycontiguous sequences typically are at least 80%, or at least 90%,complementary to a sequence to which an oligomer is intended tospecifically hybridize. Sequences that are “sufficiently complementary”allow stable hybridization of a nucleic acid oligomer with its targetsequence under appropriate hybridization conditions, even if thesequences are not completely complementary. When a contiguous sequenceof nucleotides of one single-stranded region is able to form a series of“canonical” or “Watson-Crick” hydrogen-bonded base pairs with ananalogous sequence of nucleotides of the other single-stranded region,such that A is paired with U or T and C is paired with G, thenucleotides sequences are “completely” complementary (see. e.g.,Sambrook et al., Molecular Cloning. A Laboratory Manual, 2nd ed. (ColdSpring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) at §§1.90-1.91, 7.37-7.57, 9.47-9.51 and 11.47-11.57, particularly §§9.50-9.51, 11.12-11.13, 11.45-11.47 and 11.55-11.57, incorporated byreference herein). It is understood that ranges for percent identity areinclusive of all whole and partial numbers (e.g., at least 90% includes90, 91, 93.5, 97.687, etc.). Reference to “the complement” of aparticular sequence generally indicates a completely complementarysequence unless the context indicates otherwise.

“Wobble” base pairs refer to a pairing of a G to either a U or a T.

By “preferentially hybridize” or “specifically hybridize” is meant thatunder stringent hybridization assay conditions, probes hybridize totheir target sequences, or replicates thereof, to form stableprobe:target hybrids, while at the same time formation of stableprobe:non-target hybrids is minimized. Thus, a probe hybridizes to atarget sequence or replicate thereof to a sufficiently greater extentthan to a non-target sequence, to enable one having ordinary skill inthe art to accurately detect or quantitate RNA replicates orcomplementary DNA (cDNA) of the target sequence formed during theamplification. Appropriate hybridization conditions are well-known inthe art, may be predicted based on sequence composition, or can bedetermined by using routine testing methods (see. e.g., Sambrook et al.,Molecular Cloning. A Laboratory Manual, 2nd ed. (Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y., 1989) at §§ 1.90-1.91,7.37-7.57, 9.47-9.51 and 11.47-11.57, particularly §§ 9.50-9.51,11.12-11.13, 11.45-11.47 and 11.55-11.57, incorporated by referenceherein).

By “nucleic acid hybrid,” “hybrid,” or “duplex” is meant a nucleic acidstructure containing a double-stranded, hydrogen-bonded region whereineach strand is complementary to the other, and wherein the region issufficiently stable under stringent hybridization conditions to bedetected by means including, but not limited to, chemiluminescent orfluorescent light detection, autoradiography, or gel electrophoresis.Such hybrids may comprise RNA:RNA, RNA:DNA, or DNA:DNA duplex molecules.

“Sample preparation” refers to any steps or method that treats a samplefor subsequent amplification and/or detection of HBV nucleic acidspresent in the sample. Samples may be complex mixtures of components ofwhich the target nucleic acid is a minority component. Samplepreparation may include any known method of concentrating components,such as microbes or nucleic acids, from a larger sample volume, such asby filtration of airborne or waterborne particles from a larger volumesample or by isolation of microbes from a sample by using standardmicrobiology methods. Sample preparation may include physical disruptionand/or chemical lysis of cellular components to release intracellularcomponents into a substantially aqueous or organic phase and removal ofdebris, such as by using filtration, centrifugation or adsorption.Sample preparation may include use of a nucleic acid oligonucleotidethat selectively or non-specifically capture a target nucleic acid andseparate it from other sample components (e.g., as described in U.S.Pat. No. 6,110,678 and International Patent Application Pub. No. WO2008/016988, each incorporated by reference herein).

“Separating” or “purifying” means that one or more components of asample are removed or separated from other sample components. Samplecomponents include target nucleic acids usually in a generally aqueoussolution phase, which may also include cellular fragments, proteins,carbohydrates, lipids, and other nucleic acids. “Separating” or“purifying” does not connote any degree of purification. Typically,separating or purifying removes at least 70%, or at least 80%, or atleast 95% of the target nucleic acid from other sample components.

As used herein, a “DNA-dependent DNA polymerase” is an enzyme thatsynthesizes a complementary DNA copy from a DNA template. Examples areDNA polymerase I from E. coli, bacteriophage T7 DNA polymerase, or DNApolymerases from bacteriophages T4, Phi-29, M2, or T5. DNA-dependent DNApolymerases may be the naturally occurring enzymes isolated frombacteria or bacteriophages or expressed recombinantly, or may bemodified or “evolved” forms which have been engineered to possesscertain desirable characteristics, e.g., thermostability, or the abilityto recognize or synthesize a DNA strand from various modified templates.All known DNA-dependent DNA polymerases require a complementary primerto initiate synthesis. It is known that under suitable conditions aDNA-dependent DNA polymerase may synthesize a complementary DNA copyfrom an RNA template. RNA-dependent DNA polymerases typically also haveDNA-dependent DNA polymerase activity.

As used herein, a “DNA-dependent RNA polymerase” or “transcriptase” isan enzyme that synthesizes multiple RNA copies from a double-stranded orpartially double-stranded DNA molecule having a promoter sequence thatis usually double-stranded. The RNA molecules (“transcripts”) aresynthesized in the 5′-to-3′ direction beginning at a specific positionjust downstream of the promoter. Examples of transcriptases are theDNA-dependent RNA polymerase from E. coli and bacteriophages T7, T3, andSP6.

As used herein, an “RNA-dependent DNA polymerase” or “reversetranscriptase” (“RT”) is an enzyme that synthesizes a complementary DNAcopy from an RNA template. All known reverse transcriptases also havethe ability to make a complementary DNA copy from a DNA template; thus,they are both RNA- and DNA-dependent DNA polymerases. RTs may also havean RNAse H activity. A primer is required for a reverse transcriptase toinitiate synthesis with both RNA and DNA templates.

“Thermophilic” indicates that an enzyme, e.g., a polymerase, exhibitsoptimal activity at a temperature greater than about 45° C., e.g., at atemperature in the range from about 50° C. to 99° C. In someembodiments, a thermophilic enzyme does not lose more than 50% of itsactivity upon incubation for 20 minutes at 60° C. In some embodiments, athermophilic enzyme is obtained or derived from a thermophilic organism,e.g., an organism whose optimal growth temperature is greater than orequal to about 45° C., e.g., greater than or equal to about 50° C.

As used herein, a “selective RNAse” is an enzyme that degrades the RNAportion of an RNA:DNA duplex but not single-stranded RNA,double-stranded RNA or DNA. An exemplary selective RNAse is RNAse H.Enzymes possessing the same or similar activity as RNAse H may also beused. Selective RNAses may be endonucleases or exonucleases. Mostreverse transcriptase enzymes contain an RNAse H activity in addition totheir polymerase activities. However, other sources of the RNAse H areavailable without an associated polymerase activity. The degradation mayresult in separation of RNA from a RNA:DNA complex. Alternatively, aselective RNAse may simply cut the RNA at various locations such thatportions of the RNA melt off or permit enzymes to unwind portions of theRNA. Other enzymes that selectively degrade RNA target sequences or RNAproducts of the present disclosure will be readily apparent to those ofordinary skill in the art.

As used herein, a “standard curve” is a representation that relates (1)a pre-amplification amount of a polynucleotide, and (2) sometime-dependent indicia of a post-amplification amount of a correspondingamplicon. For example, a standard curve can be a graph having knownnumbers of input template molecules plotted on the x-axis, and a timevalue required for the amplification reaction to achieve some level ofdetectable amplicon production plotted on the y-axis. Standard curvestypically are produced using control polynucleotide standards containingknown numbers of polynucleotide templates. Standard curves can be storedin electronic form or can be represented graphically. Thepre-amplification amount of an analyte polynucleotide in a test samplecan be determined by comparing a measured time-dependent value obtainedfor the test sample with a standard curve, as will be familiar to thosehaving an ordinary level of skill in the art.

The term “specificity,” in the context of an amplification and/ordetection system, is used herein to refer to the characteristic of thesystem which describes its ability to distinguish between target andnon-target sequences dependent on sequence and assay conditions. Interms of nucleic acid amplification, specificity generally refers to theratio of the number of specific amplicons produced to the number ofside-products (e.g., the signal-to-noise ratio). In terms of detection,specificity generally refers to the ratio of signal produced from targetnucleic acids to signal produced from non-target nucleic acids.

The term “sensitivity” is used herein to refer to the precision withwhich a nucleic acid amplification reaction can be detected orquantitated. The sensitivity of an amplification reaction is generally ameasure of the smallest copy number of the target nucleic acid that canbe reliably detected in the amplification system, and will depend, forexample, on the detection assay being employed, and the specificity ofthe amplification reaction, e.g., the ratio of specific amplicons toside-products.

As used herein, the terms “relative light unit” (“RLU”) and “relativefluorescence unit” (“RFU”) represent arbitrary units of measurementindicating the relative number of photons emitted by the sample at agiven wavelength or band of wavelengths. A measurement of RLU or RFUvaries with the characteristics of the detector used for themeasurement.

As used herein, the terms “TTime,” “emergence time,” and “time ofemergence” are interchangeable and represent the threshold time or timeof emergence of signal in a real-time plot of the assay data. TTimevalues estimate the time at which a particular threshold indicatingamplicon production is passed in a real-time amplification reaction.TTime and an algorithm for calculating and using TTime values aredescribed in Light et al., U.S. Pub. No. 2006/0276972, paragraphs [0517]through [0538], the disclosure of which is incorporated by referenceherein. A curve fitting procedure is applied to normalized andbackground-adjusted data. The curve fit is performed for only a portionof the data between a predetermined low bound and high bound. The goal,after finding the curve that fits the data, is to estimate the timecorresponding to the point at which the curve or a projection thereofintersects a predefined threshold value. In one embodiment, thethreshold for normalized data is 0.11. The high and low bounds aredetermined empirically as that range over which curves fit to a varietyof control data sets exhibit the least variability in the timeassociated with the given threshold value. For example, in oneembodiment, the low bound is 0.04 and the high bound is 0.36. The curveis fit for data extending from the first data point below the low boundthrough the first data point past the high bound. Next, there is made adetermination whether the slope of the fit is statistically significant.For example, if the p value of the first order coefficient is less than0.05, the fit is considered significant, and processing continues. Ifnot, processing stops. Alternatively, the validity of the data can bedetermined by the R² value. The slope m and intercept b of the linearcurve y=mx+b are determined for the fitted curve. With that information,TTime can be determined as follows:

TTime=(Threshold−b)/m.

Unless otherwise indicated, a concentration of 1 IU/ml HBV correspondsto 5 copies/ml of HBV nucleic acid. 1 log copy/ml of HBV nucleic acidcorresponds to 10 copies/ml; 2 log copies/ml of HBV nucleic acidcorresponds to 100 copies/ml; and so on, i.e., n log copies/ml equals10^(n) copies/ml.

Unless otherwise indicated, oligomer sequences appearing in tables belowfollow the conventions that lower case letters indicate 2′-O-methyl RNA,and upper case letters indicate DNA. “(c9)” indicates a —(CH₂)₉— linker.In vitro transcript (IVT) sequences are RNA unless otherwise indicated.

References, particularly in the claims, to “the sequence of SEQ ID NO:X” refer to the base sequence of the corresponding sequence listingentry and do not require identity of the backbone (e.g., RNA, 2′-O-MeRNA, or DNA) unless otherwise indicated. Furthermore, T and U residuesare to be considered interchangeable for purposes of sequence listingentries unless otherwise indicated, e.g., a sequence can be consideredidentical to SEQ ID NO: 2 regardless of whether the residue at the sixthposition is a T or a U.

B. Oligomers, Compositions, and Kits

The present disclosure provides oligomers, compositions, and kits,useful for amplifying, detecting, or quantifying HBV from a sample.

In some embodiments, amplification oligomers are provided. Amplificationoligomers generally comprise a target-hybridizing region, e.g.,configured to hybridize specifically to an HBV nucleic acid. Whileoligomers of different lengths and base composition may be used foramplifying HBV nucleic acids, in some embodiments oligomers in thisdisclosure have target-hybridizing regions from 10 to 60 bases inlength, between 14 and 50 bases in length, or between 15 and 40 bases inlength. In some embodiments, an initial amplification oligomer is usedhaving a relatively long target hybridizing region such as about 30-50nucleotides, e.g., 35-45, and at a later stage amplification oligomerswith shorter target-hybridizing regions are used, e.g., about 14-35nucleotides, such as about 15-30 nt.

In certain embodiments, an amplification oligomer as described herein isa promoter primer further comprising a promoter sequence located 5′ tothe target-hybridizing sequence and which is non-complementary to theHBV target nucleic acid. For example, in some embodiments of an oligomercombination as described herein for amplification of an HBV targetregion, an amplification oligomer as described above is a promoterprimer further comprising a promoter sequence 5′ to thetarget-hybridizing sequence. Alternatively, an amplification oligomercan be a promoter provider comprising a promoter sequence. In particularembodiments, the promoter sequence is a T7 RNA polymerase promotersequence such as, for example, a T7 promoter sequence having thesequence shown in SEQ ID NO:8. In specific variations, a promoter primercomprises the non-HBV sequence including a T7 promoter shown in one ofSEQ ID NOs:9, 10, 11, 12, or 13. In some embodiments, at least one,e.g., two, three, or four promoter primers are provided comprising atarget-hybridizing sequence that contains (+)-strand HBV sequence.

In some embodiments, an amplification oligomer is not a promoter primeror does not comprise a promoter sequence. For example, in PCR-basedapproaches the primers are generally not promoter primers, and inTMA-based approaches at least one primer that is not a promoter primeris typically used (while at least one promoter primer is also used). Insome embodiments, at least one, e.g., two, three, or four amplificationoligomers that are not promoter primers are provided comprising atarget-hybridizing sequence that contains (−)-strand HBV sequence.

In some embodiments, a first amplification oligomer is provided which isa reverse amplification oligomer, i.e., it is configured to hybridizespecifically to (+) strand HBV nucleic acid; put another way, itstarget-hybridizing sequence corresponds to the “antisense” sequence ofHBV.

In some embodiments, the target sequence of the first amplificationoligomer comprises position 449 of an HBV genomic nucleic acid such asSEQ ID NO: 1, e.g., positions 448-450, 447-451, 446-452, 445-453,444-454, 443-455, 442-456, 441-457, 440-458, or 439-459. In someembodiments, the first amplification oligomer comprises a sequencehaving up to 1 or 2 mismatches relative to SEQ ID NO: 2. In someembodiments, the first amplification oligomer comprises a sequencehaving up to 1 or 2 mismatches relative to SEQ ID NO: 3. Variousembodiments of the first amplification oligomer, including with respectto its sequence, are disclosed in the summary above, any of which can becombined to the extent feasible with the features discussed above inthis section.

In some embodiments in which the first amplification oligomer isprovided, an additional reverse amplification oligomer different fromthe first amplification oligomer is also provided which is alsoconfigured to hybridize specifically to (+) strand HBV nucleic acid.Such an additional amplification oligomer can anneal to common positionswith the first amplification oligomer, e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 common positionswith the first amplification oligomer. In some embodiments, the targetsequence of the additional amplification oligomer comprises position 449of an HBV genomic nucleic acid such as SEQ ID NO: 1, e.g., positions448-450, 447-451, 446-452, 445-453, 444-454, 443-455, 442-456, 441-457,440-458, or 439-459. In some embodiments, the additional amplificationoligomer comprises a sequence having up to 1 or 2 mismatches relative toSEQ ID NO: 2. In some embodiments, the additional amplification oligomercomprises a sequence having up to 1 or 2 mismatches relative to SEQ IDNO: 3. As described in the examples, using such an additionalamplification oligomer can improve the relative accuracy ofquantification of HBV nucleic acid despite sequence variation betweengenotypes. In some embodiments, the first amplification oligomercomprises at least 10 contiguous nucleotides of SEQ ID NO: 2 and theadditional amplification oligomer comprises at least 10 contiguousnucleotides of SEQ ID NO: 3. Various embodiments of the additionalamplification oligomer, including with respect to its sequence, aredisclosed in the summary above, any of which can be combined to theextent feasible with the features discussed above in this section.

In some embodiments, a second amplification oligomer is provided whichis a forward amplification oligomer, i.e., it is configured to hybridizespecifically to (−) strand HBV nucleic acid; put another way, itstarget-hybridizing sequence corresponds to the “antisense” sequence ofHBV.

In some embodiments, the target sequence of the second amplificationoligomer comprises position 386 or 387 of an HBV genomic nucleic acidsuch as SEQ ID NO: 1, e.g., positions 386-387, 385-388, 384-389,383-390, 382-391, 381-392, 380-393, 379-394, 378-395, 377-396, or376-397. In some embodiments, the second amplification oligomercomprises a sequence having up to 1 or 2 mismatches relative to SEQ IDNO: 18. In some embodiments, the second amplification oligomer comprisesa sequence of SEQ ID NO: 19, 20, 21, 22, or a sequence having up to 1 or2 mismatches relative thereto. In some embodiments, the secondamplification oligomer comprises a target-hybridizing sequencecomprising positions N to 397 of SEQ ID NO: 1, where N is 376, 377, 378,379, 380, 381, 382, 383, or 384, or a sequence having up to 1 or 2mismatches relative thereto. In some embodiments, the secondamplification oligomer comprises a target-hybridizing sequencecomprising positions N to 402 of SEQ ID NO: 1, where N is 376, 377, 378,379, 380, 381, 382, 383, 384, 385, 386, 387, 388, or 389, or a sequencehaving up to 1 or 2 mismatches relative thereto. Various embodiments ofthe second amplification oligomer, including with respect to itssequence, are disclosed in the summary above, any of which can becombined to the extent feasible with the features discussed above inthis section.

In some embodiments in which the second amplification oligomer isprovided, an additional forward amplification oligomer different fromthe second amplification oligomer is also provided which is alsoconfigured to hybridize specifically to (−) strand HBV nucleic acid.Such an additional amplification oligomer can anneal to common positionswith the second amplification oligomer, e.g., at least 1, 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 common positionswith the second amplification oligomer. In some embodiments, the targetsequence of the additional amplification oligomer comprises position 389of an HBV genomic nucleic acid such as SEQ ID NO: 1, e.g., positions388-390, 387-391, 386-392, 385-393, 384-394, 383-395, 382-396, 381-397,380-398, 379-399, 378-400, 377-401, or 376-402. In some embodiments, theadditional amplification oligomer comprises a sequence having up to 1 or2 mismatches relative to SEQ ID NO: 19. In some embodiments, theadditional amplification oligomer comprises a sequence having up to 1 or2 mismatches relative to SEQ ID NO: 18, 20, 21, or 22. Using such anadditional amplification oligomer can improve the relative accuracy ofquantification of HBV nucleic acid despite sequence variation betweengenotypes. In some embodiments, the second amplification oligomercomprises at least 10 contiguous nucleotides of SEQ ID NO: 18 and theadditional amplification oligomer comprises at least 10 contiguousnucleotides of SEQ ID NO: 19. The target-hybridizing region of theadditional amplification oligomer can be longer than thetarget-hybridizing region of the second amplification oligomer, e.g., by1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides, such as about 4-6nucleotides, e.g., 5 nucleotides. Various embodiments of such anadditional amplification oligomer, including with respect to itssequence, are disclosed in the summary above, any of which can becombined to the extent feasible with the features discussed above inthis section.

The first, second, and optionally additional amplification oligomersdiscussed above can be used in an amplification reaction to produce afirst amplicon, e.g., comprising positions such as 425, e.g., 420-430,416-434, 406-444, 396-454, 386-464, or 376-474 of an HBV nucleic acidsuch as SEQ ID NO: 1.

In some embodiments, a third amplification oligomer is provided which isa reverse amplification oligomer, i.e., it is configured to hybridizespecifically to (+) strand HBV nucleic acid; put another way, itstarget-hybridizing sequence corresponds to the “antisense” sequence ofHBV.

In some embodiments, the target sequence of the third amplificationoligomer comprises position 698 or 699 of an HBV genomic nucleic acidsuch as SEQ ID NO: 1, e.g., positions 698-699, 697-700, 696-701,695-702, 694-703, 693-704, 692-705, 691-706, 690-707, or 689-708. Insome embodiments, the third amplification oligomer comprises a sequencehaving up to 1 or 2 mismatches relative to SEQ ID NO: 41. Variousembodiments of the third amplification oligomer, including with respectto its sequence, are disclosed in the summary above, any of which can becombined to the extent feasible with the features discussed above inthis section.

In some embodiments, a fourth amplification oligomer is provided whichis a forward amplification oligomer, i.e., it is configured to hybridizespecifically to (−) strand HBV nucleic acid; put another way, itstarget-hybridizing sequence corresponds to the “antisense” sequence ofHBV.

In some embodiments, the target sequence of the fourth amplificationoligomer comprises position 656 of an HBV genomic nucleic acid such asSEQ ID NO: 1, e.g., positions or 655-657, 654-658, 653-659, 652-660,651-661, 650-662, 649-663, 648-664, 647-665, or 646-666. In someembodiments, the fourth amplification oligomer comprises a sequencehaving up to 1 or 2 mismatches relative to SEQ ID NO: 40. In someembodiments, the fourth amplification oligomer comprises atarget-hybridizing sequence comprising positions N to 666 of an HBVnucleic acid sequence such as SEQ ID NO: 1, where N is 646, 647, 648,649, 650, 651, 652, or 653, or a sequence having up to 1 or 2 mismatchesrelative thereto. Various embodiments of the fourth amplificationoligomer, including with respect to its sequence, are disclosed in thesummary above, any of which can be combined to the extent feasible withthe features discussed above in this section.

The third and fourth amplification oligomers discussed above can be usedin an amplification reaction to produce a second amplicon, e.g.,comprising positions such as 677 or 678, e.g., 673-682, 668-687,658-697, 648-707, or 646-708 of an HBV nucleic acid sequence such as SEQID NO: 1.

In some embodiments, a fifth amplification oligomer is provided which isa forward amplification oligomer, i.e., it is configured to hybridizespecifically to (−) strand HBV nucleic acid; put another way, itstarget-hybridizing sequence corresponds to the “antisense” sequence ofHBV.

In some embodiments, the target sequence of the fifth amplificationoligomer comprises position 264 or 265 of an HBV genomic nucleic acidsuch as SEQ ID NO: 1, e.g., positions 263-266, 258-271, 255-274, or250-279. In some embodiments, the fifth amplification oligomer comprisesa sequence having up to 1 or 2 mismatches relative to SEQ ID NO: 69. Insome embodiments, the fifth amplification oligomer comprises atarget-hybridizing sequence comprising positions N to 279 of an HBVnucleic acid sequence such as SEQ ID NO: 1, where N is 250, 251, 252,253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, or 266,or a sequence having up to 1 or 2 mismatches relative thereto. Variousembodiments of the fifth amplification oligomer, including with respectto its sequence, are disclosed in the summary above, any of which can becombined to the extent feasible with the features discussed above inthis section.

In some embodiments, a sixth amplification oligomer is provided which isa forward amplification oligomer, i.e., it is configured to hybridizespecifically to (−) strand HBV nucleic acid; put another way, itstarget-hybridizing sequence corresponds to the “sense” sequence of HBV.

In some embodiments, the target sequence of the sixth amplificationoligomer comprises position 461 or 462 of an HBV genomic nucleic acidsuch as SEQ ID NO: 1, e.g., positions 461-462, 457-466, 455-468, or452-471. In some embodiments, the sixth amplification oligomer comprisesa sequence having up to 1 or 2 mismatches relative to SEQ ID NO: 73.Various embodiments of the sixth amplification oligomer, including withrespect to its sequence, are disclosed in the summary above, any ofwhich can be combined to the extent feasible with the features discussedabove in this section.

The fifth and sixth amplification oligomers discussed above can be usedas displacers, e.g., they can facilitate amplicon production by otheroligomers through extension from their 3′ termini and concomitant stranddisplacement, making single-stranded template available for binding byother oligomers. The fifth and sixth amplification oligomers can reduceor avoid a need for a denaturation step and can enhance sensitivity.

It should be noted that the presence of, e.g., a sixth amplificationoligomer does not necessarily imply the presence of all of the first,second, third, fourth, and fifth amplification oligomers. For example,it is possible to perform an exponential amplification in the presenceonly of first and second amplification oligomers, and either or both ofthe fifth and sixth amplification oligomers can be used as displacers.Additionally, a linear amplification can be performed in the presence ofe.g., a promoter primer without any oppositely oriented oligomer. Thisnote applies mutatis mutandis to other instances where ordinal numeralsare used, e.g., the presence of a second capture oligomer does notnecessarily imply the presence of a first capture oligomer. In someembodiments, the second, fourth, and fifth amplification oligomers arepromoter primers, such that they may have any of the features ofpromoter primers discussed above.

In some embodiments, at least one initial amplification oligomer isprovided which is different from other amplification oligomers to theextent that they are present or used, such as the second, fourth, andany additional amplification oligomers. In some embodiments, an initialamplification oligomer is provided that anneals to one or more commonpositions with the second amplification oligomer and has a longertarget-hybridizing region than at least one or two other amplificationoligomers, such as the second amplification oligomer and optionally theadditional forward amplification oligomer. In some embodiments, aninitial amplification oligomer is provided that anneals to one or morecommon positions with the fourth amplification oligomer and has a longertarget-hybridizing region than the fourth amplification oligomer. Asdescribed in the examples, it was found that using an initialamplification oligomer comprising a long target-hybridizing region canimprove subsequent amplification and quantification of certain HBVgenotypes and thereby improve overall detection and quantificationperformance. The initial amplification oligomer that anneals to one ormore common positions with the second amplification oligomer and theinitial amplification oligomer that anneals to one or more commonpositions with the fourth amplification oligomer can be providedtogether. In some embodiments, the initial amplification oligomer(s) arein a composition with one or more target capture oligomers such as thosedescribed below or in the summary above.

In some embodiments, the target sequence of the initial amplificationoligomer that anneals to one or more common positions with the secondamplification oligomer comprises position 390 or 391 of an HBV genomicnucleic acid such as SEQ ID NO: 1, e.g., positions 390-391, 389-392,388-393, 387-394, 386-395, 385-396, 384-397, 383-398, 382-399, 381-400,380-401, 379-402, 378-403, 377-404, or 376-405. In some embodiments, theinitial amplification oligomer comprises a sequence having up to 1 or 2mismatches relative to SEQ ID NO: 20. In some embodiments, the initialamplification oligomer comprises a sequence of SEQ ID NO: 16 or 17, or asequence having up to 1 or 2 mismatches relative thereto. In someembodiments, the initial amplification oligomer comprises atarget-hybridizing sequence comprising positions N-405 of an HBV genomicsequence such as SEQ ID NO: 1, where N is 376, 377, 378, 379, 380, 381,382, 383, 384, 385, 386, 387, 388, 389, 390, 391, or 392, or a sequencehaving up to 1 or 2 mismatches relative thereto. Various embodiments ofthe initial amplification oligomer, including with respect to itssequence, are disclosed in the summary above, any of which can becombined to the extent feasible with the features discussed above inthis section. The initial amplification oligomer can also have featuresrecited in the summary above with respect to the second amplificationoligomer. For example, the initial amplification oligomer can compriseat least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, or 28 contiguous nucleotides of SEQ ID NO: 20, or the sequence ofSEQ ID NO: 20. In some embodiments, the initial amplification oligomeris a promoter-primer.

In some embodiments, the target sequence of the initial amplificationoligomer that anneals to one or more common positions with the fourthamplification oligomer comprises position 659 of an HBV genomic nucleicacid such as SEQ ID NO: 1, e.g., positions 658-660, 657-661, 656-662,655-663, 654-664, 653-665, 652-666, 651-667, 650-668, 649-670, 648-671,or 646-672. In some embodiments, the initial amplification oligomercomprises a sequence having up to 1 or 2 mismatches relative to SEQ IDNO: 35, optionally wherein the inosine at the sixth nucleotide from the3′ end of SEQ ID NO: 35 is not mismatched. In some embodiments, theinitial amplification oligomer comprises a sequence of SEQ ID NO: 33 or31, or a sequence having up to 1 or 2 mismatches relative thereto,optionally wherein the inosine at the sixth nucleotide from the 3′ endof SEQ ID NO: 33 or 31 is not mismatched. In some embodiments, theinitial amplification oligomer comprises a target-hybridizing sequencecomprising positions N-672 of an HBV genomic sequence such as SEQ ID NO:1, where N is 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656,657, 658, or 659, or a sequence having up to 1 or 2 mismatches relativethereto, optionally wherein the nucleotide corresponding to position 667is inosine. Various embodiments of the initial amplification oligomer,including with respect to its sequence, are disclosed in the summaryabove, any of which can be combined to the extent feasible with thefeatures discussed above in this section. The initial amplificationoligomer can also have features recited in the summary above withrespect to the fourth amplification oligomer or any amplificationoligomer comprising a target-hybridizing region comprising at least 10contiguous nucleotides of SEQ ID NO: 35. For example, the initialamplification oligomer can comprise at least 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34contiguous nucleotides of SEQ ID NO: 35 (optionally including theinosine at position 30 of SEQ ID NO: 35), or the sequence of SEQ ID NO:35. In some embodiments, the initial amplification oligomer is apromoter-primer.

In some embodiments, at least one probe oligomer is provided. Someembodiments of detection probes that hybridize to complementaryamplified sequences may be DNA or RNA oligomers, or oligomers thatcontain a combination of DNA and RNA nucleotides, or oligomerssynthesized with a modified backbone, e.g., an oligomer that includesone or more 2′-methoxy substituted ribonucleotides. Probes used fordetection of the amplified HBV sequences may be unlabeled and detectedindirectly (e.g., by binding of another binding partner to a moiety onthe probe) or may be labeled with a variety of detectable labels. Adetection probe oligomer may contain a 2′-methoxy backbone at one ormore linkages in the nucleic acid backbone.

In some embodiments, a detection probe oligomer in accordance with thepresent disclosure further includes a label. Particularly suitablelabels include compounds that emit a detectable light signal, e.g.,fluorophores or luminescent (e.g., chemiluminescent) compounds that canbe detected in a homogeneous mixture. More than one label, and more thanone type of label, may be present on a particular probe, or detectionmay rely on using a mixture of probes in which each probe is labeledwith a compound that produces a detectable signal (see. e.g., U.S. Pat.Nos. 6,180,340 and 6,350,579, each incorporated by reference herein).Labels may be attached to a probe by various means including covalentlinkages, chelation, and ionic interactions, but in some embodiments thelabel is covalently attached. For example, in some embodiments, adetection probe has an attached chemiluminescent label such as, e.g., anacridinium ester (AE) compound (see. e.g., U.S. Pat. Nos. 5,185,439;5,639,604; 5,585,481; and 5,656,744; each incorporated by referenceherein), which in typical variations is attached to the probe by anon-nucleotide linker (see. e.g., U.S. Pat. Nos. 5,585,481; 5,656,744;and 5,639,604, each incorporated by reference herein).

A detection probe oligomer in accordance with the present disclosure mayfurther include a non-target-hybridizing sequence. In some applications,probes exhibiting at least some degree of self-complementarity aredesirable to facilitate detection of probe:target duplexes in a testsample without first requiring the removal of unhybridized probe priorto detection. Specific embodiments of such detection probes include, forexample, probes that form conformations held by intramolecularhybridization, such as conformations generally referred to as hairpins.Particularly suitable hairpin probes include a “molecular torch” (see.e.g., U.S. Pat. Nos. 6,849,412; 6,835,542; 6,534,274; and 6,361,945,each incorporated by reference herein) and a “molecular beacon” (see.e.g., Tyagi et al., supra; U.S. Pat. Nos. 5,118,801 and 5,312,728,supra). In yet other embodiments, a detection probe is a linearoligomers that does not substantially form conformations held byintramolecular bonds.

By way of example, structures referred to as “molecular beacons”comprise nucleic acid molecules having a target complementary sequence,an affinity pair (or nucleic acid arms) holding the probe in a closedconformation in the absence of a target nucleic acid sequence, and alabel pair that interacts when the probe is in a closed conformation.Hybridization of the target nucleic acid and the target complementarysequence separates the members of the affinity pair, thereby shiftingthe probe to an open conformation. The shift to the open conformation isdetectable due to reduced interaction of the label pair, which may be,for example, a fluorophore and a quencher (e.g., DABCYL and EDANS).Molecular beacons are fully described in U.S. Pat. No. 5,925,517, thedisclosure of which is hereby incorporated by reference. Molecularbeacons useful for detecting HBV specific nucleic acid sequences may becreated by appending to either end of one of the probe (e.g.,target-hybridizing) sequences disclosed herein, a first nucleic acid armcomprising a fluorophore and a second nucleic acid arm comprising aquencher moiety. In this configuration, the HBV specific probe sequencedisclosed herein serves as the target-complementary “loop” portion ofthe resulting molecular beacon, while the self-complementary “arms” ofthe probe represent the “stem” portion of the probe.

Another example of a self-complementary hybridization assay probe thatmay be used in conjunction with the disclosure is a structure commonlyreferred to as a “molecular torch” (sometimes referred to simply as atorch). These self-reporting probes are designed to include distinctregions of self-complementarity (coined “the target binding domain” and“the target closing domain”) which are connected by a joining region(e.g., a —(CH₂)₉— linker) and which hybridize to one another underpredetermined hybridization assay conditions. When exposed to anappropriate target or denaturing conditions, the two complementaryregions (which may be fully or partially complementary) of the moleculartorch melt, leaving the target binding domain available forhybridization to a target sequence when the predetermined hybridizationassay conditions are restored. Molecular torches are designed so thatthe target binding domain favors hybridization to the target sequenceover the target closing domain. The target binding domain and the targetclosing domain of a molecular torch include interacting labels (e.g.,fluorescent/quencher) positioned so that a different signal is producedwhen the molecular torch is self-hybridized as opposed to when themolecular torch is hybridized to a target nucleic acid, therebypermitting detection of probe:target duplexes in a test sample in thepresence of unhybridized probe having a viable label associatedtherewith. Molecular torches are fully described in U.S. Pat. No.6,361,945, the disclosure of which is hereby incorporated by reference.

Molecular torches and molecular beacons in some embodiments are labeledwith an interactive pair of detectable labels. Examples of detectablelabels that are members of an interactive pair of labels include thosethat interact with each other by FRET or non-FRET energy transfermechanisms. Fluorescence resonance energy transfer (FRET) involves theradiationless transmission of energy quanta from the site of absorptionto the site of its utilization in the molecule, or system of molecules,by resonance interaction between chromophores, over distancesconsiderably greater than interatomic distances, without conversion tothermal energy, and without the donor and acceptor coming into kineticcollision. The “donor” is the moiety that initially absorbs the energy,and the “acceptor” is the moiety to which the energy is subsequentlytransferred. In addition to FRET, there are at least three other“non-FRET” energy transfer processes by which excitation energy can betransferred from a donor to an acceptor molecule.

When two labels are held sufficiently close that energy emitted by onelabel can be received or absorbed by the second label, whether by a FRETor non-FRET mechanism, the two labels are said to be in “energy transferrelationship” with each other. This is the case, for example, when amolecular beacon is maintained in the closed state by formation of astem duplex, and fluorescent emission from a fluorophore attached to onearm of the probe is quenched by a quencher moiety on the opposite arm.

Exemplary label moieties for the disclosed molecular torches andmolecular beacons include a fluorophore and a second moiety havingfluorescence quenching properties (i.e., a “quencher”). In thisembodiment, the characteristic signal is likely fluorescence of aparticular wavelength, but alternatively could be a visible lightsignal. When fluorescence is involved, changes in emission are In someembodiments due to FRET, or to radiative energy transfer or non-FRETmodes. When a molecular beacon having a pair of interactive labels inthe closed state is stimulated by an appropriate frequency of light, afluorescent signal is generated at a first level, which may be very low.When this same probe is in the open state and is stimulated by anappropriate frequency of light, the fluorophore and the quenchermoieties are sufficiently separated from each other that energy transferbetween them is substantially precluded. Under that condition, thequencher moiety is unable to quench the fluorescence from thefluorophore moiety. If the fluorophore is stimulated by light energy ofan appropriate wavelength, a fluorescent signal of a second level,higher than the first level, will be generated. The difference betweenthe two levels of fluorescence is detectable and measurable. Usingfluorophore and quencher moieties in this manner, the molecular beaconis only “on” in the “open” conformation and indicates that the probe isbound to the target by emanating an easily detectable signal. Theconformational state of the probe alters the signal generated from theprobe by regulating the interaction between the label moieties.

Examples of donor/acceptor label pairs that may be used in connectionwith the disclosure, making no attempt to distinguish FRET from non-FRETpairs, include fluorescein/tetramethylrhodamine, IAEDANS/fluororescein,EDANS/DABCYL, coumarin/DABCYL, fluorescein/fluorescein, BODIPY FL/BODIPYFL, fluorescein/DABCYL, lucifer yellow/DABCYL, BODIPY/DABCYL,eosine/DABCYL, erythrosine/DABCYL, tetramethylrhodamine/DABCYL, TexasRed/DABCYL, CY5/BH1, CY5/BH2, CY3/BH1, CY3/BH2 and fluorescein/QSY7 dye.Those having an ordinary level of skill in the art will understand thatwhen donor and acceptor dyes are different, energy transfer can bedetected by the appearance of sensitized fluorescence of the acceptor orby quenching of donor fluorescence. When the donor and acceptor speciesare the same, energy can be detected by the resulting fluorescencedepolarization. Non-fluorescent acceptors such as DABCYL and the QSY7dyes advantageously eliminate the potential problem of backgroundfluorescence resulting from direct (i.e., non-sensitized) acceptorexcitation. Exemplary fluorophore moieties that can be used as onemember of a donor-acceptor pair include fluorescein, ROX, and the CYdyes (such as CY5). Exemplary quencher moieties that can be used asanother member of a donor-acceptor pair include DABCYL and the BLACKHOLE QUENCHER moieties which are available from Biosearch Technologies,Inc., (Novato, Calif.).

Oligomers that are not intended to be extended by a nucleic acidpolymerase, e.g., probe oligomers and capture oligomers, can include ablocker group that replaces the 3′ OH to prevent enzyme-mediatedextension of the oligomer in an amplification reaction. For example,blocked amplification oligomers and/or detection probes present duringamplification in some embodiments do not have a functional 3′ OH andinstead include one or more blocking groups located at or near the 3′end. A blocking group near the 3′ end is in some embodiments within fiveresidues of the 3′ end and is sufficiently large to limit binding of apolymerase to the oligomer, and other embodiments contain a blockinggroup covalently attached to the 3′ terminus. Many different chemicalgroups may be used to block the 3′ end, e.g., alkyl groups,non-nucleotide linkers, alkane-diol dideoxynucleotide residues, andcordycepin.

While oligonucleotide probes of different lengths and base compositionmay be used for detecting HBV nucleic acids, some embodiments of probesin this disclosure are from 10 to 60 bases in length, or between 14 and50 bases in length, or between 15 and 30 bases in length. A first probeoligomer can be provided that is configured to specifically hybridize tothe first amplicon discussed above. Alternatively or in addition, asecond probe oligomer can be provided that is configured to specificallyhybridize to the first amplicon discussed above.

In some embodiments, the target sequence of the first probe oligomercomprises position 424 of an HBV genomic nucleic acid such as SEQ ID NO:1, e.g., positions 423-425, 421-427, 419-429, 417-431, 415-433, 413-435,411-437, 410-438, 409-439, or 408-440. In some embodiments, the probeoligomer comprises a sequence having up to 1 or 2 mismatches relative toSEQ ID NO: 82. In some embodiments, the probe oligomer comprises asequence of SEQ ID NO: 29, or a sequence having up to 1 or 2 mismatchesrelative thereto. Various embodiments of the probe oligomer, includingwith respect to its sequence, are disclosed in the summary above, any ofwhich can be combined to the extent feasible with the features discussedabove in this section.

In some embodiments, the target sequence of the second probe oligomercomprises position 675 or 676 of an HBV genomic nucleic acid such as SEQID NO: 1, e.g., positions 675-676, 674-677, 673-678, 672-679, 671-680,670-681, 669-682, or 668-683. In some embodiments, the probe oligomercomprises a sequence having up to 1 or 2 mismatches relative to SEQ IDNO: 83. In some embodiments, the probe oligomer comprises a sequence ofSEQ ID NO: 84, 85, 40, or a sequence having up to 1 or 2 mismatchesrelative thereto. Various embodiments of the probe oligomer, includingwith respect to its sequence, are disclosed in the summary above, any ofwhich can be combined to the extent feasible with the features discussedabove in this section.

In some embodiments, at least one capture oligomer is provided, e.g.,two, three, or four capture oligomers. It is understood that when two ormore capture oligomers are present, their target-hybridizing sequencesare different from each other. The one or more capture oligomerscomprise a target-hybridizing sequence configured to specificallyhybridize to HBV nucleic acid, e.g., from 10 to 60 bases in length, orbetween 14 and 50 bases in length, or between 15 and 30 bases in length.For example, in specific embodiments of capture probes, the one, two,three, or four capture probes have target-hybridizing sequences selectedfrom SEQ ID NO: 49, 53, 57, 61, and 96-104. The target-hybridizingsequence is covalently attached to a sequence or moiety that binds to animmobilized probe, e.g., an oligomer attached to a solid substrate, suchas a bead.

In more specific embodiments, the capture oligomer includes a tailportion (e.g., a 3′ tail) that is not complementary to the HBV targetsequence but that specifically hybridizes to a sequence of theimmobilized binding partner (e.g., immobilized probe), thereby servingas the moiety allowing the target nucleic acid to be separated fromother sample components, such as previously described in, e.g., U.S.Pat. No. 6,110,678, incorporated herein by reference. Any sequence maybe used in a tail region, which is generally about 5 to 50 nt long, andcertain embodiments include a substantially homopolymeric tail (“poly-Nsequence”) of at least about 10 nt, e.g., about 10 to 40 nt (e.g., A₁₀to A₄₀), such as about 14 to 33 nt (e.g., A₁₄ to A₃₀ or T₃A₁₄ to T₃A₃₀),that bind to a complementary immobilized sequence (e.g., poly-T)attached to a solid support, e.g., a matrix or particle. For example, inspecific embodiments of a capture probe comprising a 3′ tail, the one,two, three, or four capture probes have sequences selected from SEQ IDNO: 45, 46, 47, and 48.

In some embodiments, a first capture oligomer is provided. In someembodiments, the target sequence of the first capture oligomer comprisesposition 719 of an HBV genomic nucleic acid such as SEQ ID NO: 1, e.g.,positions 718-720, 716-722, 714-724, 712-726, 710-728, 709-729, 708-730,or 707-731. In some embodiments, the first capture oligomer comprises asequence having up to 1 or 2 mismatches relative to SEQ ID NO: 49. Insome embodiments, the first capture oligomer comprises a sequence havingup to 1 or 2 mismatches relative to SEQ ID NO: 99. In some embodiments,the first capture oligomer comprises a sequence having up to 1 or 2mismatches relative to SEQ ID NO: 45. Various embodiments of the firstcapture oligomer, including with respect to its sequence, are disclosedin the summary above, any of which can be combined to the extentfeasible with the features discussed above in this section.

In some embodiments, a second capture oligomer is provided. In someembodiments, the target sequence of the second capture oligomercomprises position 745 of an HBV genomic nucleic acid such as SEQ ID NO:1, e.g., positions 744-746, 742-748, 740-750, 738-752, 736-754, 735-755,734-756, or 733-757. In some embodiments, the second capture oligomercomprises a sequence having up to 1 or 2 mismatches relative to SEQ IDNO: 53. In some embodiments, the second capture oligomer comprises asequence having up to 1 or 2 mismatches relative to SEQ ID NO: 100, 101,or 104. In some embodiments, the second capture oligomer comprises asequence having up to 1 or 2 mismatches relative to SEQ ID NO: 46.Various embodiments of the second capture oligomer, including withrespect to its sequence, are disclosed in the summary above, any ofwhich can be combined to the extent feasible with the features discussedabove in this section.

In some embodiments, a third capture oligomer is provided. In someembodiments, the target sequence of the third capture oligomer comprisesposition 1180 or 1181 of an HBV genomic nucleic acid such as SEQ ID NO:1, e.g., positions 1180-1181, 1178-1183, 1176-1185, 1174-1187,1172-1189, 1170-1191, 1169-1192, or 1168-1193. In some embodiments, thethird capture oligomer comprises a sequence having up to 1 or 2mismatches relative to SEQ ID NO: 57. In some embodiments, the thirdcapture oligomer comprises a sequence having up to 1 or 2 mismatchesrelative to SEQ ID NO: 96. In some embodiments, the third captureoligomer comprises a sequence having up to 1 or 2 mismatches relative toSEQ ID NO: 102 In some embodiments, the third capture oligomer comprisesa sequence having up to 1 or 2 mismatches relative to SEQ ID NO: 47.Various embodiments of the third capture oligomer, including withrespect to its sequence, are disclosed in the summary above, any ofwhich can be combined to the extent feasible with the features discussedabove in this section.

In some embodiments, a fourth capture oligomer is provided. In someembodiments, the target sequence of the fourth capture oligomercomprises position 1303 of an HBV genomic nucleic acid such as SEQ IDNO: 1, e.g., positions 1302-1304, 1300-1306, 1298-1308, 1296-1310,1294-1312, 1292-1314, 1291-1315, or 1290-1316. In some embodiments, thefourth capture oligomer comprises a sequence having up to 1 or 2mismatches relative to SEQ ID NO: 61. In some embodiments, the fourthcapture oligomer comprises a sequence having up to 1 or 2 mismatchesrelative to SEQ ID NO: 97, 98, or 103. In some embodiments, the fourthcapture oligomer comprises a sequence having up to 1 or 2 mismatchesrelative to SEQ ID NO: 48. Various embodiments of the fourth captureoligomer, including with respect to its sequence, are disclosed in thesummary above, any of which can be combined to the extent feasible withthe features discussed above in this section.

Internal control oligomers can be provided, e.g., for confirming that anegative result is valid by establishing that conditions were suitablefor amplification. An exemplary control target capture oligomer is SEQID NO: 80. Exemplary control amplification oligomers are SEQ ID NOs: 77and 78. An exemplary control probe oligomer is SEQ ID NO:79. A controltemplate that can be amplified by the control amplification oligomerscan also be provided. Control templates may be prepared according toknown protocols. See, e.g., U.S. Pat. No. 7,785,844, which isincorporated herein by reference, and which describes an internalcontrol consisting of an in vitro synthesized transcript containing aportion of HIV-1 sequence and a unique sequence targeted by the internalcontrol probe.

In certain aspects of the disclosure, a combination of at least twooligomers is provided for determining the presence or absence of HBV orquantifying HBV in a sample. In some embodiments, the oligomercombination includes at least two amplification oligomers suitable foramplifying a target region of an HBV target nucleic acid, e.g., havingthe sequence of SEQ ID NO: 1 or 105-125, or any HBV isolate or constructreferred to in the examples or for which an accession number is providedherein. In such embodiments, at least one amplification oligomercomprises a target-hybridizing sequence in the sense orientation (“senseTHS”) and at least one amplification oligomer comprises atarget-hybridizing sequence in the antisense orientation (“antisenseTHS”), where the sense THS and antisense THS are each configured tospecifically hybridize to a target sequence within an HBV sequence. Itis understood that the target-hybridizing sequences are selected suchthat the HBV sequence targeted by antisense THS is situated downstreamof the HBV sequence targeted by the sense THS (i.e., the at least twoamplification oligomers are situated such that they flank the targetregion to be amplified).

The oligomers can be provided in various combinations (e.g., kits orcompositions), e.g., comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, or 16 of a first amplification oligomer, additional reverseamplification oligomer, second amplification oligomer, additionalforward amplification oligomer, third amplification oligomer, fourthamplification oligomer, fifth amplification oligomer, sixthamplification oligomer, initial amplification oligomer that anneals toone or more common positions with the second amplification oligomer,initial amplification oligomer that anneals to one or more commonpositions with the fourth amplification oligomer, first probe oligomer,second probe oligomer, first capture oligomer, second capture oligomer,third capture oligomer, and fourth capture oligomer, such as at leastone initial amplification oligomer and at least one capture oligomer, afirst capture oligomer and second capture oligomer, optionally furthercomprising at least one initial amplification oligomer, a first captureoligomer and third capture oligomer, optionally further comprising atleast one initial amplification oligomer; a first capture oligomer andfourth capture oligomer, optionally further comprising at least oneinitial amplification oligomer, a second capture oligomer and thirdcapture oligomer, optionally further comprising at least one initialamplification oligomer, a second capture oligomer and fourth captureoligomer, optionally further comprising at least one initialamplification oligomer, a third capture oligomer and fourth captureoligomer, optionally further comprising at least one initialamplification oligomer, a first amplification oligomer and a secondamplification oligomer, optionally further comprising a first probeoligomer, a first, second, and additional reverse amplificationoligomer, optionally further comprising a first probe oligomer, a first,second, and additional forward amplification oligomer, optionallyfurther comprising a first probe oligomer, a first, second, additionalforward, and additional reverse amplification oligomer, optionallyfurther comprising a first probe oligomer, an initial amplificationoligomer that anneals to one or more common positions with the secondamplification oligomer, at least one capture oligomer, a firstamplification oligomer, and a second amplification oligomer, optionallyfurther comprising a first probe oligomer, an initial amplificationoligomer that anneals to one or more common positions with the secondamplification oligomer, at least two capture oligomers, a firstamplification oligomer, and a second amplification oligomer, optionallyfurther comprising a first probe oligomer, a third amplificationoligomer and a fourth amplification oligomer, optionally furthercomprising a second probe oligomer, a third amplification oligomer,fourth amplification oligomer, and an initial amplification oligomerthat anneals to one or more common positions with the fourthamplification oligomer, optionally further comprising a second probeoligomer, a third amplification oligomer, fourth amplification oligomer,an initial amplification oligomer that anneals to one or more commonpositions with the fourth amplification oligomer, and at least onecapture oligomer, optionally further comprising a second probe oligomer,an initial amplification oligomer that anneals to one or more commonpositions with the second amplification oligomer, at least two captureoligomers, a first amplification oligomer, and a second amplificationoligomer, optionally further comprising a first probe oligomer, aninitial amplification oligomer that anneals to one or more commonpositions with the second amplification oligomer, at least one captureoligomer, a first amplification oligomer, a second amplificationoligomer, a third amplification oligomer, and a fourth amplificationoligomer, optionally further comprising a third and/or fourth captureoligomer, or an initial amplification oligomer that anneals to one ormore common positions with the second amplification oligomer, an initialamplification oligomer that anneals to one or more common positions withthe fourth amplification oligomer, at least one capture oligomer, afirst amplification oligomer, a second amplification oligomer, a thirdamplification oligomer, and a fourth amplification oligomer, optionallyfurther comprising first and second probe oligomers. Combinations canfurther comprise a control oligomer or combination thereof e.g., twocontrol amplification oligomers, a control target capture oligomer,and/or a control probe oligomer. In some embodiments, both first andsecond amplification oligomers are present. In some embodiments, bothinitial and third amplification oligomers are present.

In some embodiments, a combination does not comprise more than 17, 16,15, 14, 13, 12, 11, 10, or 9 distinct oligomers, not including controloligomers. In such embodiments, variants present in trace amounts (e.g.,about 15 mol % or less or about 10 mol % or less relative to a majorspecies of oligomer, such as the oligomer with the most similar sequenceto the variant), such as may result from misincorporation, doubleincorporation, omission, or other errors during oligomer synthesis, arenot considered a distinct oligomer.

In some embodiments, a combination of oligomers is provided as describedbelow in any of the examples or individual reactions described in theexamples.

In some embodiments, a combination of oligomers, e.g., in a kit orcomposition, is configured to specifically hybridize to nucleic acid ofat least three, four, five, six, seven, eight, or nine HBV genotypes(e.g., types A, B, C, C2, D, E, F, G, or H)), optionally with minimalcross-reactivity to other, non-HBV nucleic acids suspected of being in asample (e.g., other bloodborne pathogens, such one or more, or all, ofthe microorganisms and/or bloodborne viruses listed in Table 8). In someembodiments, a combination of oligomers can be used to quantify suchstrains within 1 log of HBV A. In some embodiments, a combination ofoligomers can be used to quantify such strains within 0.5 log of HBV A.In some aspects, the compositions of the instant disclosure areconfigured to specifically hybridize to HBV nucleic acid with minimalcross-reactivity to one or more, or all, of Hepatitis A, Rubella,Hepatitis C, Herpes simplex 1, Herpes simplex 2, HIV2, Parvovirus,Dengue, CMV, HTLV, Epstein-Barr, and West Nile viruses. In someembodiments, the compositions of the instant disclosure are configuredto specifically hybridize to HBV nucleic acid with minimalcross-reactivity to one or more, or all, of C. albicans, P. acnes, S.aureus, S. epidermis, or N. gonorrhoeae. In one aspect, the compositionsof the instant disclosure are part of a multiplex system that furtherincludes components and methods for detecting one of more of theseorganisms.

Also provided by the disclosure is a reaction mixture for determiningthe presence or absence of an HBV target nucleic acid or quantifying theamount thereof in a sample. A reaction mixture in accordance with thepresent disclosure comprises at least one or more of the following: anoligomer combination as described herein for amplification of an HBVtarget nucleic acid; a capture probe oligomer as described herein forpurifying the HBV target nucleic acid; and a detection probe oligomer asdescribed herein for determining the presence or absence of an HBVamplification product. In some embodiments, any oligomer combinationdescribed above is present in the reaction mixture. The reaction mixturemay further include a number of optional components such as, forexample, arrays of capture probe nucleic acids. For an amplificationreaction mixture, the reaction mixture will typically include otherreagents suitable for performing in vitro amplification such as, e.g.,buffers, salt solutions, appropriate nucleotide triphosphates (e.g.,dATP, dCTP, dGTP, dTTP, ATP, CTP, GTP and UTP), and/or enzymes (e.g.,reverse transcriptase, and/or RNA polymerase), and will typicallyinclude test sample components, in which an HBV target nucleic acid mayor may not be present. In addition, for a reaction mixture that includesa detection probe together with an amplification oligomer combination,selection of amplification oligomers and detection probe oligomers for areaction mixture are linked by a common target region (i.e., thereaction mixture will include a probe that binds to a sequenceamplifiable by an amplification oligomer combination of the reactionmixture).

Also provided by the subject disclosure are kits for practicing themethods as described herein. A kit in accordance with the presentdisclosure comprises at least one or more of the following: anamplification oligomer combination as described herein for amplificationof an HBV target nucleic acid; at least one capture probe oligomer asdescribed herein for purifying the HBV target nucleic acid; and at leastone detection probe oligomer as described herein for determining thepresence or absence of an HBV amplification product. In someembodiments, any oligomer combination described above is present in thekit. The kits may further include a number of optional components suchas, for example, arrays of capture probe nucleic acids. Other reagentsthat may be present in the kits include reagents suitable for performingin vitro amplification such as, e.g., buffers, salt solutions,appropriate nucleotide triphosphates (e.g., dATP, dCTP, dGTP, dTTP, ATP,CTP, GTP and UTP), and/or enzymes (e.g., reverse transcriptase, and/orRNA polymerase). Oligomers as described herein may be packaged in avariety of different embodiments, and those skilled in the art willappreciate that the disclosure embraces many different kitconfigurations. For example, a kit may include amplification oligomersfor only one target region of an HBV genome, or it may includeamplification oligomers for multiple HBV target regions, such as forproducing first and second amplicons as described above. In addition,for a kit that includes a detection probe together with an amplificationoligomer combination, selection of amplification oligomers and detectionprobe oligomers for a kit are linked by a common target region (i.e.,the kit will include a probe that binds to a sequence amplifiable by anamplification oligomer combination of the kit). In certain embodiments,the kit further includes a set of instructions for practicing methods inaccordance with the present disclosure, where the instructions may beassociated with a package insert and/or the packaging of the kit or thecomponents thereof.

C. Methods and Uses

Any method disclosed herein is also to be understood as a disclosure ofcorresponding uses of materials involved in the method directed to thepurpose of the method. Any of the oligomers comprising HBV sequence andany combinations (e.g., kits and compositions) comprising such anoligomer are to be understood as also disclosed for use in detecting orquantifying HBV, and for use in the preparation of a composition fordetecting or quantifying HBV.

Broadly speaking methods can comprise one or more of the followingcomponents: target capture, in which HBV nucleic acid is annealed to acapture oligomer and optionally to an initial amplification oligomer,isolation, e.g., washing, to remove material not associated with acapture oligomer, linear amplification; exponential amplification; andamplicon detection, e.g., amplicon quantification, which may beperformed in real time with exponential amplification. Certainembodiments involve each of the foregoing steps. Certain embodimentsinvolve exponential amplification without linear amplification. Certainembodiments involve washing, isolation, and linear amplification.Certain embodiments involve exponential amplification and amplicondetection. Certain embodiments involve any two of the components listedabove. Certain embodiments involve any two components listed adjacentlyabove, e.g., washing and linear amplification, or linear amplificationand exponential amplification.

In some embodiments, amplification comprises contacting the sample withat least two oligomers for amplifying an HBV nucleic acid target regioncorresponding to an HBV target nucleic acid, where the oligomers includeat least two amplification oligomers as described above (e.g., one ormore oriented in the sense direction and one or more oriented in theantisense direction for exponential amplification); (2) performing an invitro nucleic acid amplification reaction, where any HBV target nucleicacid present in the sample is used as a template for generating anamplification product; and (3) detecting the presence or absence of theamplification product, thereby determining the presence or absence ofHBV in the sample, or quantifying the amount of HBV nucleic acid in thesample.

In some embodiments, amplification comprises contacting the sample withat least four oligomers for amplifying an HBV nucleic acid target regioncorresponding to an HBV target nucleic acid, where the oligomers includeat least two amplification oligomers for producing a first amplicon asdescribed above (e.g., one or more oriented in the sense direction andone or more oriented in the antisense direction for exponentialamplification) and at least two amplification oligomers for producing asecond amplicon as described above (e.g., one or more oriented in thesense direction and one or more oriented in the antisense direction forexponential amplification); (2) performing an in vitro nucleic acidamplification reaction, where any HBV target nucleic acid present in thesample is used as a template for generating an amplification product;and (3) detecting the presence or absence of the first or secondamplicons, thereby determining the presence or absence of HBV in thesample, or quantifying the amount of HBV nucleic acid in the sample.

A detection method in accordance with the present disclosure can furtherinclude the step of obtaining the sample to be subjected to subsequentsteps of the method. In certain embodiments, “obtaining” a sample to beused includes, for example, receiving the sample at a testing facilityor other location where one or more steps of the method are performed,and/or retrieving the sample from a location (e.g., from storage orother depository) within a facility where one or more steps of themethod are performed.

In certain embodiments, the method further includes purifying the HBVtarget nucleic acid from other components in the sample, e.g., before anamplification, such as before a capture step. Such purification mayinclude methods of separating and/or concentrating organisms containedin a sample from other sample components, or removing or degradingnon-nucleic acid sample components, e.g., protein, carbohydrate, salt,lipid, etc. In some embodiments, DNA in the sample is degraded, e.g.,with DNase, and optionally removing or inactivating the DNase orremoving degraded DNA.

In particular embodiments, purifying the target nucleic acid includescapturing the target nucleic acid to specifically or non-specificallyseparate the target nucleic acid from other sample components.Non-specific target capture methods may involve selective precipitationof nucleic acids from a substantially aqueous mixture, adherence ofnucleic acids to a support that is washed to remove other samplecomponents, or other means of physically separating nucleic acids from amixture that contains HBV nucleic acid and other sample components.

Target capture typically occurs in a solution phase mixture thatcontains one or more capture probe oligomers that hybridize specificallyto the HBV target sequence under hybridizing conditions, usually at atemperature higher than the T_(m) of thetail-sequence:immobilized-probe-sequence duplex. For embodimentscomprising a capture probe tail, the HBV-target:capture-probe complex iscaptured by adjusting the hybridization conditions so that the captureprobe tail hybridizes to the immobilized probe. Certain embodiments usea particulate solid support, such as paramagnetic beads.

Isolation can follow capture, wherein the complex on the solid supportis separated from other sample components. Isolation can be accomplishedby any appropriate technique, e.g., washing a support associated withthe HBV-target-sequence one or more times (e.g., 2 or 3 times) to removeother sample components and/or unbound oligomer. In embodiments using aparticulate solid support, such as paramagnetic beads, particlesassociated with the HBV-target may be suspended in a washing solutionand retrieved from the washing solution, In some embodiments by usingmagnetic attraction. To limit the number of handling steps, the HBVtarget nucleic acid may be amplified by simply mixing the HBV targetsequence in the complex on the support with amplification oligomers andproceeding with amplification steps.

Linear amplification can be performed, e.g., by contacting the targetnucleic acid sequence with a first phase amplification reaction mixturethat supports linear amplification of the target nucleic acid sequenceand lacks at least one component that is required for its exponentialamplification. In some embodiments, the first phase amplificationreaction mixture includes an amplification enzyme selected from areverse transcriptase, a polymerase, and a combination thereof. Thepolymerase is typically selected from an RNA-dependent DNA polymerase, aDNA-dependent DNA polymerase, a DNA-dependent RNA polymerase, and acombination thereof. In some embodiments, the first phase amplificationreaction mixture further includes a ribonuclease (RNase), such as anRNase H or a reverse transcriptase with an RNase H activity. In someembodiments, the first phase amplification mixture includes a reversetranscriptase with an RNase H activity and an RNA polymerase.

In some embodiments, the first phase amplification mixture may alsoinclude an amplification oligonucleotide. The amplificationoligonucleotide can include a 5′ promoter sequence for an RNApolymerase, such as T7 RNA polymerase, and/or a blocked 3′ terminus thatprevents its enzymatic extension. In addition, the first phaseamplification mixture may sometimes include a blocker oligonucleotide toprevent enzymatic extension of the target nucleic sequence beyond adesired end-point.

As noted above, the key feature of the first phase amplificationreaction is its inability to support an exponential amplificationreaction because one or more components required for exponentialamplification are lacking, and/or an agent is present which inhibitsexponential amplification, and/or the temperature of the reactionmixture is not conducive to exponential amplification, etc. Withoutlimitation, the lacking component required for exponential amplificationand/or inhibitor and/or reaction condition may be selected from thefollowing group: an amplification oligonucleotide (e.g., anamplification oligonucleotide comprising a 5′ promoter sequence for anRNA polymerase, a non-promoter amplification oligonucleotide, or acombination thereof), an enzyme (e.g., a polymerase, such as an RNApolymerase), a nuclease (e.g., an exonuclease, an endonuclease, acleavase, an RNase, a phosphorylase, a glycosylase, etc), an enzymeco-factor, a chelator (e.g., EDTA or EGTA), ribonucleotide triphosphates(rNTPs), deoxyribonucleotide triphosphates (dNTPs), Mg²⁺, a salt, abuffer, an enzyme inhibitor, a blocking oligonucleotide, pH,temperature, salt concentration and a combination thereof. In somecases, the lacking component may be involved indirectly, such as anagent that reverses the effects of an inhibitor of exponentialamplification which is present in the first phase reaction.

Exponentially amplifying an HBV target sequence utilizes an in vitroamplification reaction using at least two amplification oligomers thatflank a target region to be amplified.

In some embodiments, at least first and second amplification oligomersas described above are provided. In particular embodiments, the targetregion to be amplified substantially corresponds to a region of SEQ IDNO: 1 including nucleotide position 417 or 418, e.g., about positions415-420, 410-425, 405-430, 400-435, 395-440, 390-445, 385-450, 380-455,or 376-459 (including oligomer sequences incorporated into theamplification product).

In some embodiments, at least third and fourth amplification oligomersas described above are provided. In particular embodiments, the targetregion to be amplified substantially corresponds to a region of SEQ IDNO: 1 including nucleotide position 677, e.g., about positions 675-679,670-684, 665-689, 660-694, 655-699, 650-704, or 646-708 (includingoligomer sequences incorporated into the amplification product).

Particularly suitable amplification oligomer combinations foramplification of these target regions are described above. In someembodiments, the target regions flanked by the first and secondamplification oligomers and by the third and fourth amplificationoligomers are amplified in the same reaction mixture. Suitableamplification methods include, for example, replicase-mediatedamplification, polymerase chain reaction (PCR), ligase chain reaction(LCR), strand-displacement amplification (SDA), andtranscription-mediated or transcription-associated amplification (TMA).

For example, some amplification methods that use TMA amplificationinclude the following steps. Briefly, the target nucleic acid thatcontains the sequence to be amplified is provided as single-strandednucleic acid (e.g., ssRNA such as HBV RNA). Those skilled in the artwill appreciate that, alternatively, DNA can be used in TMA;conventional melting of double stranded nucleic acid (e.g., dsDNA) maybe used to provide single-stranded target nucleic acids. A promoterprimer (e.g., a third amplification oligomer comprising a promoter asdescribed above) binds specifically to the target nucleic acid at itstarget sequence and a reverse transcriptase (RT) extends the 3′ end ofthe promoter primer using the target strand as a template to create acDNA extension product, resulting in an RNA:DNA duplex if ssRNA was theoriginal template. An RNase digests the RNA strand of the RNA:DNA duplexand a second primer binds specifically to its target sequence, which islocated on the cDNA strand downstream from the promoter primer end. RTsynthesizes a new DNA strand by extending the 3′ end of the other primerusing the first cDNA template to create a dsDNA that contains afunctional promoter sequence. An RNA polymerase specific for thepromoter sequence then initiates transcription to produce RNAtranscripts that are about 100 to 1000 amplified copies (“amplicons”) ofthe initial target strand in the reaction. Amplification continues whenthe other primer binds specifically to its target sequence in each ofthe amplicons and RT creates a DNA copy from the amplicon RNA templateto produce an RNA:DNA duplex. RNase in the reaction mixture digests theamplicon RNA from the RNA:DNA duplex and the promoter primer bindsspecifically to its complementary sequence in the newly synthesized DNA.RT extends the 3′ end of the promoter primer to create a dsDNA thatcontains a functional promoter to which the RNA polymerase binds totranscribe additional amplicons that are complementary to the targetstrand. The autocatalytic cycles of making more amplicon copies repeatduring the course of the reaction resulting in about a billion-foldamplification of the target nucleic acid present in the sample. Theamplified products may be detected in real-time during amplification, orat the end of the amplification reaction by using a probe that bindsspecifically to a target sequence contained in the amplified products.Detection of a signal resulting from the bound probes indicates thepresence of the target nucleic acid in the sample.

In some embodiments, the method utilizes a “reverse” TMA reaction. Insuch variations, the initial or “forward” amplification oligomer is apriming oligonucleotide that hybridizes to the target nucleic acid inthe vicinity of the 3′-end of the target region. A reverse transcriptase(RT) synthesizes a cDNA strand by extending the 3′-end of the primerusing the target nucleic acid as a template. The other or “reverse”amplification oligomer is a promoter primer or promoter provider havinga target-hybridizing sequence configured to hybridize to atarget-sequence contained within the synthesized cDNA strand. Where thesecond amplification oligomer is a promoter primer, RT extends the 3′end of the promoter primer using the cDNA strand as a template to createa second, cDNA copy of the target sequence strand, thereby creating adsDNA that contains a functional promoter sequence. Amplification thencontinues essentially as described above in the preceding paragraph forinitiation of transcription from the promoter sequence utilizing an RNApolymerase. Alternatively, where the second amplification oligomer is apromoter provider, a terminating oligonucleotide, which hybridizes to atarget sequence that is in the vicinity to the 5′-end of the targetregion, is typically utilized to terminate extension of the primingoligomer at the 3′-end of the terminating oligonucleotide, therebyproviding a defined 3′-end for the initial cDNA strand synthesized byextension from the priming oligomer. The target-hybridizing sequence ofthe promoter provider then hybridizes to the defined 3′-end of theinitial cDNA strand, and the 3′-end of the cDNA strand is extended toadd sequence complementary to the promoter sequence of the promoterprovider, resulting in the formation of a double-stranded promotersequence. The initial cDNA strand is then used a template to transcribemultiple RNA transcripts complementary to the initial cDNA strand, notincluding the promoter portion, using an RNA polymerase that recognizesthe double-stranded promoter and initiates transcription therefrom. Eachof these RNA transcripts is then available to serve as a template forfurther amplification from the first priming amplification oligomer.

The detection step may be performed using any of a variety of knowntechniques to detect a signal specifically associated with the amplifiedtarget sequence, such as, e.g., by hybridizing the amplification productwith a labeled detection probe and detecting a signal resulting from thelabeled probe. The detection step may also provide additionalinformation on the amplified sequence, such as, e.g., all or a portionof its nucleic acid base sequence. Detection may be performed after theamplification reaction is completed, or may be performed simultaneouslywith amplifying the target region, e.g., in real time. In oneembodiment, the detection step allows homogeneous detection, e.g.,detection of the hybridized probe without removal of unhybridized probefrom the mixture (see. e.g., U.S. Pat. Nos. 5,639,604 and 5,283,174,each incorporated by reference herein). In some embodiments, the nucleicacids are associated with a surface that results in a physical change,such as a detectable electrical change. Amplified nucleic acids may bedetected by concentrating them in or on a matrix and detecting thenucleic acids or dyes associated with them (e.g., an intercalating agentsuch as ethidium bromide or cyber green), or detecting an increase indye associated with nucleic acid in solution phase. Other methods ofdetection may use nucleic acid detection probes that are configured tospecifically hybridize to a sequence in the amplified product anddetecting the presence of the probe:product complex, or by using acomplex of probes that may amplify the detectable signal associated withthe amplified products (e.g., U.S. Pat. Nos. 5,424,413; 5,451,503; and5,849,481; each incorporated by reference herein). Directly orindirectly labeled probes that specifically associate with the amplifiedproduct provide a detectable signal that indicates the presence of thetarget nucleic acid in the sample. In particular, the amplified productwill contain a target sequence in or complementary to a sequence in theHBV genomic RNA, and a probe will bind directly or indirectly to asequence contained in the amplified product to indicate the presence ofHBV nucleic acid in the tested sample.

In embodiments that detect the amplified product near or at the end ofthe amplification step, a linear detection probe may be used to providea signal to indicate hybridization of the probe to the amplifiedproduct. One example of such detection uses a luminescentally labeledprobe that hybridizes to target nucleic acid. Luminescent label is thenhydrolyzed from non-hybridized probe. Detection is performed bychemiluminescence using a luminometer (see, e.g., International PatentApplication Pub. No. WO 89/002476, incorporated by reference herein). Inother embodiments that use real-time detection, the detection probe maybe a hairpin probe such as, for example, a molecular beacon, moleculartorch, or hybridization switch probe that is labeled with a reportermoiety that is detected when the probe binds to amplified product. Suchprobes may comprise target-hybridizing sequences andnon-target-hybridizing sequences. Various forms of such probes have beendescribed previously (see, e.g., U.S. Pat. Nos. 5,118,801; 5,312,728;5,925,517; 6,150,097; 6,849,412; 6,835,542; 6,534,274; and 6,361,945;and US Patent Application Pub. Nos. 20060068417A1 and 20060194240A1;each incorporated by reference herein).

In some embodiments, a molecular torch (sometimes referred to simply asa torch) is used for detection. In some embodiments, the torch is aprobe oligomer as disclosed above.

In general, the disclosed methods can involve the step of consulting astandard curve that relates pre-amplification amounts of analytepolynucleotide and post-amplification amounts of analyte amplicon.

Since real-time amplification reactions advantageously featurequantitative relationships between the number of analyte polynucleotidesinput into the reaction and the number of analyte amplicons synthesizedas a function of time, the number of analyte polynucleotides present ina test sample can be determined using a standard curve. For example, aplurality of amplification reactions containing known amounts of apolynucleotide standard can be run in parallel with an amplificationreaction prepared using a test sample containing an unknown number ofanalyte polynucleotides. Alternatively, a standard curve can be preparedin advance so that it is unnecessary to prepare a curve each time ananalytical procedure is carried out. Such a curve prepared in advancecan even be stored electronically in a memory device of a testinginstrument. A standard curve having pre-amplification amounts of thepolynucleotide standard on a first axis and some indicia of the timerequired to effect a certain level of nucleic acid amplification (suchas a time-of-emergence above a background signal) on a second axis isthen prepared. The post-amplification amount of analyte ampliconmeasured for the test reaction is then located on the post-amplificationaxis of the standard curve. The corresponding value on the other axis ofthe curve represents the pre-amplification amount of analytepolynucleotide that was present in the test reaction. Thus, determiningthe number of molecules of analyte polynucleotide present in the testsample is accomplished by consulting the standard curve, or moreparticularly by comparing the quantitative results obtained for the testsample with the standard curve, a procedure that will be familiar tothose having an ordinary level of skill in the art.

The procedures described herein can easily be used to quantify analytepolynucleotides (e.g., HBV nucleic acid) present in a test sample.Indeed, if a plurality of standard control amplification reactions areinitiated using known numbers of an analyte polynucleotide standard, andif a test reaction that includes an unknown number of analytepolynucleotide molecules is carried out, then it becomes possible aftermeasuring the time required to effect a certain level of amplificationin each reaction to determine the number of analyte polynucleotidemolecules that must have been present in the test sample. Therelationship between the number of analyte polynucleotide moleculesinput into standard amplification reaction and the time required toeffect a certain level of amplification is conveniently establishedusing a graph. Determining the number of analyte polynucleotidemolecules present in a test sample is simply a matter of determiningfrom the standard graph the number of analyte polynucleotide moleculesthat correspond to a measured analyte amplicon signal strength. Thisillustrates how analyte polynucleotide standards can be used inconnection with polynucleotide amplification reactions to quantifypre-amplification amounts of analyte polynucleotide contained in testsamples.

In some embodiments, quantification is performed based on one or both offirst and second amplicons such as those discussed above. In someembodiments, levels of the first and second amplicons are determined,e.g., based on signals from first and second probe oligomers (e.g.,labeled probe oligomers) configured to specifically hybridize to thefirst and second amplicons, respectively. The levels can be compared toa predetermined threshold to determine how to proceed with determining alevel of HBV nucleic acid in the sample. For example, if one or both ofthe levels is about equal to or above the predetermined threshold, thenthe higher of the levels can be used to determine the level of HBVnucleic acid in the sample. On the other hand, if one or both of thelevels is below the predetermined threshold, then the average of thelevels can be used to determine the level of HBV nucleic acid in thesample. In some embodiments, the average is an arithmetic mean (e.g., 20copies/ml based on first and second levels of 10 and 30 copies/ml). Insome embodiments, the average is a geometric mean (e.g., 1.2 logcopies/ml based on first and second levels of 1.1 and 1.3 logcopies/ml).

Levels can be expressed in various ways, e.g., as concentrations,absolute numbers of copies, mass, emergence time, or RLU or RFU. Levelscan be logarithmic or arithmetic. Levels can be converted betweendifferent forms of expression. For example, RFU versus time can beconverted to an emergence time, and emergence time can be converted to alogarithmic value using a calibration curve. As a further example, thelogarithmic value can be converted to an arithmetic value. In someembodiments, a calibration curve or other appropriate standard is usedto aid in comparing a level to a predetermined threshold.

In some embodiments, the predetermined threshold is at a value whereexpected instrument error is greater than or about equal to expectederror due to a point mutation, or at a value where expected error due toa point mutation is greater than or about equal to expected randomerror. Random error represents the variation that occurs betweenreplicate measurements due to sources of error such as variability inbiochemical processes, sample and reagent handling, and instrumentperformance. In some embodiments, the predetermined threshold is withinabout 50 IU/ml, 40 IU/ml, 30 IU/ml, 20 IU/ml, or 10 IU/ml of the valuewhere expected instrument error is equal to expected error due to apoint mutation. In some embodiments, the predetermined threshold iswithin about 1, 0.5, or 0.25 log IU/ml of the value where expectedinstrument error is equal to expected error due to a point mutation. Theexpected errors can be determined using control experiments, e.g.,replicates for instrument error and a comparison of point mutants to HBVnucleic acid without the mutation for expected error due to a pointmutation.

Using a predetermined threshold near the value where expected randomerror is about equal to expected error due to a point mutation can bebeneficial in that when amplicon levels are both below the value, it islikely that random error is the primary source of variability andaveraging is likely to reduce total error. On the other hand, when atleast one amplicon level is above the value, mutations are more likelyto be the primary source of variability such that using the highermeasured level is likely to reduce total error.

Exemplary predetermined thresholds are provided in the summary above interms of IU/ml values, which are understood to be convertible to otherforms as discussed above, including copies/ml, log copies/ml, emergencetime, etc. Additionally, depending on the instrument used, alternativevalues for the predetermined threshold may be desirable.

In some embodiments, a method or use can provide substantiallyequivalent quantification (e.g., within 1, 0.5, or 0.25 logs) of atleast three, four, five, six, seven, eight, or nine HBV genotypes (e.g.,genotypes A, B, C, C2, D, E, F, G, or H), optionally with minimalcross-reactivity to other, non-HBV nucleic acids suspected of being in asample (e.g., other bloodborne pathogens). In some aspects, the methodsHepatitis A, Rubella, Hepatitis C, Herpes simplex 1, Herpes simplex 2,HIV2, Parvovirus, Dengue, CMV, HTLV, Epstein-Barr, and West Nileviruses. In some embodiments, the the methods and uses of the instantdisclosure show minimal cross-reactivity to one or more, or all, of C.albicans, P. acnes, S. aureus, S. epidermis, or N. gonorrhoeae. In oneaspect, the methods and uses of the instant disclosure are multiplexedwith methods for detecting one of more of the foregoing viruses ormicrobes. In general, minimal cross-reactivity is understood as showingat least about 95% specificity, e.g., at least about 96%, 97%, 98%, or99%.

EXAMPLES

The following examples are provided to illustrate certain disclosedembodiments and are not to be construed as limiting the scope of thisdisclosure in any way.

General Reagents and Methods.

Unless otherwise indicated, amplifications were performed isothermallyusing transcription-mediated amplification with T7 RNA polymerase andreverse transcriptase. Biphasic TMA was carried out essentially asdescribed in U.S. Pat. No. 9,139,870, which is incorporated herein byreference. In general, the last primer added in the biphasic procedureswas the T7 primer for each amplicon to be produced, or the shorter T7primer(s) for each amplicon to be produced where a combination of two ormore different T7 primer sequences were used. Exemplary amplificationoligomers include those having the sequences of SEQ ID NOs: 2, 3, 14,15, 30, and 41.

Amplification reactions were conducted for various primer combinationsusing about 5 to 10 pmoles per reaction of T7 primer and nonT7 primer.

Detection used molecular torches as probe oligomers which contained a5′-fluorophore (e.g., FAM or ROX) and a 3′-quencher (e.g., DABCYL)(“5F3D” for FAM and DABCYL or “5R3D” for ROX and DABCYL). Torches arediscussed in detail in U.S. Pat. No. 6,849,412, which is incorporated byreference. Torches generally contained a —(CH₂)₉— linker near the 3′-end(e.g., between the 5^(th) and 6^(th) or between the 4^(th) and 5^(th)nucleotides from the 3′-end). Exemplary probe oligomers include thosehaving the sequences of SEQ ID NOs: 29 and 40. Target capture wasperformed essentially as described in U.S. Pat. No. 8,034,554, which isincorporated herein by reference. Exemplary target capture oligomersinclude those having the sequences of SEQ ID NOs: 45-48 and 87-95.

Exemplary internal control oligomers and template are discussed in U.S.Pat. No. 7,785,844, which is incorporated herein by reference.

Unless otherwise indicated, “HBV database” sequences are from a databaseof approximately 4300 HBV isolate sequences obtained from human donors.

Example 1—Target Capture

Target capture was performed with various exemplary target captureoligomers (TCOs) selected from TCOs having a sequence of SEQ ID NO:45-48 or 87-95 singly and in combination in the presence of initialamplification oligomers (see Example 2), followed by washing linearamplification, exponential amplification, and detection. A copy-to-IUconversion factor of 5 copies/IU was used. Without any addition of TCO,the sensitivity was about 4% or less when 2 IU/mL of WHO standard HBVvirus was tested in serum, compared to the sensitivity of up to about89% when a combination of multiple TCOs was used. Use of various singleTCOs gave a sensitivity in the range of about 30-60%. This shows abenefit that can be provided by using multiple exemplary TCOs.

Example 2—Initial Amplification Oligomers

The functionality of T7 initial amplification oligomers was demonstratedas follows. HBV nucleic acid concentrations of 2 IU/ml, 10 IU/ml, and2000 IU/ml were used as starting material in capture-amplificationreactions. Target capture was performed with a combination of TCOsselected from TCOs having a sequence of SEQ ID NO: 45-48 or 87-95,followed by washing, linear amplification, exponential amplification,and detection. Initial amplification oligomers were omitted in theexperiments whose results appear in FIGS. 4A-B. Accordingly, linearamplification is not believed to have occurred in the experimentsrepresented in FIGS. 4A-B, as no amplification oligomers were addeduntil the commencement of the exponential amplification phase. The A376and A35 initial amplification oligomers (SEQ ID NO: 16 and 31) werepresent at the capture stage in the experiments whose whose resultsappear in FIGS. 4C-D.

At 2000 IU/ml, HBV nucleic acid was detected with reproducible emergencetimes in each experiment (indicated with arrows in FIGS. 4A-D). At thelower concentrations of HBV nucleic acid of 2 IU/ml and 10 IU/ml(indicated with brackets in FIGS. 4A-D; 2 IU/ml traces in gray and 10IU/ml traces in black), the emergence times without T7 initialamplification oligomers (FIGS. 4A-B) were spread over a range of timeshigher than about 27 minutes for each of the amplicons detected by the408-435 probe oligomer and the 668A probe oligomer. With the T7 initialamplification oligomers, the emergence times were generally at about16-22 minutes for the amplicon detected by the 408-435 probe oligomerand at about 18-26 minutes for the amplicon detected by the 668A probeoligomer, although in isolated instances 2 IU/ml samples showed lateremergence times. The 2 IU/ml and 10 IU/ml emergence time data wereimproved when the initial amplification oligomers were used in that thetraces for these experiments showed earlier, more consistent emergencetimes that had less overlap than in the absence of the initialamplification oligomers (FIG. 4C vs. FIG. 4A; and FIG. 4D vs. FIG. 4B),consistent with the initial amplification oligomers facilitating a lowerlimit of quantification.

Example 3—NT7 Amplification Oligomer (−)02

Amplifications were performed on a range of HBV clone sequencescorresponding to sequences from the HBV database using a set ofoligomers at a concentration of 2000 IU/ml (3.3 log IU/ml), in which theNT7 (−)02 oligomer (SEQ ID NO: 3) was lacking and procedures wereotherwise as in Example 2 with the two initial amplification oligomersbeing present. Most sequences were quantified to within about 0.25 logsof the target value, but clone 4G (in which there is a A to G mutationat the NT7 binding site of the corresponding region) wasunder-quantified by about 2 logs (not shown). Reactions with the (−)02oligomer included at 0.2, 0.3, and 0.4 pmol/μl showed quantification inline with other clones and within about 0.25 logs of target, and theeffect of adding the (−)02 oligomer on quantification of other cloneswas minimal.

Example 4—Displacer Oligomers

HBV DNA is partially double-stranded. Displacer oligos such as the259-290 oligomer (SEQ ID NO: 67) or the 452B oligomer (SEQ ID NO: 73)can improve assay performance by generating single stranded templatethrough extension of the displacer oligo and concomitant stranddisplacement.

The effect of using displacer oligos is shown below, in Table 1.Procedures were as in Example 2 with the two initial amplificationoligomers present except that the displacer oligomers used were asindicated in Table 1.

TABLE 1 Sensitivity of detection of HBV with different displaceroligomers. Both Displacers 452B No Displacers Probe N Present 259-290only only Present 408-435 27 89% 63% 33% 33% (SEQ ID NO: 29) 668A 27 89%74% 74% 82% (SEQ ID NO: 40)

Example 5—Exemplary Internal Control Oligomers

Oligomers according to SEQ ID NO: 77 (NT7 amplification oligomer), 78(T7 amplification oligomer), 79 (probe), and 80 (capture) were evaluatedfor use as an internal control (a.k.a. general internal control [GIC],IC). Including the appropriate IC oligomers in the target capture andamplification reagents along with IC template in the target capturereagent did not significantly affect assay performance (not shown).Modest slowing based on resource competition (e.g., about 1 to 3 minutedifference in emergence time at lower target concentrations) is notconsidered a significant effect.

Example 6—HBV Subtype Detection and Clinical Comparison

Paul-Ehrlich-Institut (PEI) HBV genotype reference panels and anadditional genotype H clinical sample (Boca Biolistics) were tested inreplicates of 5. Procedures were as in Example 2 with the two initialamplification oligomers being present. FIG. 5 shows the quantitationresults compared to results obtained from commercially available Abbottand Roche assays (single replicates). The PEI panel samples weregenerally quantified within 0.3 log copies of the target, comparingfavorably to the individual measurements from the Abbott and Rocheassays.

Example 7—Reproducibility, Linearity, and Data Analysis

Reproducibility.

A set of 796 individual donor samples with representation of GenotypesA-H and a range of viral loads was tested for reproducibility. The assaywas as described in Example 2 including the two initial amplificationoligomers. Quantification was reproducible over a wide range ofconcentrations of HBV nucleic acid as demonstrated in FIG. 6A.

Linearity.

Quantification was also linear with emergence time for detection of bothamplicons over a range encompassing from 2 to 9 log copies/ml ofdouble-stranded HBV DNA (FIG. 6B, amplicon detected by 408-435 probeoligomer, FIG. 6C, amplicon detected by 668A probe oligomer).

Data Analysis.

It was observed that precision was lower at the low end ofconcentrations, e.g., below about 50 IU/ml (about 1.7 log IU/ml) (FIG.6A). It was also found that divergent measurements of amplicon 1 andamplicon 2 (e.g., where amplicon 1 indicated a concentration below about50 IU/ml and amplicon 2 indicated a concentration above about 50 IU/ml,or vice versa) sometimes resulted from the presence of a mutation in theHBV sequence that delayed amplification and suppressed the observedconcentration accordingly (data not shown).

In light of this phenomenon and the comparatively higher accuracy andprecision of single amplicon quantification above about 50 IU/ml, apiecewise analytical process was developed in which the assay result wasreported as the maximum of the amplicon 1 and 2 observations if eitheror both were greater than or equal to 50 IU/ml, and otherwise thearithmetic mean of the amplicon 1 and 2 observations was reported. Thispiecewise process was found to improve overall accuracy (e.g., expressedas the frequency of errors exceeding a threshold such as 0.25 logcopies/ml relative to target over a panel of different genotypes andconcentrations) relative to each of (i) always reporting the mean and(ii) always reporting the maximum. It is understood that the transitionbeing at 50 IU/ml is not critical to obtain a benefit with respect tooverall accuracy; for example, transition values such as about 25 IU/mlor 100 IU/ml are also expected to be effective.

Example 8—Effect of Quantifying for Amplicons 1+2 on Accuracy andReactivity in Low Concentration Assays

The effect of including reagents for amplification and detection ofamplicon 2 in addition to amplicon 1 was evaluated. Procedures were asin Example 2 with the two initial amplification oligomers being present,except that for the Amplicon 1 only data, the A35, A02, A08, and 668Aoligomers were not present. Accuracy was evaluated at 10 IU/ml.Sensitivity was evaluated at 5 IU/ml.

Quantification of the Amplicon 1+2 results was as described in Example7, using a 50 IU/ml transition value for the piecewise analyticalprocess. Relative to amplicon 1 only, including amplification andanalysis of amplicon 2 reduced total error for Genotypes B-F (Table 2).Reactivity improved or stayed about the same for all genotypes,including genotypes B, D, and E in which reactivity improved to 100%(Table 3).

TABLE 2 Accuracy of Amplicon 1 vs. Amplicon 1 + 2 QuantificationAmplicon 1 Amplicon 1 + 2 Genotype Total Error Total Error (10 IU/ml) N(log IU/ml) N (log IU/ml) A 54 1.08 10 1.11 B 53 1.03 10 0.81 C 54 1.1310 0.75 D 53 1.06 10 0.81 E 54 1.34 10 0.97 F 54 0.9 10 0.45 Total error= bias + 2 × (Standard Deviation)

TABLE 3 Reactivity of Amplicon 1 vs. Amplicon 1 + 2 Detection GenotypeAmplicon 1 Amplicon 1 + 2 (5 IU/ml) N % Reactive N % Reactive A 54 98.110 100 B 54 92.6 10 100 C 54 87 10 90 D 54 87 10 100 E 54 96.3 10 100 F54 100 10 100

Example 9—Additional Characterization of Assay Performance

The assay as described in Example 2 including the two initialamplification oligomers was further characterized as follows.

Quantification Across Genotypes.

Genotypes B-H and C2 were all quantified within about 0.15 logs ofgenotype A by the amplicons individually or in combination as shown inTable 4. Each of genotypes B, C, C2, and E-H were quantified within 0.1logs of genotype A when data from both amplicons were used,demonstrating improved consistency of quantification.

TABLE 4 Quantification Across Genotypes. Amplicons Amplicons AmpliconAmplicon 1 + 2 Amplicon 1 Amplicon 2 Target Log Positivity 1 + 2 Log 1Log 2 Log Diff. from Diff. from Diff. from Sample Copies/mL (%)Copies/mL Copies/mL Copies/mL Genotype A Genotype A Genotype A GenotypeA 4 100.00% 3.97 3.99 3.95 0 0 0 Genotype B 4 100.00% 3.93 3.87 3.970.04 0.12 −0.02 Genotype C 4 100.00% 3.88 3.87 3.9 0.09 0.12 0.05Genotype C2 4 100.00% 3.91 3.92 3.91 0.06 0.07 0.04 Genotype D 4 100.00%3.82 3.84 3.81 0.15 0.15 0.14 Genotype E 4 100.00% 3.9 3.9 3.9 0.07 0.090.05 Genotype F 4 100.00% 3.95 3.84 4.04 0.02 0.15 −0.09 Genotype G 4100.00% 3.91 3.85 3.97 0.06 0.14 −0.02 Genotype H 4 100.00% 3.96 3.884.03 0.01 0.11 −0.08

Clinical Specificity.

Clinical specificity was assessed by testing 292 fresh and 747 frozenHBV negative clinical specimens. A total of 521 plasma and 581 serumspecimens were tested. Specificity was calculated as the percentage ofHBV negative samples for which HBV DNA was not detected. HBV DNA was notdetected in 1038/1039 total samples (99.9% specificity, 95% confidenceinterval: 99.5-100%). The single false positive occurred with a frozenserum sample (Table 5).

TABLE 5 Clinical Specificity results. Valid Replicates Not (n) DetectedSpecificity Fresh Plasma 145 145 100% Frozen Plasma 376 376 100% FreshSerum 147 147 100% Frozen Serum 371 370 99.7%  Total 1039 1038 99.9% (95% CI: 99.5-100%)

Cross-Reactivity.

To assess whether the assay would cross react with microorganisms orviruses that could be present in clinical samples, resulting in falsepositive results or bias to quantification accuracy, 5 microorganismsand 15 blood borne viruses (BBV) were spiked into HBV negative normaldonors (Table 6). None of the microorganisms contributed to falsepositive results in the absence of HBV virus. In the presence of HBVVirus at 2000 IU/mL (i.e., 10000 copies/ml or 4 log copies/ml), none ofthe microorganisms interfered with detection. The HBV-positive sampleswith an additional microorganism or blood borne virus all showed 100%reactivity and were quantified within an average of 0.21 log copies. Themaximum difference observed was 0.38 log copies for HIV-2 in detectionof amplicon 2 and HTLV in detection of both amplicons.

TABLE 6 Analysis of Cross-Reactivity. # of % Condition Microorganism NPositive Reactive Microorganism Neg Control 5 0 0.0% SpecificityNeisseria gonorrboeae 5 0 0.0% Propionibacterium acnes 5 0 0.0% Candidaalbicans 5 0 0.0% Staphylococcus epidermis 5 0 0.0% Staphylococcusaureus 5 0 0.0% Amplicon Amplicon Amplicon 1 + 2 # of % 1 Mean 2 MeanMean Condition Microorganism/BBV N Positive Reactive LogCopy LogCopyLogCopy Microorganism HBV Pos Control 5 5 100.0% 4.15 4.06 4.10Analytical Neisseria gonorrboeae 5 5 100.0% 4.12 3.99 4.06 SensitivityPropionibacterium acnes 5 5 100.0% 4.13 4.08 4.11 Candida albicans 5 5100.0% 4.14 4.04 4.09 Staphylococcus epidermis 5 5 100.0% 4.12 3.97 4.05Staphylococcus aureus 5 5 100.0% 4.13 4.02 4.07 Bloodborne HBV PosControl 5 5 100.0% 4.14 4.04 4.09 Virus Rubella 5 5 100.0% 3.89 3.723.81 Analytical HSV1 5 5 100.0% 3.94 3.80 3.87 Sensitivity HSV2 5 5100.0% 3.98 3.79 3.89 Flu Vaccinated 5 5 100.0% 4.02 3.82 3.93 EBV 5 5100.0% 3.90 3.73 3.82 HIV2 5 5 100.0% 3.86 3.66 3.77 Parvo 5 5 100.0%4.00 3.84 3.93 CMV 5 5 100.0% 3.97 3.83 3.90 HBV Vaccinated 5 5 100.0%3.95 3.87 3.91 HAV 5 5 100.0% 3.95 3.85 3.90 HTLV 4 4 100.0% 3.76 3.663.71 WNV (3,000 c/mL) 5 5 100.0% 4.00 3.97 3.98 HCV (3,000 c/mL) 5 5100.0% 4.05 3.98 4.02 Dengue (3,000 c/mL) 5 5 100.0% 4.12 4.06 4.09Abbreviations: HSV, herpes simplex virus; EBV, Epstein Barr virus; HIV,human immunodeficiency virus; CMV, cytomegalovirus; HAV, hepatitis Avirus; HTLV, human T-lymphotropic virus; WNV, West Nile virus.

In the following table, lower case letters indicate 2′Ome RNA and uppercase letters indicate DNA.

TABLE OF SEQUENCES SEQ ID NO Description Sequence   1 Representative   1 TTCCACAGCT TTCCACCAAG CTCTGCAAGA TCCCAGAGTC AGGGGCCTGT ATTTTCCTGCHBV A1 sequence,  61 TGGTGGCTCC AGTTCAGGAA CACTCAACCC TGTTCCAACT ATTGCCTCTC ACATCTCGTCGenBank Acc. No. 121 AATCTCCTCG AGGATTGGGG ACCCTGCACC GAACATGGAG AACATCACAT CAGGATTCCTAB116092 181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTTGTTG ACAAGAATCC TCACAATACC 241 GCAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAGCAC CCGTGTGTCT 301 TGGCCAAAAT TCGCAGTCCC CAACCTCCAA TCACTCACCA ACCTCCTGTC CTCCAATTTG 361 TCCTGGTTAT CGCTGGATGT GTCTGCGGCG TTTTATCATA TTCCTCTTCA TCCTGCTGCT 421 ATGCCTCATC TTCTTATTGG TTCTTCTGGA TTATCAAGGT ATGTTGCCCG TTTGTCCTCT 481 AATTCCAGGA TCAACAACAA CCAGCACGGG ACCCTGCAAA ACCTGCACGA CTCCTGCTCA 541 AGGGAACTCT ATGTTTCCCT CATGTTGCTG TACAAAACCT ACGGATGGAA ATTGCACCTG 601 TATTCCCATC CCATCATCTT GGGGTTTCGC AAAATTCCTA TGGGAGTGGG CCTCAGTCCG 661 TTTCTCTTGT CTCAGTTTAC TAGTGCCATT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAC 721 TGTTTGGCTT TTAGCTATAT GGATGATGTG GTACTGGGGG CCAAGTCTGT ACAACATCTT 781 GAGTCCCTTT ACACCGCTGT TACCAATTTT CTTTTGTCTT TGGGTATACA TTTAAACCCT 841 AACAAAACAA AGAGATGGGG TTATTCCCTG AATTTCATGG GTTATGTAAT TGGAAGTTGG 901 GGTACATTGC CACAGGATCA TATTGTACAA AAAATCAAAC ACTGTTTTAG AAAACTTCCT 961 GTAAATCGAC CTATTGATTG GAAAGTATGT CAGAGAATTG TGGGTCTTTT GGGCTTTGCA1021 GCTCCATTTA CACAATGTGG TTACCCTGCA TTAATGCCTT TGTATGCATG TATACAGGCG1081 AAACAGGCTT TTACTTTCTC GCCAACTTAC AAGGCCTTTC TAAGTAAACA GTATATGAAC1141 CTTTACCCCG TTGCCCGGCA ACGGCCTGGT CTGTGCCAAG TGTTTGCTGA CGCAACCCCC1201 ACTGGCTGGG GCTTGGCCAT CGGCCATCAG CGCATGCGTG GAACCTTTGT GGCTCCTCTG1261 CCGATCCATA CTGCGGAACT CCTAGCCGCT TGTTTTGCTC GCAGCAGGTC TGGAGCAAAA1321 CTCATCGGAA CTGATAATTC TGTCGTCCTT TCTCGGAAGT ATACATCCTT TCCATGGCTG1381 CTAGGTTGTA CTGCCAACTG GATTCTTCGC GGGACGTCCT TTGTCTACGT CCCGTCGGCG1441 CTGAATCCCG CGGACGACCC TTCGCGAGGC CGCTTGGGGC TGTATCGTCC CCTTCTCCGT1501 CTGCCGTACC GTCCGACCAC GGGGCGCACC TCTCTTTACG CGGTCTCCCC GTCTGTGCCT1561 TCTCATCTGC CGGTCCGTGT GCACTTCGCT TCACCTCTGC ACGTTGCATG GAGACCACCG1621 TGAACGCCCA TCAGGTCCTG CCCAAGGTCT TATATAAGAG GACTCTTGGA CTCTCAGCAA1681 TGTCAACGAC CGACCTTGAG GCCTACTTCA AAGACTGTGT GTTTAAAGAC TGGGAGGAGT1741 TGGGGGAGGA GATTAGGTTA ATGATCTTTG TATTAGGAGG CTGTAGGCAT AAATTGGTCT1801 GCGCACCATC ATCATGCAAC TTTTTCACCT CTGCCTAATC ATCTCTTGTA CATGTCCCAC1861 TTTTCAAGCC TCCAAGCTGT GCCTTGGATG GCTTTGGGGC ATGGACATTG ACCCTTATAA1921 AGAATTTGGA GCTACTGTGG AGTTACTTTC ATTTTTGCCT TCTGACTTCT TTCCTTCCGT1981 CCGGGATCTA CTAGATACAG TCGCAGCTCT ATTTCGGGAT GCCTTAGAGT CTCCTGAGCA2041 TTGCTCAGCT CACCACACAG CACTAAGGCA AGTCATTCTC TGCTGGGGGG AATTAATGAC2101 TCTAGCTACC TGGGTGGGTA CTAATTTGCA AGATCCAGCA TCCAGGGATC TAGTAGTCAG2161 TTATGTTAAT GATAACATGG GCCTAAAGAT CAGGCAATTA TTATGGTTTC ATACTTCTTG2221 CATTACTTTT GGAAGAGAAA CTGTCCTTGA GTATTTGGTC TCTTTCGGAG TGTGGATTCG2281 CACTCCTCCA GCCTATAGAC CACCAAATGC CCCTATCTTA TCAACACTTC CGGAAACTAC2341 TGTTGTTAGA CGACGAGACC GAGGCAGGTC CCCTAGAAGA AGAACTCCCT CGCCTCGCAG2401 ACGAAGATCT CAATCGCCGC GTCGCAGAAG ATCTCAATCT CGGGAACCTC AATGTTAGTA2461 TTCCTTGGAC TCATAAGGTG GGAAATTTTA CTGGACTTTA TTCTTCTACT GTCCCTATCT2521 TTAATCCTGA ATGGCAAACA CCGTCTTTTC CTAAAATTCA TTTACATGAA GACATTGCTA2581 ATAGGTGTCA GCAATTTGTA GGCCCTCTCA CTGTAAATGA AAAAAGAAGA CTGAAATTAA2641 TTATGCCTGC TAGGTTTTAT CCTAACAGCA CAAAATATTT GCCTTTAGAC AAAGGGATTA2701 AAACTTATTA TCCTGATCAG GTAGTTAATC ATTACTTTCA AACCCGACAT TATTTACATA2761 CTCTTTGGAA GGCTGGGATT CTATATAAGA GGGAAACTAC ACGTAGCGCC TCATATTGCG2821 GGTCACCATA TTCTTGGGAA CAAGAGCTAC ATCATGGGAG GTTGGTCATC AAAACCTCGC2881 AAAGGCATGG GGACGAACCT TTCTGTTCCC AACCCGCTGG GATTCTTTCC CGATCATCAG2941 TTGGACCCTG CATTCGGAGC CAATGCAAAC AATCCAGATT GGGACCTCAA CCCCATCAAG3001 GACCACTGGC CACAAGCCAA CCAGGTAGGA GTGGGAGCAT TTGGACCAGG GCTCACTCCC3061 CCACACGGAG GTGTTTTGGG GTGGAGCCCT CAGGCTCAAG GCATATTGGC CACCGTGCCA3121 ACAGTGCCTC CTCCTGCCTC CACCAATCGG CAGTCGGGAA GGCAGCCTAC TCCCATTTCT3181 CCACCTCTAA GAGACAGTCA TCCTCAGGCC ATGCAGTGGA A   2 NT7 amplificationGGCACCTAGTCCAGAAGAACCAA oligomer 474-455   3 NT7 amplificationGGCACCTAGTCCAGAAGAACC oligomer (-)02   4 amplification CAGAAGAACColigomer subsequence   5 amplification TAGTCCAGAA oligomer subsequence  6 amplification GCACCTAGTC oligomer subsequence   7 amplificationGAAGAACCAA oligomer subsequence   8 Exemplary T7 TAATACGACTCACTATAGpromoter   9 Sequence comprising TAATACGACTCACTATAGGGAGA T7 promoter  10Sequence comprising TAATACGACTCACTATAGGGAGACCACAACG T7 promoter  11Sequence comprising AATTTAATACGACTCACTATAG T7 promoter  12Sequence comprising AATTTAATACGACTCACTATAGGGAGA T7 promoter  13Sequence comprising AATTTAATACGACTCACTATAGGGAGACCACAACG T7 promoter  14T7 amplification AATTTAATACGACTCACTATAGGGAGAGATGTGTCTGCGGCGTTTTATColigomer 376-397  15 T7 amplificationAATTTAATACGACTCACTATAGGGAGAGATGTGTCTGCGGCGTTTTATCATCTT oligomer 376-402 16 T7 amplificationAATTTAATACGACTCACTATAGGGAGAGATGTGTCTGCGGCGTTTTATCATCTTCCT oligomer A376 17 amplification GGAGAGATGTGTCTGCGGCGTTTTATCATCTTCCT oligomer A376subsequence  18 amplification GGAGAGATGTGTCTGCGGCGTTTTATColigomer 376-397 subsequence  19 amplificationGGAGAGATGTGTCTGCGGCGTTTTATCATCTT oligomer 376-402 subsequence  20amplification GATGTGTCTGCGGCGTTTTATCATCTTCCT oligomer A376 subsequence 21 amplification GATGTGTCTGCGGCGTTTTATC oligomer 376-397 subsequence 22 amplification GATGTGTCTGCGGCGTTTTATCATCTT oligomer 376-402subsequence  23 amplification GCGTTTTATC oligomer subsequence  24amplification CTGCGGCGTT oligomer subsequence  25 amplificationTGTGTCTGCG oligomer subsequence  26 amplification TTATCATCTToligomer subsequence  27 amplification TCATCTTCCT oligomer subsequence 28 amplification GGAGAGATGT oligomer subsequence  29 probe oligomercccacaagaagaugaggcauagcagcaggauga(C9)guggg 408-435  30 amplificationAATTTAATACGACTCACTATAGGGAGACCACAACGGTGGGCCTCAGTCCGTTTCTC oligomer A02 31 amplificationAATTTAATACGACTCACTATAGGGAGACCACAACGGTGGGCCTCAGTCCGTTTCTCITGGCToligomer A35  32 amplification GGAGACCACAACGGTGGGCCTCAGTCCGTTTCTColigomerA02 subsequence  33 amplificationGGAGACCACAACGGTGGGCCTCAGTCCGTTTCTCITGGCT oligomerA35 subsequence  34amplification CCACAACGGTGGGCCTCAGTCCGTTTCTC oligomer A02 subsequence  35amplification CCACAACGGTGGGCCTCAGTCCGTTTCTCITGGCT oligomer A35subsequence  36 amplification TCCGTTTCTC oligomer subsequence  37amplification CTCAGTCCGT oligomer subsequence  38 amplificationTGGGCCTCAG oligomer subsequence  39 amplification TCTCITGGCToligomer subsequence  40 probe oligomer 668Augcgcuaguaaacugagccag(C9)gcgca  41 NT7 amplificationCCTGCGAACCACTGAACAAA oligomer A08  42 amplification CACTGAACAAAoligomer subsequence  43 amplification GAACCACTGA oligomer subsequence 44 amplification CCTGCGAACC oligomer subsequence  45 Capture oligomerGGGCTTTCCCCCACTGTTTGGCTTTTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 0707b  46Capture oligomer 733AGTTATATGGATGATGTGGTATTGGTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  47Capture oligomer 1168GGTCTGTGCCAAGTGTTTGCTGACGCTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  48Capture oligomer 1290TTGTTTTGCTCGCAGCCGGTCTGGAGCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  49Capture oligomer GGGCTTTCCCCCACTGTTTGGC 0707b targethybridizing sequence  50 Capture oligomer ACTGTTTGGC subsequence  51Capture oligomer CCCCCACTGT subsequence  52 Capture oligomer GGGCTTTCCCsubsequence  53 Capture oligomer 733 AGTTATATGGATGATGTGGTATTGGtarget hybridizing sequence  54 Capture oligomer GTGGTATTGG subsequence 55 Capture oligomer ATGATGTGGT subsequence  56 Capture oligomerTATGGATGAT subsequence  57 Capture oligomer 1168GGTCTGTGCCAAGTGTTTGCTGACGC target hybridizing sequence  58Capture oligomer TTGCTGACGC subsequence  59 Capture oligomer AGTGTTTGCTsubsequence  60 Capture oligomer TGCCAAGTGT subsequence  61Capture oligomer 1290 TTGTTTTGCTCGCAGCCGGTCTGGAGCG target hybridizingsequence  62 Capture oligomer GTCTGGAGCG subsequence  63Capture oligomer AGCCGGTCTG subsequence  64 Capture oligomer CTCGCAGCCGsubsequence  65 T₃A₃₀ TTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  66 A₃₀AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  67 AmplificationAATTTAATACGACTCACTATAGGGAGAAGACTCGTGGTGGACTTCTCTCAATTTTCToligomer 259-290 (T7 displacer)  68 AmplificationGGAGAAGACTCGTGGTGGACTTCTCTCAATTTTCT oligomer 259-290 subsequence  69Amplification AGACTCGTGGTGGACTTCTCTCAATTTTCT oligomer 259-290subsequence  70 Amplification TCAATTTTCT oligomer 259-290 subsequence 71 Amplification TTCTCTCAAT oligomer 259-290 subsequence  72Amplification TGGACTTCTC oligomer 259-290 subsequence  73 AmplificationTATCAAGGTATGTTGCCCGT oligomer 452B (NT7 displacer)  74 AmplificationTGTTGCCCGT oligomer 452B subsequence  75 Amplification AGGTATGTTGoligomer 452B subsequence  76 Amplification TATCAAGGTA oligomer 452Bsubsequence  77 Control NT7 GATTATATAGGACGACAAG amplificationoligomer 4102  78 Control T7AATTTAATACGACTCACTATAGGGAGAGATGATTGACTTGTGATTCCGC amplificationoligomer 4203  79 Control Probe gcaug(c9)gugcgaauugggacaugcoligomer 4180-4197 C9(5-6)  80 Control captureucguucacuauuggucucugcauucTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA oligomer 4277 81 Control capture cguucacuauuggucucugcauuc oligomer targethybridizing sequence  82 Probe oligomer aagaagaugaggcauagcagcaggauga408-435 subsequence  83 Probe oligomer gcuaguaaac 668A subsequence  84Probe oligomer uaguaaacugagccag 668A subsequence  85 Probe oligomergcuaguaaacugagccag(C9)gc 668A subsequence  86 Control amplifi-GATGATTGACTTGTGATTCCGC cation oligomer 4203 subsequence  87Capture oligomer 1168GGTCTGTGCCAAGTGTTTGCTGACGCTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  88Capture oligomer 1254TCCTCTGCCGATCCATACTGCGGAACTCCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  89Capture oligomer 1290TTGTTTTGCTCGCAGCCGGTCTGGAGCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  90Capture oligomer 707GGGCTTTCCCCCACTGTTTGGCTTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  91Capture oligomer 733AGTTATATGGATGATGTGGTATTGGTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  92Capture oligomer 794CCGCTGTTACCAATTTTCTTTTGTCTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  93Capture oligomerGGUCUGUGCCAAGUGUUUGCUGACGCTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1168MR  94Capture oligomerGUCUGUGCCAAGUGUUUGCUGACGCTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1290MR  95Capture oligomerAGUUAUAUGGAUGAUGUGGUACUGGTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 733MR  96Capture oligomer 1168 GGTCTGTGCCAAGTGTTTGCTGACGC target hybridizingsequence  97 Capture oligomer 1254 TCCTCTGCCGATCCATACTGCGGAACTCCtarget hybridizing sequence  98 Capture oligomer 1290TTGTTTTGCTCGCAGCCGGTCTGGAGCG target hybridizing sequence  99Capture oligomer 707 GGGCTTTCCCCCACTGTTTGGCTTTT target hybridizingsequence 100 Capture oligomer 733 AGTTATATGGATGATGTGGTATTGGtarget hybridizing sequence 101 Capture oligomer 794CCGCTGTTACCAATTTTCTTTTGTC target hybridizing sequence 102Capture oligomer GGUCUGUGCCAAGUGUUUGCUGACGC 1168MR targethybridizing sequence 103 Capture oligomer GUCUGUGCCAAGUGUUUGCUGACGC1290MR target hybridizing sequence 104 Capture oligomerAGUUAUAUGGAUGAUGUGGUAUUGG 733MR target hybridizing sequence 105Representative HBV  1 AATTCCACTG CCTTCCACCA AGCTCTGCAG GATCCCAAAG TCAGGGGTCT GTATTTTCCTA2 sequence, 61 GCTGGTGGCT CCAGTTCAGG AACAGTAAAC CCTGCTCCGA ATATTGCCTC TCACATCTCGGenBank Acc. No.121 TCAATCTCCG CGAGGACTGG GGACCCTGTG ACGAATATGG AGAACATCAC ATCAGGATTCAY707087, positions181 CTAGGACCCC TGCTCGTGTT ACAGGCGGGG TTTTTCTTGT TGACAAGAAT CCTCACAATA1-900241 CCGCAGAGTC TAGACTCGTG GTGGACTTCT CTCAATTTTC TAGGGGGATC ACCCGTGTGT301 CTTGGCCAAA ATTCGCAGTC CCCAACCTCC AATCACTCAC CAACCTCCTG TCCTCCAATT361 TGTCCTGGTT ATCGCTGGAT GTGTCTGCGG CGTTTTATCA TATTCCTCTT CATCCTGCTG421 CTATGCCTCA TCTTCTTGTT GGTTCTTCTG GATTATCAAG GTATGTTGCC CGTTTGTCCT481 CTAATTCCAG GAACAACAAC AACCAGTACG GGACCATGCA AAACCTGCAC GACTCCTGCT541 CAAGGCAACT CTATGTTTCC CTCATGTTGC TGTACAAAAC CTTCGGATGG AAATTGCACC601 TGTATTCCCA TCCCATCGTC TTGGGCTTTC GCAAAATACC TATGGGAGTG GGCCTCAGTC661 CGTTTCTCTT GGCTCAGTTT ACTAGTGCCA TTTGTTCAGT GGTTCGTAGG GCTTTCCCCC721 ACTGTTTGGC TTTCAGCTAT ATGGATGATG TGGTATTGGG GGCCAAGTCT GTACAGCATC781 GTGAGTCCCT TTATACCGCT GTTACCAATT TTCTTTTGTC TCTGGGTATA CATTTAAACC841 CTAACAAAAC AAAAAGATGG GGTTATTCCC TAAACTTCAT GGGTTACATA ATTGGAAGTT901 GGGGAACGTT GCCACAGGAT CATATTGTAC AAAAGATCAA ACACTGTTTT AGAAAACTTC106 Representative HBV  1 TTCCACAAAT TTCCACCAAG CTCTGCAAGA TCCCAGAGTC AGGGGCCTGT ATCTTCCTGCA3 sequence, 61 TGGTGGCTCC AGTTCAGGAA CAGTCAACCC TGCTCCGAAT ATTGCCTCTC ACATCTCGTCGenBank Acc. No.121 AATCTCCTCG AGGATTGGGG ACCCTGCGCC GAACATGGAG AACATCACAT CAGGATTCCT181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTCGTTG ACAAAAATCC TCACAATACCAB194951, positions241 GCAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAGCAC CCGTGTGTCT1-900301 TGGCCAAAAT TCGCAGTCCC CAACCTCCAA TCACTCACCA ACCTCCTGTC CTCCAATTTG361 TCCTGGTTAT CGCTGGATGT GTCTGCGGCG TTTTATCATA TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTATTGG TTCTTCTGGA TTGTCAAGGT ATGTTGCCCG TTTGTCCTCT481 AATTCCAGGA TCCACAACCA CCAGTACGGG ACCCTGCAGA ACCTGCACGA CTCCTGCTCA541 AGGCAACTCT ATGTTTCCCT CATGTTGCTG TACAAAACCT ACGGACGGAA ATTGCACCTG601 TATTCCCATC CCATCATCCT GGGCTTTCGC AAAATACCTA TGGGGGTGGG CCTCAGTCCG661 TTTCTCCTGG CTCAGTTTAC TAGTGCCATT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAT721 TGTTTGGCTT TCAGCTATAT GGATGATGTG GTATTGGGGG CCAAGTCTGT ACAACATCTT781 GAGTCCCTTT ATACCGCTGT TACCAATTTT CTTTTGGCTT TGGGCATACA TTTAAACCCT841 AACAAAACAA AAAGATGGGG TTATTCCCTT AACTTCATGG GATACATAAT TGGAAGTTGG107 Representative HBV  1 TTCCACCACT TTCCACCAAA CTCTTCAAGA TCCCAGAGTC AGGGCTCTGT ACCTTCCTGCB1 sequence, 61 TGGTGGCTCC AGTTCAGGAA TAGTAAGCCC TGCTCAGAAT ACTGTCTCTG CCATATCGTCGenBank Acc. No.121 AATCTTATCG ACGACTGGGG ACCCTGTGCC GAACATGGAG AACATCGCAT CAGGACTCCTAB014366, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTCGTTG ACAAAAATCC TCACAATACC1-900241 ACAGAGTCTA GACTCGTGGT GGACTTCTCT CAGTTTTCTA GGGGGAACAC CCGTGTGTCT301 TGGCCAAAAT TCGCAGTCCC AAATCTCCAG TCACTCACCA ACCTGTTGTC CTCCAATTTG361 TCCTGGTTAT CGCTGGATGT ATCTGCGGCG TTTTATCATC TGCCTCTGCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TTTGTCCTCT481 AATTCCAGGA TCATCAACCA CCAGCACGGG ACCATGCAAG ACCTGCACAA CTCCTGCTCA541 AGGAACCTCT ATGTTTCCCT CATGTTGCTG TACAAAACCT ACGGACGGAA ACTGCACCTG601 TATTCCCATC CCATCATCTT GGGCTTTCGC AAAATTCCTA TGGGAGTGGG CCTCAGTCCG661 TTTCTCTTGG CTCAGTTTAC TAGTGCCATT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAC721 TGTCTGGCTT TCAGTTATAT GGATGATGTG GTATTGGGGG CCAAGTCTGT ACAACATCTT781 GAGTCCCTTT ATGCCGCTGT TACCAATTTT CTTTTGTCTT TGGGTATACA TTTAAACCCT841 CACAAAACAA AAAGATGGGG ATATTCCCTT AATTTCATGG GATATGTAAT TGGGAGTTGG108 Representative HBV  1 CTCCACCACT TTCCACCAAA CTCTTCAAGA TCCCAGAGTC AGGGCCCTGT ACTTTCCTGCB2 sequence, 61 TGGTGGCTCC AGTTCAGGAA CAGTGAGCCC TGCTCAGAAT ACTGTCTCTG CCATATCGTCGenBank Acc. No.121 AATCTTATCG AAGACTGGGG ACCCTGTACC GAACATGGAG AACATCGCAT CAGGACTCCTAY596111, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTCGTTG ACAAAAATCC TCACAATACC1-900241 ACAGAGTCTA GACTCGTGGT GGACTTCTCT CAGTTTTCTA GGGGAAACAC CCGTGTGTCT301 TGGCCAAAAT TCGCAGTCCC AAATCTCCAG TCACTCACCA ACCTGTTGTC CTCCAATTTG361 TCCTGGTTAT CGCTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTGCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TTTGTCCTCT481 AATTCCAGGA TCATCAACAA CCAGCACCGG ACCATGCAAA ACCTGCACAA CTTCTGCTCA541 AGGAACCTCT ATGTTTCCCT CATGTTGCTG TACAAAACCT ACGGACGGAA ACTGCACCTG601 TATTCCCATC CCATCATCTT GGGCTTTCGC AAAATACCTA TGGGAGTGGG CCTCAGTCCG661 TTTCTCTTGG CTCAGTTTAC TAGTGCCATT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAC721 TGTCTGGCTT TCAGTTATAT GGATGATGTG GTTTTGGGGG CCAAGACTGT ACAGCATCTT781 GAGTCCCTTT ATGCCGCTGT TACCAATTTT CTTTTGTCTT TGGGCATACA TTTAAACCCT841 CACAAAACAA AAAGATGGGG ATATTCCCTT AACTTCATGG GATATGTAAT TGGGAGTTGG109 Representative HBV  1 CTCCACCACG TTCCACCAAA CTCTTCAAGA TCCCAGAGTC AGGGCTCTGT ACTTTCCTGCB3 sequence, 61 TGGTGGCTCC AGTTCAGGAA CAGTAAACCC TGTTCAGAAC ACTGTCTCTT CCATATCGTCGenBank Acc. No.121 AATCTTATCG AAGACTGGGG ACCCTGTGCC GAACATGGAG AACATCGCAT CAGGACTCCTM54923, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTTGTTG ACAAAAATCC TCACAATACC1-900241 ACAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAACAC CCGTGTGTCT301 TGGCCAAAAT TCGCAGTCCC AAATCTCCAG TCACTCACCA ACTTGTTGTC CTCCGATTTG361 TCCTGGTTAT CGCTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTGCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TTTGTCCTCT481 AATTCCAGGA TCATCAACCA CCAGCACCGG ACCATGCAAA ACCTGCACGA CTCCTGCTCA541 AGGAACCTCT ATGTTTCCCT CATGTTGCTG TACAAAACCT ACGGACGGAA ACTGCACCTG601 TATTCCCATC CCATCATCTT GGGCTTTCGC AAAATACCTA TGGGAGTGGG CCTCAGTCCG661 TTTCTCTTGG CTCAGTTTAC TAGTGCCATT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAC721 TGTCTGGCTT TCAGTTATAT GGATGATGTG GTTTTGGGGG CCAAGTCTGT ACAACATCTT781 GAGTCCCTTT ATGCCGCTGT TACCAATTTT CTTTTGTCTT TGGGTATACA TTTAAACCCT841 CAGAAAACAA AAAGATGGGG CTACTCCCTC AACTTCATGG GGTATGTAAT TGGAAGTTGG110 Representative HBV  1 CTCCACCACT TTCCATCAAA CTCTTCAAGA TCCCAGAGTC AGGGCTCTGT ACTTTCCTGCB4 sequence, 61 TGGTGGCTCC AGTTCAGGAA TAGTAAACCC TGCTCAGAAT ACTGCCTCTG CCATATCATCGenBank Acc. No.121 AACCTTCTCG AAGACTGGGG ACCCTGTACC GAACATGGAG AACATCGCAT CAGGACTCCTAB073835, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTCGTTG ACAAAAATCC TCACAATACC1-900241 ACAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAACAC CCGTGTGTCT301 TGGCCAAAAT TCGCAGTCCC AAATCTCCAG TCACTCACCA ACTTGTTGTC CTCCAACTTG361 TCCTGGTTAT CGCTGGATGT ATCTGCGGCG TTTTATCATA TTCCTCTGCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TTTGTCCTCT481 AATTCCAGGA TCATCAACCA CCAGCACCGG ACCCTGCAGA ACCTGCACGA CTCCTGCTCA541 AGGAACCTCT ATGTTTCCCT CATGTTGCTG TACAAAACCT ACGGACGGAA ACTGCACCTG601 TATTCCCATC CCATCATCTT GGGCTTTCGC AAAATTCCTA TGGGAGTGGG CCTCAGTCCG661 TTTCTCTTGG CTCAGTTTAC TAGTGCCGTT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAC721 TGTCTGGCTT TCAGTTATAT GGATGATGTG GTATTGGGGG CCAAATCTGT ACAACATCTT781 GAGTCCCTTT ATGCCGCTGT TACCAATTTT CTTTTGTCTT TGGGTATACA TTTAAACCCT841 CACAAAACAA AAAGATGGGG ATATTCCCTT AATTTCATGG GATATGTAAT TGGTAGTTGG111 Representative HBV  1 AACTCCACAA CATTCCACCA AGCTCTGCTA GACCCCAGAG TGAGGGGCCT ATACTTTCCTC1 sequence, 61 GCTGGTGGCT CCAGTTCCGG AACAGTAAAC CCTGTTCCGA CTACTGCCTC ACCCATATCGGenBank Acc. No.121 TCAATCTTCT CGAGGACTGG GGACCCTGCA CCGAACATGG AGAGCACAAC ATCAGGATTCAY123424, positions181 CTAGGACCCC TGCTCGTGTT ACAGGCGGGG TTTTTCTTGT TGACAAGAAT CCTCACAATA1-900241 CCACAGAGTC TAGACTCGTG GTGGACTTCT CTCAATTTTC TAGGGGGAGC ACCCACGTGT301 CTTGGCCAAA ATTCGCAGTC CCCAACCTCC AATCACTCAC CAACCTCTTG TCCTCCAATT361 TGTCCTGGTT ATCGTTGGAT GTGTCTGCGG CGTTTTATCA TATTCCTCTT CATCCTGCTG421 CTATGCCTCA TCTTCTTGTT GGTTCTTCTG GACTACCAAG GTATGTTGCC CGTTTGTCCT481 CTACTTCCAA GAACATCAAC TACCAGCACG GGACCATGCA AGACCTGCAC GATTCCTGCT541 CAAGGAACCT CTATGTTTCC CTCTTGTTGC TGTACAAAAC CTTCGGACGG AAACTGCACT601 TGTATTCCCA TCCCATCATC TTGGGCTTTC GCAAGATTCC TATGGGAGTG GGCCTCAGTC661 CGTTTCTCCT GGCTCAGTTT ACTAGTGCCA TTTGTTCAGT GGTTCGTAGG GCTTTCCCCC721 ACTGTTTGGC TTTCAGTTAT ATGGATGATG TGGTATTGGG GGCCAAGTCT GTACAACATC781 TTGAGTCCCT TTTTACCTCT ATTACCAATT TTCTTTTGTC TTTGGGTATA CATTTGAACC841 CCAATAAAAC CAAACGTTGG GGCTATTCCC TTAATTTCAT GGGATATGTA ATTGGATGTT112 Representative HBV  1 CTCCAGCACA TTCCACCAAG CTCTGCTAGA TCCCAGAGTG AGGGGCCTAT ACTTTCCTGCC2 sequence, 61 TGGTGGCTCC AGTTCCGGAA CAGTAAACCC TGTTCCGACT ACTGCCTCTC CCATATCGTCGenBank Acc. No.121 AATCTTCTCG AGGACTGGGG ACCCTGCACC GAATATGGAG AGCACCACAT CAGGATTCCTAF223955, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTTGTTG ACAAGAATCC TCACAATACC1-900241 ACAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAGCAC CCACGTGTCC301 TGGCCAAAAT TTGCAGTCCC CAACCTCCAA TCACTCACCA ACCTCTTGTC CTCCAATTTG361 TCCTGGTTAT CGCTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTACCAAGGT ATGTTGCCCG TTTGTCCTCT481 ACTTCCAGGA ACATCAACTA CCAGCACGGG ACCATGCAGG ACCTGCACGA TTCCTGCTCA541 AGGAACCTCT ATGTTTCCCT CTTGTTGCTG TACAAAACCT TCGGACGGAA ATTGCACTTG601 TATTCCCATC CCATCATCTT GGGCTTTCGC AAGATTCCTA TGGGAGTGGG CCTCAGTCCG661 TTTCTCCTGG CTCAGTTTAC TAGTGCCATT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAC721 TGTTTGGCTT TCAGTTATAT GGATGATGTG GTATTGGGGG CCAAGTCTGT ACAACATCTT781 GAATCCCTTT TTACCGCTAT TACCAATTTT CTTTTGTCTT TGGGTATACA TTTAAACCCT841 AATAAAACCA AACGTTGGGG CTACTCCCTT AACTTTATGG GATATGTCAT TGGAAGTTGG113 Representative HBV  1 CTCCACAACA TTCCAACAAG CTCTGCAGGA TCCCAGAGTC AGGGTCCTTT ATTTTCCTGCC3 sequence, 61 TGGTGGCTCC AGTTCCGGAA CAGTAAACCC TGTTCCGACT ACTGCCTCTC TCATTTCGTCGenBank Acc. No.121 AATCTTCTCG AGGATTGGGG ACCCTGTAAC GAACATGGAG AACACAACAT CAGGATTCCTX75665, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTTGTTG ACAAAAATCC TCACAATACC1-900241 ACAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAGCAC CCGTGTGTCC301 TGGCCAAAAT TCGCAGTCCC CAACCTCCAA TCACTCACCA ACCTCTTGTC CTCCAATTTG361 TCCTGGCTAT CGCTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTACCAAGGT ATGTTGCCCG TTTGTCCTCT481 ACTTCCAGGA ACATCAACTA CCAGCACGGG ACCATGCAAG ACCTGCACGA TTCCTGCTCA541 AGGAACCTCT ATGTTTCCCT CATGTTGCTG TACAAAACCT TCGGACGGAA ACTGCACTTG601 TATTCCCATC CCATCATCCT GGGCTTTCGT AAGATTCCTA TGGGAGTGGG CCTCAGTCCG661 TTTCTCCTGG CTCAGTTTAC TAGCGCCATT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAC721 TGTTTGGCTT TCAGTTATAT GGATGATGTG GTATTGGGGG CCAAGTCTGT ACAACATCTT781 GAGTCCCTTT ATACCTCTAT TACCAATTTT CTTTTGTCTT TGGGTATACA TTTAAACCCT841 AATAAAACCA AAAGATGGGG CTATTCCCTT AACTTCATGG GCTATGTAAT TGGAAGTTGG114 Representative HBV  1 AACTCCACTA CCTTCCACCA AACTCTGCAA GATCCCAGAG TGAGAGGCCT GTATTTCCCTD1 sequence, 61 GCTGGTGGCT CCAGTTCAGG AACAGTAAAC CCTGTTCCGA CTACTGTCTC TCACATATCGGenBank Acc. No.121 TCAATCTTCT CGAGGATTGG GGACCCTGCG CTGAACATGG AGAACATCAC ATCAGGATTCAB104712, positions181 CTAGGACCCC TGCTCGTGTT ACAGGCGGGG TTTTTCTTGT TGACAAGAAT CCTCACAATA1-900241 CCGCAGAGTC TAGACTCGTG GTGGACTTCT CTCAATTTTC TAGGGGGAAC TACCGTGTGT301 CTTGGCCAAA ATTCGCAGTC CCCAACCTCC AATCACTCAC CAACCTCCTG TCCTCCAACT361 TGTCCTGGTT ATCGCTGGAT GTGTCTGCGG CGTTTTATCA TCTTCCTCTT CATCCTGCTG421 CTATGCCTCA TCTTCTTGTT GGTTCTTCTG GACTATCAAG GTATGTTGCC CGTTTGTCCT481 CTAATTCCAG GATCTTCAAC TACCAGCACG GGACCATGCA GAACCTGCAC GACTCCTGCT541 CAAGGAACCT CTATGTATCC CTCCTGCTGC TGTACCAAAC CTTCGGACGG AAATTGCACC601 TGTATTCCCA TCCCATCATC CTGGGCTTTC GGAAAATTCC TATGGGAGTG GGCCTCAGCC661 CGTTTCTCCT GGCTCAGTTT ACTAGTGCCA TTTGTTCAGT GGTTCGTAGG GCTTTCCCCC721 ACTGTTTGGC TTTCAGTTAT ATGGATGATG TGGTATTGGG GGCCAAGTCT GTACAGCATC781 TTGAGTCCCT TTTTACCGCT GTTACCAATT TTCTTTTGTC TTTGGGTATA CATTTAAACC841 CTAACAAAAC AAAAAGATGG GGTTACTCTT TACATTTCAT GGGTTATGTC ATTGGATGTT115 Representative HBV  1 AACTCCACTA CCTTCCACCA AACTCTGCAA GATCCCAGAG TGAGAGGCCT GTATTTCCCTD2 sequence, 61 GCTGGTGGCT CCAGTTCAGG AACAGTAAAC CCTGTTCCGA CTACTGTCTC TCACATATCGGenBank Acc. No.121 TCAATCTTCT CGAGGATTGG GGACCCTGCG CTGAACATGG AGAACATCAC ATCAGGATTCAB205126, positions181 CTAGGACCCC TGCTCGTGTT ACAGGCGGGG TTTTTCTTGT TGACAAGAAT CCTCACAATA1-900241 CCGCAGAGTC TAGACTCGTG GTGGACTTCT CTCAATTTTC TAGGGGGAAC TACCGTGTGT301 CTTGGCCAAA ATTCGCAGTC CCCAACCTCC AATCACTCAC CAACCTCCTG TCCTCCAACT361 TGTCCTGGTT ATCGCTGGAT GTGTCTGCGG CGTTTTATCA TCTTCCTCTT CATCCTGCTG421 CTATGCCTCA TCTTCTTGTT GGTTCTTCTG GACTATCAAG GTATGTTGCC CGTTTGTCCT481 CTAATTCCAG GATCTTCAAC TACCAGCACG GGACCATGCA GAACCTGCAC GACTCCTGCT541 CAAGGAACCT CTATGTATCC CTCCTGCTGC TGTACCAAAC CTTCGGACGG AAATTGCACC601 TGTATTCCCA TCCCATCATC CTGGGCTTTC GGAAAATTCC TATGGGAGTG GGCCTCAGCC661 CGTTTCTCCT GGCTCAGTTT ACTAGTGCCA TTTGTTCAGT GGTTCGTAGG GCTTTCCCCC721 ACTGTTTGGC TTTCAGTTAT ATGGATGATG TGGTATTGGG GGCCAAGTCT GTACAGCATC781 TTGAGTCCCT TTTTACCGCT GTTACCAATT TTCTTTTGTC TTTGGGTATA CATTTAAACC841 CTAACAAAAC AAAAAGATGG GGTTACTCTT TACATTTCAT GGGTTATGTC ATTGGATGTT116 Representative HBV  1 TTCCACAACC TTCCACCAAA CTCTGCAAGA TCCCAGAGTG AGAGGCCTGT ATTTCCCTGCD3 sequence, 61 TGGTGGCTCC AGTTCAGGAA CAGTAAACCC TGTTCCGACT ACTGCCTCTC CCTTATCGTCGenBank Acc. No.121 AATCTTCTCG AGGATTGGGG ACCCTGCGCC GAACATGGAG AACATCACAT CAGGATTCCTAY233291, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTTGTTG ACAAGAATCC TCACAATACC1-900241 GCAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAACTA CCGTGTGTCT301 TGGCCAAAAT TCGCAGTCCC CAACCTCCAA TCACTCACCA ACCTCCTGTC CTCCAACTTG361 TCCTGGTTAT CGCTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TGTGTCCTCT481 AATTCCAGGA TCCTCAACCA CCAGCACGGG ACCATGCCGA ACCTGCACGA CTCCTGCTCA541 AGGAACCTCT ATGTATCCCT CCTGTTGCTG TACCAAACCT TCGGACGGAA ATTGCACCTG601 TATTCCCATC CCATCATCCT GGCCTTTCGG AAAATTCCTA TGGGAGTGGG CCTCAGCCCG661 TTTCTCCTGG CTCAGTTTAC TAGTGCCATT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAC721 TGTTTGGCTT TCAGTTATAT GGATGATGTG GTATTGGGGG CCAAGTCTGT ACAGCATCTT781 GAGTCCCTTT TTACCGCTGT TACCAATTTT CTTTTGTCTT TGGGTATACA TTTAAACCCT841 AACAAAACAA AGAGATGGGG TTACTCTCTA AATTTTATGG GGTATGTCAT TGGATGTTAT117 Representative HBV  1 CTCCACAACC TTCCACCAAA CTCTGCAAGA TCCCAGAGTG AGAGGCCTGT ATCTCCCTGCD4 sequence, 61 TGGTGGCTCC AGTTCAGGAA CAGTAAACCC TGTTCCGACT ACTGCCTCTC CCATATCGTCGenBank Acc. No.121 AATCTTCTCG AGGATTGGGG ACCTTGCGCT GAACATGGAG AACATCACAT CAGGATTCCTAB048702, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTTGTTG ACAAGAATCC TCACAATACC1-900241 GCAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAACTA CCGTGTGTCT301 TGGCCAAAAT TCGCAGTCCC CAACCTCCAA TCACTCACCA ACCTCCTGTC CTCCAACTTG361 TCCTGGTTAT CGCTGGATGT TTCTGCGGCG TTTTATCATC TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA TTATCAAGGT ATGTTGCCCG TTTGTCCTCT481 AATTCCAGGA TCATCAACCA CCAGCACGGG ACCCTGCAGA ACCTGCACGA CTCCTGCTCA541 AGGAACCTCT ATGTATCCCT CCTGTTGCTG TACAAAACCT TCGGATGGAA ACTGCACCTG601 TATTCCCATC CCATCATCCT GGGCTTTCGG AAAATTCCTA TGGGAGTGGG CCTCAGCCCG661 TTTCTCTTGG CTCAGTTTAC TAGTGCCATT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAC721 TGTTTGGCTT TCAGTTATAT GGATGATGTG GTATTGGGGG CCAAGTCTGT ACAGCACCTT781 GAGTCCCTTT TTACCGCTGT TACCAATTTT CTTTTGTCTT TGGGTATACA TTTAAACCCT841 AACAAAACAA AAAGATGGGG TTATTCTCTA AATTTCATGG GCTATGTCAT TGGAAGTTGG118 Representative HBV E  1 TTCCACAACA TTCCACCAAG CTCTGCAGGA TCCCAGAGTA AGAGGCCTGT ATTTTCCTGCsequence, GenBank 61 TGGTGGCTCC AGTTCCGGAA CAGTGAACCC TGTTCCGACT ACTGCCTCAC TCATCTCGTCAcc. No. AB205191,121 AATCTTCTCG AGGATTGGGG ACCCTGCACC GAACATGGAA GGCATCACAT CAGGATTCCTpositions 1-900181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTTGTTG ACAAAAATCC TCACAATACC241 GCAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAGCTC CCGTGTGTCT301 TGGCCAAAAT TCGCAGTCCC CAACCTCCAA TCACTCACCA ACCTCTTGTC CTCCAATTTG361 TCCTGGCTAT CGCTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TTTGTCCTCT481 AATTCCAGGA TCATCAACCA CCAGTACGGG ACCCTGCCGA ACCTGCACGA CTCTTGCTCA541 AGGAACCTCT ATGTTTCCCT CATGTTGCTG TTCAAAACCT TCGGACGGAA ATTGCACTTG601 TATTCCCATC CCATCATCAT GGGCTTTCGG AAAATTCCTA TGGGAGTGGG CCTCAGCCCG661 TTTCTCCTGG CTCAGTTTAC TAGTGCCATT TGTTCAGTGG TTCGCCGGGC TTTCCCCCAC721 TGTCTGGCTT TCAGTTATAT GGATGATGTG GTATTGGGGG CCAAGTCTGT ACAACATCTT781 GAGTCCCTTT ATACCGCTGT TACCAATTTT CTTTTGTCTT TGGGTATACA TTTAAATCCA841 AACAAAACAA AAAGATGGGG ATATTCCCTA AATTTCATGG GTTATGTAAT TGGAAGTTGG119 Representative HBV  1 GAACTCAACT CAGTTCCACC AGGCTCTGTT AGATCCGAGG GTAAGGGCTC TGTATTTTCCF1a sequence, 61 TGCTGGTGGC TCCAGTTCAG AGACACAGAA CCCTGCTCCG ACTATTGCCT CTCTCACATCGenBank Acc. No.121 ATCAATCTTC TTGAAGACTG GGGGCCCTGC TATGAACATG GACAACATCA CATCAGGACTAY090459, positions181 CCTAGGACCC CTGCTCGTGT TACAGGCGGT GTGTTTCTTG TTGACAAAAA TCCTCACAAT1-900241 ACCACAGAGT CTAGACTCGT GGTGGACTTC TCTCAATTTT CTAGGGGGAA CACCAGGGTG301 TCCTGGCCAA AATTCGCAGT CCCCAACCTC CAATCACTTA CCAACCTCCT GTCCTCCAAC361 TTGTCCTGGT TATCGCTGGA TGTGTCTGCG GCGTTTTATC ATCTTCCTCT TCATCCTGCT421 GCTATGCCTC ATCTTCTTGT TGGTTCTTCT GGACTATCAA GGTATGTTGC CCGTTTGTCC481 TCTACTTCCA GGATCCACGA CCACCAGCAC GGGACCATGC AAAACCTGCA CAACTCTTGC541 TCAAGGAACC TCTATGTTTC CCTCCTGCTG CTGTTCCAAA CCTTCGGACG GAAACTGCAC601 TTGTATTCCC ATCCCATCAT CCTGGGCTTT AGGAAAATAC CTATGGGAGT GGGCCTCAGC661 CCGTTTCTCC TGGCTCAGTT TACTAGTGCA ATTTGTTCAG TGGTGCGTAG GGCTTTCCCC721 CACTGTTTGG CTTTTAGTTA TATGGATGAT CTGGTATTGG GGGCCAAATC TGTGCAGCAT781 CTTGAGTCCC TTTATACCGC TGTTACCAAT TTTCTGTTAT CTGTGGGTAT CCATTTAAAT841 ACCTCTAAAA CGAAAAGATG GGGCTATACT TTAAATTTCA TGGGATATGT TATTGGCAGT120 Representative HBV  1 CTCCACTCAG TTCCACCAGG CTCTGTTAGA TCCGAGGGTA AGGGCTCTGT ATTTTCCTGCF1b sequence, 61 TGGTGGCTCC AGTTCAGAGA CACAGAACCC TGCTCCGACT ATTGCCTCTC TCACATCATCGenBank Acc. No.121 AATCTTCTTG AAGACTGGGG GCCCTGCTAC GAACATGGAC AACATCACAT CAGGACTCCTAF223963, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGTGTG TTTCTTGTTG ACAAAAATCC TCACAATACC1-900241 ACAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAACAC CCGGGTGTCC301 TGGCCAAAAT TCGCAGTCCC CAACCTCCAA TCACTTACCA ACCTCCTGTC CTCCAACTTG361 TCCTGGCTAT CGCTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTGTGGA CTATCAAGGT ATGTTGCCCG TTTGTCCTCC481 ACTTCCAGGA TCCACGACCA CCAGCACGGG ACCATGCAAA ACCTGCACAA CTCTTGCTCA541 AGGAACCTCT ATGTTTCCCT CTTGCTGCTG TTCCAAACCC TCGGACGGAA ACTGCACTTG601 TATTCCCATC CCATCATCCT GGGCTTTAGG AAAATACCTA TGGGAGTGGG CCTCAGCCCG661 TTTCTCCTGG CTCAGTTTAC TAGTGCAATT TGTTCAGTGG TGCGTAGGGC TTTCCCCCAC721 TGTCTGGCTT TTAGTTATAT GGATGATCTG GTATTGGGGG CCAAATCTGT GCAGCATCTT781 GAGTCCCTTT ATACCGCTGT TACCAATTTT CTGTTATCTG TGGGTATCCA TTTAAATACC841 TCGAAAACAA AAAGATGGGG TTATACCCTA AATTTCATGG GTTATGTTAT TGGCAGTTGG121 Representative HBV  1 CTCAACCCAG TTCCACCAGG CTCTGTTGGA TCCCAGGGTA AGGGCTCTGT ACTTCCCTGCF2 sequence, 61 TGGTGGCTCC AGTTCAGGGA CACAGAACCC TGCTCCGACT ATTGCCTCTC TCACATCATCGenBank Acc. No.121 AATCTTCTCG AAGACTGGGG GCCCTGCTAT GAACATGGAC AACATTACAT CAGGACTCCTAY311369, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGTGTG TTTCTTGTTG ACAAAAATCC TCACAATACC1-900241 ACAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGACTAC CCGGGTGTCC301 TGGCCAAAAT TCGCAGTCCC CAACCTCCAA TCACTTACCA ACCTCCTGTC CTCCAACTTG361 TCCTGGCTAT CGTTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TTTGTCCTCT481 ACTTCCAGGA TCCACGACCA CCAGCACGGG ACCCTGCAAA ACCTGCACAA CTCTTGCACA541 AGGAACCTCT ATGTTTCCCT CCTGTTGCTG TTCCAAACCC TCGGACGGAA ACTGCACTTG601 TATTCCCATC CCATCATCTT GGGCTTTAGG AAAATACCTA TGGGAGTGGG CCTCAGCCCG661 TTTCTCCTGG CTCAGTTTAC TAGTGCAATT TGTTCAGTGG TGCGTCGGGC TTTCCCCCAC721 TGTTTGGCTT TTAGTTATAT GGATGATCTG GTATTGGGGG CCAAATCTGT GCAGCATCTT781 GAGTCCCTTT ATACCGCTGT TACCAATTTT CTGTTATCTG TGGGTATCCA TTTAAATACC841 TCTAAAACAA AAAGATGGGG GTACTCCCTA CATTTTATGG GCTATGTCAT TGGTAGTTGG122 Representative HBV  1 CTCAACCCAG TTCCACCAGG CTCTGTTAGA TCCGAGGGTA AGGGCTCTGT ATTTTCCTGCF3 sequence, 61 TGGTGGCTCC AGTTCAGGGA CACAGAACCC TGTTCCGACT ATTGCCTCTC TCACATCATCGenBank Acc. No.121 AATCTTCTCG AAGACTGGGG GCCCTGCTAT GAACATGGAG AACATCACAT CAGGACTCCTAB036915, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGTGTG TTTCTTGTTG ACAAAAATCC TCACAATACC1-900241 ACAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGACTAC CCGGGTGTCC301 TGGCCAAAAT TCGCAGTCCC CAACCTCCAA TCACTTACCA ACCTCCTGTC CTCCAACTTG361 TCCTGGCTAT CGTTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TTTGTCCTCT481 ACTTCCAGGA TCCACAACCA CCAGCACGGG ACCATGCAAA ACCTGCACAA CTCTTGCTCA541 AGGAACCTCT ATGTTTCCCT CCTGTTGCTG TTCCAAACCC TCGGACGGAA ACTGCACCTG601 TATTCCCATC CCATCATCTT GGGCTTTAGG AAAATACCTA TGGGAGTGGG CCTCAGCCCG661 TTTCTCCTGG CTCAGTTTAC TAGTGCAATT TGTTCAGTGG TGCGTAGGGC TTTCCCCCAC721 TGTCTGGCTT TTAGTTATAT GGATGATCTG GTATTGGGGG CCAAATCTGT GCAGCATCTT781 GAGTCCCTTT ATACCGCTGT TACCAATTTT TTGTTATCTG TGGGTATCCA TTTAAATACT841 TCTAAAACAA AAAGATGGGG TTACAACCTA CATTTCATGG GTTATGTTAT TGGTAGTTGG123 Representative HBV  1 CTCAACCCAG TTCCACCAGG CCCTGTTGGA TCCGAGGGTA AGGGCTCTGT CTCCTCCTGCF4 sequence, 61 TGGTGGCTCC AGTTCAGAGA CACAGAACCC TGCTCCGACT ATTGCCTCTC TCACATCATCGenBank Acc. No.121 AATCTTCTCG AAAACTGGGG GCCCTGCTAT GAACATGGAC AACATCACAT CAGGACTCCTAB166850, positions181 AGGACCCCTG CTCGTGTTAC AGGCGGTGTG TTTCTTGTTG ACAAAAATCC GCACAATACC1-900241 ACAGAGTCTA GACTTGTGGT GGACTTCTCT CAATTTTCTA GGGGGACTAC CCGGGTGTCC301 TGGCCAAAAT TCGCAGTCCC CAACCTCCAA TCACTTACCA ACCTCCTGTC CTCCAACTTG361 TCCTGGCTAT CGTTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TTTGTCCTCT481 AATTCCAGGA TCTACGACCA CCAGCACGGG ACCATGCAAA ACCTGCACAA CTCTTGCTCA541 AGGAACCTCT ATGTTTCCCT CCTGTTGCTG TTCAAAACCT TCGGACGGAA ACTGCACCTG601 TATTCCCATC CCATCATCTT GGGCTTTAGG AAAATACCTA TGGGAGTGGG CCTCAGCCCG661 TTTCTCCTGG CTCAGTTTAC TAGTGCAATT TGTTCAGTGG TGCGTAGGGC TTTCCCCCAC721 TGTCTGGCTT TTAGTTATAT GGATGATCTG GTATTGGGGG CCAAATCTGT GCAGCATCTT781 GAGTCCCTTT ATACCGCTGT TACCAATTTT CTGTTATCTG TGGGTATCCA TTTGAATACC841 TCTAAAACAA AAAGATGGGG TTACAATTTA CATTTCATGG GTTATATCAT TGGTAGTTGG124 Representative HBV  1 CTCTACAGCA TTCCACCAAG CTCTACAAAA TCCCACAGTC AGGGGCCTGT ATCTTCCTGCG sequence, GenBank 61 TGGTGGCTCC AGTTCAGGGA TAGTGAACCC TGTTCCGACT ATTGCCTCTC ACATCTCGTCAcc. No. AB064312,121 AATCTTCTCC AGGATTGGGG ACCCTGCACC GAACATGGAG AACATCACAT CAGGATTCCTpositions 1-900181 AGGACCCCTG CTCGTGTTAC AGGCGGGGTT TTTCTTGTTG ACAAGAATCC TCACAATACC241 GCAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GGGGGAGTGC CCGTGTGTCC301 TGGCCTAAAT TCGCAGTCCC CAACCTCCAA TCACTCACCA ATCTCCTGTC CTCCAACTTG361 TCCTGGCTAT CGCTGGATGT GTCTGCGGCG TTTTATCATA TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TTTGTCCTCT481 GATTCCAGGA TCCTCGACCA CCAGTACGGG ACCCTGCAAA ACCTGCACGA CTCCTGCTCA541 AGGCAACTCT ATGTATCCCT CATGTTGCTG TACAAAACCT TCGGACGGAA ATTGCACCTG601 TATTCCCATC CCATCATCTT GGGCTTTCGC AAAATACCTA TGGGAGTGGG CCTCAGTCCG661 TTTCTCTTGG CTCAGTTTAC TAGTGCCATT TGTTCAGTGG TTCGTAGGGC TTTCCCCCAC721 TGTCTGGCTT TCAGCTATAT GGATGATGTG GTATTGGGGG CCAAATCTGT ACAACATCTT781 GAGTCCCTTT ATACCGCTGT TACCAATTTT CTTTTGTCTT TGGGTATACA TCTAAACCCT841 GACAAAACAA AAAGATGGGG TTATTCCTTA AATTTTATGG GATATGTAAT TGGAAGTTGG125 Representative HBV  1 CTCAACACAG TTCCACCAAG CACTGTTAGA TCCGAGAGTA AGGGGTCTGT ATTTTCCTGCH sequence, GenBank 61 TGGTGGCTCC AGTTCAGAAA CACAGAACCC TGCTCCGACT ATTGCCTCTC TCACATCATCAcc. No. AB059659,121 AATCTTCTCG AAGACTGGGG ACCCTGCTAT GAACATGGAG AACATCACAT CAGGACTCCTpositions 1-900181 AGGACCCCTT CCCGTGTTAC AGGGGGTGTT TTTCTCGTTG ACAAAAATCC TCACAATACC241 ACAGAGTCTA GACTCGTGGT GGACTTCTCT CAATTTTCTA GAGGTACCAC CCGGGTGTCC301 TGGCCAAAAT TCGCAGTCCC CAATCTCCAA TCACTTACCA ACCTCCTGTC CTCCAACTTG361 TCCTGGCTAT CGTTGGATGT GTCTGCGGCG TTTTATCATC TTCCTCTTCA TCCTGCTGCT421 ATGCCTCATC TTCTTGTTGG TTCTTCTGGA CTATCAAGGT ATGTTGCCCG TGTGTCCTCT481 ACTTCCAGGA TCTACAACCA CCAGCACGGG ACCCTGCAAA ACCTGCACCA CTCTTGCTCA541 AGGAACCTCT ATGTTTCCCT CCTGCTGCTG TACCAAACCT TCGGACGGAA ATTGCACCTG601 TATTCCCATC CCATCATCTT GGGCTTTCGG AAAATACCTA TGGGAGTGGG CCTCAGCCCG661 TTTCTCTTGG CTCAGTTTAC TAGTGCAATT TGTTCAGTGG TGCGTAGGGC TTTCCCCCAC721 TGTCTGGCTT TTAGTTATAT GGATGATTTG GTATTGGGGG CCAAATCTGT GCAGCATCTT781 GAGTCCCTTT ATACCGCTGT TACCAATTTT TTGTTATCTG TGGGCATCCA TTTGAACACA841 GCTAAAACAA AAAGGTGGGG TTATTCCTTA CACTTTATGG GTTATATAAT TGGGAGTTGG

What is claimed is:
 1. A composition or kit comprising at least first,second, third, and fourth amplification oligomers, wherein: the firstamplification oligomer comprises a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of one of SEQ ID NOs: 2 or3; the second amplification oligomer comprises a target-hybridizingsequence comprising at least 10 contiguous nucleotides of one of SEQ IDNOs: 20, 21, or 22; the third amplification oligomer comprises atarget-hybridizing sequence comprising at least 10 contiguousnucleotides of SEQ ID NO: 41; and the fourth amplification oligomercomprises a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 34 or 35; wherein thetarget-hybridizing sequences of the first, second, third, and fourthamplification oligomers each comprise at least about 14 contiguousnucleotides of Hepatitis B virus sequence or a complement thereof.
 2. Amethod of detecting Hepatitis B virus in a sample, comprising:contacting the sample with at least first, second, third, and fourthamplification oligomers, thereby forming a composition, performing anucleic acid amplification reaction in the composition which produces atleast first and second amplicons in the presence of a Hepatitis B virusnucleic acid, and quantifying the first and second amplicons, wherein:the first amplicon is produced through extension of the first and secondamplification oligomers in the presence of the Hepatitis B virus nucleicacid; the second amplicon is produced through extension of the third andfourth amplification oligomers in the presence of the Hepatitis B virusnucleic acid; the first amplification oligomer comprises atarget-hybridizing sequence comprising at least 10 contiguousnucleotides of one of SEQ ID NOs: 2 or 3; the second amplificationoligomer comprises a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 20, 21, or 22; the thirdamplification oligomer comprises a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of SEQ ID NO: 41; and thefourth amplification oligomer comprises a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of one of SEQ ID NOs: 34or 35; wherein the target-hybridizing sequences of the first, second,third, and fourth amplification oligomers each comprise at least about14 contiguous nucleotides of Hepatitis B virus sequence or a complementthereof.
 3. The composition or kit of claim 1 or method of claim 2,wherein one or more of the first, second, third, and fourthamplification oligomers is a promoter-primer.
 4. The composition, kit,or method of any one of the preceding claims, wherein the secondamplification oligomer is a promoter-primer.
 5. The composition, kit, ormethod of any one of the preceding claims, wherein the fourthamplification oligomer is a promoter-primer.
 6. The composition, kit, ormethod of any one of claims 3-6, wherein one or more of thepromoter-primers comprises a T7 promoter located 5′ of thetarget-hybridizing sequence.
 7. The composition, kit, or method of anyone of claims 3-7, wherein one or more promoter-primers comprises thesequence of SEQ ID NO: 8, 9, 10, 11, 12, or
 13. 8. The composition, kit,or method of any one of the preceding claims, wherein one or more of thefirst, second, third, and fourth amplification oligomers comprises anon-nucleotide detectable label.
 9. The composition, kit, or method ofany one of the preceding claims, wherein the first amplificationoligomer comprises a target-hybridizing sequence comprising at leastone, two, or three of SEQ ID NOs: 4, 5, 6, or
 7. 10. The composition,kit, or method of any one of the preceding claims, wherein the secondamplification oligomer comprises a target-hybridizing sequencecomprising at least one, two, three, four, or five of SEQ ID NOs: 23,24, 25, 26, 27, and
 28. 11. The composition, kit, or method of any oneof the preceding claims, wherein the third amplification oligomercomprises a target-hybridizing sequence comprising at least one, two, orthree of SEQ ID NOs: 42, 43, and
 44. 12. The composition, kit, or methodof any one of the preceding claims, wherein the fourth amplificationoligomer comprises a target-hybridizing sequence comprising at leastone, two, or three of SEQ ID NOs: 36, 37, 38, and
 39. 13. Thecomposition, kit, or method of any one of the preceding claims, whereinthe first amplification oligomer comprises at least 11, 12, 13, 14, 15,16, 17, 18, 19, or 20 contiguous nucleotides of SEQ ID NO:
 3. 14. Thecomposition, kit, or method of any one of the preceding claims, whereinthe first amplification oligomer comprises the sequence of SEQ ID NO: 3.15. The composition, kit, or method of any one of the preceding claims,wherein the first amplification oligomer comprises at least 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, or 22 contiguous nucleotides of SEQ IDNO:
 2. 16. The composition, kit, or method of any one of the precedingclaims, wherein the first amplification oligomer comprises the sequenceof SEQ ID NO:
 2. 17. The composition, kit, or method of any one of thepreceding claims, wherein the composition or kit further comprises anadditional amplification oligomer different from the first amplificationoligomer, comprising at least 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20contiguous nucleotides of SEQ ID NO:
 3. 18. The composition, kit, ormethod of claim 17, wherein the additional amplification oligomercomprises the sequence of SEQ ID NO:
 3. 19. The composition, kit, ormethod of any one of the preceding claims, wherein the secondamplification oligomer comprises at least 11, 12, 13, 14, 15, 16, 17,18, 19, 20, or 21 contiguous nucleotides of SEQ ID NO:
 21. 20. Thecomposition, kit, or method of any one of the preceding claims, whereinthe second amplification oligomer comprises the sequence of SEQ ID NO:21.
 21. The composition, kit, or method of any one of the precedingclaims, wherein the second amplification oligomer comprises the sequenceof SEQ ID NO:
 14. 22. The composition, kit, or method of any one of thepreceding claims, wherein the second amplification oligomer comprises atleast 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26contiguous nucleotides of SEQ ID NO:
 22. 23. The composition, kit, ormethod of any one of the preceding claims, wherein the secondamplification oligomer comprises the sequence of SEQ ID NO:
 22. 24. Thecomposition, kit, or method of any one of the preceding claims, whereinthe second amplification oligomer comprises the sequence of SEQ ID NO:15.
 25. The composition, kit, or method of any one of the precedingclaims, wherein the second amplification oligomer comprises at least 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28contiguous nucleotides of SEQ ID NO:
 20. 26. The composition, kit, ormethod of any one of the preceding claims, wherein the secondamplification oligomer comprises the sequence of SEQ ID NO:
 20. 27. Thecomposition, kit, or method of any one of the preceding claims, whereinthe third amplification oligomer comprises at least 11, 12, 13, 14, 15,16, 17, 18, or 19 contiguous nucleotides of SEQ ID NO:
 41. 28. Thecomposition, kit, or method of any one of the preceding claims, whereinthe third amplification oligomer comprises the sequence of SEQ ID NO:41.
 29. The composition, kit, or method of any one of the precedingclaims, wherein the fourth amplification oligomer comprises at least 10contiguous nucleotides of SEQ ID NO: 35 including the inosine atposition 30 of SEQ ID NO:
 35. 30. The composition, kit, or method of anyone of the preceding claims, wherein the fourth amplification oligomercomprises at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, or 28 contiguous nucleotides of SEQ ID NO:
 34. 31. Thecomposition, kit, or method of any one of the preceding claims, whereinthe fourth amplification oligomer comprises the sequence of SEQ ID NO:34.
 32. The composition, kit, or method of any one of the precedingclaims, wherein the fourth amplification oligomer comprises the sequenceof SEQ ID NO:
 30. 33. The composition, kit, or method of any one of thepreceding claims, wherein the composition or kit further comprises afifth amplification oligomer comprising at least 10 contiguousnucleotides of the sequence of SEQ ID NO: 69 and at least about 14contiguous nucleotides of Hepatitis B virus sequence or a complementthereof.
 34. The composition, kit, or method of claim 33, wherein thefifth amplification oligomer comprises at least one or two of SEQ ID NO:70, 71, or
 72. 35. The composition, kit, or method of claim 33 or claim34, wherein the fifth amplification oligomer comprises at least 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29contiguous nucleotides of SEQ ID NO:
 69. 36. The composition, kit, ormethod of any one of claims 33-35, wherein the fifth amplificationoligomer comprises the sequence of SEQ ID NO:
 69. 37. The composition,kit, or method of any one of claims 33-36, wherein the fifthamplification oligomer is a promoter-primer.
 38. The composition, kit,or method of any one of claims 33-37, wherein the fifth amplificationoligomer comprises the sequence of SEQ ID NO:
 67. 39. The composition,kit, or method of any one of the preceding claims, wherein thecomposition or kit further comprises a sixth amplification oligomercomprising at least 10 contiguous nucleotides of the sequence of SEQ IDNO: 73 and at least about 14 contiguous nucleotides of Hepatitis B virussequence or a complement thereof.
 40. The composition, kit, or method ofclaim 39, wherein the sixth amplification oligomer comprises at leastone or two of SEQ ID NO: 74, 75, or
 76. 41. The composition, kit, ormethod of any one of the preceding claims, wherein the sixthamplification oligomer comprises at least 11, 12, 13, 14, 15, 16, 17,18, or 19 contiguous nucleotides of SEQ ID NO:
 73. 42. The composition,kit, or method of any one of the preceding claims, wherein the sixthamplification oligomer comprises the sequence of SEQ ID NO:
 73. 43. Thecomposition or method of any one of the preceding claims, wherein thecomposition further comprises HBV nucleic acid.
 44. The composition,kit, or method of any one of the preceding claims, wherein thecomposition or kit further comprises at least one DNA polymerase. 45.The composition, kit, or method of claim 44, wherein the DNA polymeraseis a reverse transcriptase.
 46. The composition, kit, or method of claim44 or claim 45, wherein the DNA polymerase is thermophilic.
 47. Thecomposition, kit, or method of claim 44 or claim 45, wherein the DNApolymerase is mesophilic.
 48. The composition, kit, or method of any oneof the preceding claims, wherein the composition or kit furthercomprises an RNA polymerase.
 49. The composition, kit, or method of anyone of claim 48, wherein the RNA polymerase is T7 RNA polymerase. 50.The composition, kit, or method of any one of the preceding claims,wherein the composition or kit further comprises at least one, at leasttwo, or each of Mg2+, a buffer, and dNTPs.
 51. The composition, kit, ormethod of any one of the preceding claims, wherein the composition orkit further comprises rNTPs.
 52. The composition, kit, or method of anyone of the preceding claims, wherein the composition or kit furthercomprises a first control amplification oligomer and a second controlamplification oligomer that do not hybridize specifically to HBV. 53.The composition, kit, or method of claim 52, wherein the first controlamplification oligomer comprises at least 10, 11, 12, 13, 14, 15, 16,17, 18, or 19 contiguous nucleotides of the sequence of SEQ ID NO: 77.54. The composition, kit, or method of claim 52 or claim 53, wherein thesecond control amplification oligomer comprises at least 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, or 22 contiguous nucleotides of thesequence of SEQ ID NO:
 86. 55. The composition, kit, or method of anyone of claims 52 to 54, wherein the first control amplification oligomeror the second control amplification oligomer is a promoter-primer. 56.The composition, kit, or method of any one of claims 52 to 55, whereinthe composition or kit further comprises at least one control probeoligomer configured to hybridize specifically to an amplicon producedfrom the first and second control amplification oligomers.
 57. Thecomposition, kit, or method of claim 56, wherein the control probeoligomer comprises at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, or 23 contiguous nucleotides of the sequence of SEQ ID NO: 79.58. The composition, kit, or method of any one of the preceding claims,wherein the composition or kit further comprises at least one probeoligomer configured to hybridize specifically to an amplicon producedfrom the first and second amplification oligomers.
 59. The composition,kit, or method of claim 58, wherein the probe oligomer comprises atleast 10 contiguous nucleotides of the sequence of SEQ ID NO: 29 and atleast about 14 contiguous nucleotides of Hepatitis B virus sequence or acomplement thereof.
 60. The composition, kit, or method of claim 58 orclaim 59, wherein the probe oligomer comprises at least 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 contiguousnucleotides of SEQ ID NO:
 82. 61. The composition, kit, or method of anyone of claims 58 to 60, wherein the probe oligomer comprises thesequence of SEQ ID NO:
 82. 62. The composition, kit, or method of anyone of claims 58 to 61, wherein the probe oligomer comprises at least10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,or 28 contiguous nucleotides of SEQ ID NO:
 82. 63. The composition, kit,or method of any one of claims 58 to 62, wherein the probe oligomercomprises the sequence of SEQ ID NO:
 29. 64. The composition, kit, ormethod of any one of claims 58 to 63, wherein the composition or kitfurther comprises at least one probe oligomer configured to hybridizespecifically to an amplicon produced from the third and fourthamplification oligomers.
 65. The composition, kit, or method of claim64, wherein the probe oligomer comprises at least 10 contiguousnucleotides of the sequence of SEQ ID NO: 40 and at least about 14contiguous nucleotides of Hepatitis B virus sequence or a complementthereof.
 66. The composition, kit, or method of any one of claims 64 to65, wherein the probe oligomer comprises at least 10, 11, 12, 13, 14, or15 contiguous nucleotides of SEQ ID NO:
 83. 67. The composition, kit, ormethod of any one of claims 64 to 66, wherein the probe oligomercomprises the sequence of SEQ ID NO:
 83. 68. The composition, kit, ormethod of any one of claims 64 to 67, wherein the probe oligomercomprises at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, or 25 contiguous nucleotides of SEQ ID NO:
 40. 69. A probe oligomercomprising a target-hybridizing region comprising the sequence of SEQ IDNO:
 83. 70. The composition, kit, method, or probe oligomer of any oneof claims 64-69, wherein the probe oligomer comprises the sequence ofSEQ ID NO:
 84. 71. The composition, kit, method, or probe oligomer ofany one of claims 64-70, wherein the probe oligomer comprises thesequence of SEQ ID NO:
 85. 72. The composition, kit, method, or probeoligomer of any one of claims 64-71, wherein the probe oligomercomprises at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, or 25 contiguous nucleotides of SEQ ID NO:
 40. 73. The composition,kit, method, or probe oligomer of any one of claims 64-72, wherein theprobe oligomer comprises the sequence of SEQ ID NO:
 40. 74. Anamplification oligomer comprising a target-hybridizing region comprisingat least 10 contiguous nucleotides of SEQ ID NO: 35 including theinosine at position 30 of SEQ ID NO: 35 and at least 14 contiguousnucleotides of HBV sequence.
 75. The composition, kit, method, oramplification oligomer of any one of claims 1-68 or 70-74, wherein theamplification oligomer comprising a subsequence of SEQ ID NO: 34 or 35comprises at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 contiguous nucleotides ofSEQ ID NO:
 35. 76. The composition, kit, method, or amplificationoligomer of any one of claims 1-68 or 70-74, wherein the amplificationoligomer comprising a subsequence of SEQ ID NO: 34 or 35 comprises thesequence of SEQ ID NO:
 35. 77. The composition, kit, method, oramplification oligomer of any one of claims 1-68 or 70-74, wherein theamplification oligomer comprising a subsequence of SEQ ID NO: 34 or 35comprises the sequence of SEQ ID NO:
 31. 78. The composition, kit,method, or probe oligomer of any one of claims 58-73 or 75-77, whereinat least one probe oligomer comprises a non-nucleotide detectable label.79. The composition, kit, method, or probe oligomer of any one of claims58-73 or 75-78, wherein the non-nucleotide detectable label is afluorescent label.
 80. The composition, kit, method, or probe oligomerof claim 79, wherein the probe oligomer comprises a quencher.
 81. Thecomposition, kit, method, or probe oligomer of claim 80, wherein thenon-nucleotide detectable label is a fluorescent label and the quencherabsorbs fluorescence to a greater extent when the probe is free thanwhen the probe is annealed to a target nucleic acid.
 82. Thecomposition, kit, method, or probe oligomer of any one of claims 79-81,wherein the fluorescent label is FAM, HEX, or acridine.
 83. Thecomposition, kit, method, or probe oligomer of any one of claims 80-82,wherein the quencher is DABCYL or ROX.
 84. The composition, kit, method,or probe oligomer of any one of claims 80-83, wherein the fluorescentlabel is attached to the 5′-terminus of the probe oligomer and thequencher is attached to the 3′-terminus of the probe oligomer, or thefluorescent label is attached to the 3′-terminus of the probe oligomerand the quencher is attached to the 5′-terminus of the probe oligomer.85. The composition, kit, method, or probe oligomer of any one of claims58-73 or 75-84, wherein at least about half, at least about 90%, or allof the sugars in the probe oligomer are 2′-O-methyl-ribose.
 86. Thecomposition, kit, method, or probe oligomer of any one of claims 58-73or 75-85, wherein the probe oligomer comprises a firstself-complementary region at its 5′ end and a second self-complementaryregion at its 3′ end.
 87. The composition, kit, method, or probeoligomer of claim 86, wherein the self-complementary regions canhybridize to form about 4 to 7 Watson-Crick or wobble base pairs. 88.The composition, kit, method, or probe oligomer of claim 87, wherein theself-complementary regions can hybridize to form about 5 Watson-Crick orwobble base pairs.
 89. A composition or kit comprising two or moredifferent capture oligomers selected from the following captureoligomers (i)-(iv): (i) a first capture oligomer comprising atarget-hybridizing sequence comprising at least 10 contiguousnucleotides of SEQ ID NO: 49 or 99; (ii) a second capture oligomercomprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of SEQ ID NO: 53, 100, 101, or 104; (iii) a thirdcapture oligomer comprising a target-hybridizing sequence comprising atleast 10 contiguous nucleotides of SEQ ID NO: 57, 96, or 102; (iv) afourth capture oligomer comprising a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of SEQ ID NO: 61, 97, 98,or 103; wherein the target-hybridizing sequences of the two or moredifferent capture oligomers each comprise at least about 14 contiguousnucleotides of Hepatitis B virus sequence or a complement thereof.
 90. Amethod of isolating HBV nucleic acid from a sample, comprising:contacting the sample with two or more different capture oligomersselected from the following capture oligomers (i)-(iv) under conditionspermissive for forming one or more complexes of a capture oligomer andHBV nucleic acid, thereby forming a composition: (i) a first captureoligomer comprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of SEQ ID NO: 49 or 99; (ii) a second captureoligomer comprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of SEQ ID NO: 53, 100, 101, or 104; (iii) a thirdcapture oligomer comprising a target-hybridizing sequence comprising atleast 10 contiguous nucleotides of SEQ ID NO: 57, 96, or 102; (iv) afourth capture oligomer comprising a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of SEQ ID NO: 61, 97, 98,or 103; wherein the target-hybridizing sequences of the two or moredifferent capture oligomers each comprise at least about 14 contiguousnucleotides of Hepatitis B virus sequence or a complement thereof; andisolating the capture oligomers from the composition.
 91. The method ofclaim 90, wherein isolating the capture oligomers comprises associatingthe capture oligomers with a solid support, and washing the solidsupport.
 92. The method of claim 91, wherein the solid support comprisesa poly-N sequence which is complementary to a portion of at least one orat least two capture oligomers.
 93. The method of claim 91, wherein thesolid support comprises a binding agent that recognizes an affinity tagpresent in at least one or at least two capture oligomers.
 94. Thecomposition or kit of claim 89 or the method of any one of claims 90-93,wherein the composition or kit comprises at least three of the captureoligomers (i)-(iv).
 95. The composition, kit, or method of claim 94,wherein the composition or kit comprises capture oligomers (i)-(iv). 96.The composition, kit, or method of any one of claims 89-95, wherein thefirst capture oligomer comprises a target-hybridizing sequencecomprising at least one of SEQ ID NOs: 50, 51, and
 52. 97. Thecomposition, kit, or method of any one of claims 89-96, wherein thefirst capture oligomer comprises at least 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, or 24 contiguous nucleotides of SEQ ID NO: 49.98. The composition, kit, or method of any one of claims 89-97, whereinthe first capture oligomer comprises the sequence of SEQ ID NO:
 49. 99.The composition, kit, or method of any one of claims 89-98, wherein thesecond capture oligomer comprises a target-hybridizing sequencecomprising at least one of SEQ ID NOs: 54, 55, and
 56. 100. Thecomposition, kit, or method of any one of claims 89-99, wherein thesecond capture oligomer comprises the sequence at least 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 contiguous nucleotides of SEQID NO:
 53. 101. The composition, kit, or method of any one of claims89-100, wherein the second capture oligomer comprises of SEQ ID NO: 53.102. The composition, kit, or method of any one of claims 89-101,wherein the third capture oligomer comprises a target-hybridizingsequence comprising at least one of SEQ ID NOs: 58, 59, and
 60. 103. Thecomposition, kit, or method of any one of claims 89-102, wherein thethird capture oligomer comprises at least 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides of SEQ ID NO:57.
 104. The composition, kit, or method of any one of claims 89-103,wherein the third capture oligomer comprises the sequence of SEQ ID NO:57.
 105. The composition, kit, or method of any one of claims 89-104,wherein the fourth capture oligomer comprises a target-hybridizingsequence comprising at least one of SEQ ID NOs: 62, 63, and
 64. 106. Thecomposition, kit, or method of any one of claims 89-105, wherein thefourth capture oligomer comprises at least 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 contiguous nucleotides of SEQID NO:
 61. 107. The composition, kit, or method of any one of claims89-106, wherein the fourth capture oligomer comprises the sequence ofSEQ ID NO:
 61. 108. The composition, kit, or method of any one of claims89-107, wherein at least one of the capture oligomers further comprisesa non-nucleotide affinity label.
 109. The composition, kit, or method ofany one of claims 89-108, wherein at least one of the capture oligomersfurther comprises a non-HBV sequence.
 110. The composition, kit, ormethod of any one of claims 89-109, wherein the two, three, or fourcapture oligomers further comprise a non-HBV sequence.
 111. Thecomposition, kit, or method of any one of claims 89-110, wherein atleast one, two, three, or four capture oligomers further comprise apoly-N sequence.
 112. The composition, kit, or method of claim 111,wherein the poly-N sequence is a poly-A or poly-T sequence.
 113. Thecomposition, kit, or method of any one of claims 89-112, wherein thecomposition or kit further comprises at least one amplification oligomerselected from a first amplification oligomer comprising atarget-hybridizing sequence comprising at least 10 contiguousnucleotides of one of SEQ ID NOs: 2 or 3; a second amplificationoligomer comprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 20, 21, or 22; a thirdamplification oligomer comprising a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of SEQ ID NO: 41; a thefourth amplification oligomer comprising a target-hybridizing sequencecomprising at least 10 contiguous nucleotides of one of SEQ ID NOs: 34or 35; wherein the target-hybridizing sequences of the first, second,third, and fourth amplification oligomers each comprise at least about14 contiguous nucleotides of Hepatitis B virus sequence or a complementthereof.
 114. The composition, kit, or method of claim 113, wherein thecomposition or kit comprises the first amplification oligomer as recitedin any one of claims 8, 9, or 13-17.
 115. The composition, kit, ormethod of claim 113 or 114, wherein the composition or kit comprises thesecond amplification oligomer as recited in any one of claims 4, 8, 10,or 19-26.
 116. The composition, kit, or method of claim 115, wherein thesecond amplification oligomer comprises at least 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 contiguous nucleotides of SEQID NO: 22 and the composition or kit further comprises an additionalamplification oligomer that is different from the second amplificationoligomer and comprises at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, or 28 contiguous nucleotides of SEQ ID NO:20.
 117. The composition, kit, or method of claim 116, wherein thesecond amplification oligomer comprises the sequence of SEQ ID NO: 22.118. The composition, kit, or method of claim 116 or claim 117, whereinthe additional amplification oligomer comprises the sequence of SEQ IDNO:
 20. 119. The composition, kit, or method of any one of claims113-118, wherein the composition or kit comprises the thirdamplification oligomer as recited in any one of claims 8, 11, or 27-28.120. The composition, kit, or method of any one of claims 113-119,wherein the composition or kit comprises the amplification oligomercomprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 34 or 35 as recited in anyone of claims 5, 8, 12, or 29-32.
 121. The method of any one of claims113-120, further comprising performing a linear amplification wherein atleast one amplification oligomer is extended.
 122. The method of claim121, wherein prior to the linear amplification, the amplificationoligomer is associated with a complex of HBV nucleic acid and a captureoligomer and the complex is associated with a solid support, and themethod comprises washing the solid support.
 123. The method of claim122, wherein the solid support is a population of microbeads.
 124. Themethod of claim 123, wherein the microbeads of the population aremagnetic.
 125. The method of any one of claims 122-124, whereinfollowing the washing step, the method comprises adding one or moreadditional amplification oligomers oppositely oriented to anamplification oligomer associated with the complex of HBV nucleic acidand the capture oligomer.
 126. The method of claim 125, wherein one ormore oppositely oriented additional amplification oligomer is apromoter-primer.
 127. The method of claim 125, wherein one or moreoppositely oriented additional amplification oligomer is not apromoter-primer.
 128. The method of any one of claims 125-127, whereinthe one or more oppositely oriented additional amplification oligomerincludes the first amplification oligomer as recited in any one ofclaims 8, 9, or 13-17.
 129. The method of any one of claims 125-128,wherein the one or more oppositely oriented additional amplificationoligomer includes the second amplification oligomer as recited in anyone of claims 4, 8, 10, or 19-26.
 130. The method of any one of claims125-129, wherein the one or more oppositely oriented additionalamplification oligomer includes the third amplification oligomer asrecited in any one of claims 8, 11, or 27-28.
 131. The method of any oneof claims 125-130, wherein the one or more oppositely orientedadditional amplification oligomer includes the amplification oligomercomprising a target-hybridizing sequence comprising at least 10contiguous nucleotides of one of SEQ ID NOs: 34 or 35 as recited in anyone of claims 1, 5, 8, 12, or 29-32.
 132. The method of any one ofclaims 121-131, further comprising performing an exponentialamplification following the linear amplification.
 133. The method ofclaim 132, wherein the exponential amplification istranscription-mediated amplification.
 134. The method, composition, oroligomer of any one of the preceding claims, wherein one, two, three,four, or more target-hybridizing sequences comprise at least about 15,16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides ofHepatitis B virus sequence or a complement thereof.
 135. A method ofdetermining a level of Hepatitis B virus in a sample comprising firstand second Hepatitis B amplicons associated with first and secondlabels, respectively, the method comprising: detecting a first signalemitted from the first label; detecting a second signal emitted from thesecond label; determining whether the first signal or the second signalis above a predetermined threshold; and calculating a level of HepatitisB virus in the sample, wherein if the first signal or the second signalis above a predetermined threshold, the level is calculated from thegreater of the first and second signals; and wherein if the first signaland the second signal are below a predetermined threshold, the level iscalculated from an average of the first and second signals.
 136. Themethod of claim 135, wherein the sample is an in vitro sample.
 137. Themethod of claim 135 or claim 136, comprising determining the average ofthe first and second signals by determining first and second levelscorresponding to the first and second signals, and arithmeticallyaveraging the first and second levels.
 138. The method of any one ofclaims 135-137, wherein the level of Hepatitis B virus is aconcentration.
 139. The method of any one of claims 135-137, wherein thelevel of Hepatitis B virus is an amount.
 140. The method of any one ofclaims 135-139, wherein one or both of the first and second ampliconscomprise sequence from the S ORF of HBV.
 141. The method of any one ofclaims 135-140, wherein one or both of the first and second ampliconscomprise sequence from the P ORF of HBV.
 142. The method of any one ofclaims 135-141, wherein one or both of the first and second ampliconscomprise sequence from the overlap of the S and P ORFs of HBV.
 143. Themethod of any one of claims 135-142, wherein the first ampliconcomprises at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20contiguous nucleotides of one of SEQ ID NOs: 2 or
 3. 144. The method ofany one of claims 135-143, wherein the first amplicon comprises at least10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleotides ofone of SEQ ID NOs: 20, 21, or
 22. 145. The method of any one of claims135-144, wherein the second amplicon comprises at least 10, 11, 12, 13,14, 15, 16, 17, 18, 19, or 20 contiguous nucleotides of SEQ ID NO: 41.146. The method of any one of claims 135-145, wherein the secondamplicon comprises at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or20 contiguous nucleotides of one of SEQ ID NOs: 34 or
 35. 147. Themethod of any one of claims 135-146, wherein the predetermined thresholdis at a value where expected random error is greater than or about equalto expected error due to a point mutation.
 148. The method of any one ofclaims 135-146, wherein the predetermined threshold is at a value whereexpected error due to a point mutation is greater than or about equal toexpected random error.
 149. The method of any one of claims 135-148,wherein the predetermined threshold corresponds to a concentration inthe range of about 10 IU/ml to about 200 IU/ml.
 150. The method of claim149, wherein the predetermined threshold is in the range of about 20IU/ml to about 40 IU/ml, about 40 IU/ml to about 60 IU/ml, about 60IU/ml to about 80 IU/ml, or about 80 IU/ml to about 100 IU/ml.
 151. Themethod of any one of claims 135-150, wherein the first label, the secondlabel, or both are fluorescent.
 152. The method of claim 151, wherein atleast one of the first and second labels is attached to a probe. 153.The method of claim 152, wherein the probe comprises a quencher.
 154. Akit or composition comprising the probe oligomer of any one of claims69-73 or 78-88.
 155. A kit or composition comprising the amplificationoligomer of any one of claims 74-77.
 156. The kit or composition ofclaim 155, further comprising the probe oligomer of any one of claims69-73 or 78-88.
 157. The kit or composition of any one of claims154-156, further comprising at least one, two, three, or four of thefirst amplification oligomer as recited in any one of claims 1, 8, 9, or13-17; the second amplification oligomer as recited in any one of claims1, 4, 8, 10, or 19-26; the third amplification oligomer as recited inany one of claims 1, 8, 11, or 27-28; or the fourth amplificationoligomer as recited in any one of claims 1, 5, 8, 12, or 29-32.
 158. Thekit or composition of any one of claims 154-157, further comprising aprobe oligomer as recited in any one of claims 58-63.
 159. The kit orcomposition of any one of claims 154-158, further comprising at leastone, two, three, or four of the first capture oligomer as recited in anyone of claim 89 or 96-98; the second capture oligomer as recited in anyone of claim 89 or 99-101; the third capture oligomer as recited in anyone of claim 89 or 102-104; or the fourth capture oligomer as recited inany one of claim 89 or 105-107.
 160. The kit or composition of any oneof claims 154-159, further comprising at least one or two of the fifthamplification oligomer as recited in any one of claims 33-38; or thesixth amplification oligomer as recited in any one of claims 39-42. 161.The kit or composition of any one of claims 154-160, further comprisingan additional amplification oligomer as recited in any one of claims 17,18, or 116, wherein, if the kit or composition comprises the secondamplification oligomer as recited in any one of claims 1, 4, 8, 10, or19-26, the additional amplification oligomer is different from thesecond amplification oligomer.
 162. A kit according to any one of claims1-68, 70-73, 75-89, 94-120, or 154-161.
 163. A composition according toany one of claims 1-68, 70-73, 75-89, 94-120, or 154-161.
 164. Thecomposition of claim 163, which is aqueous, frozen, or lyophilized.